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ABSTRACT 
 
The aim of the study was to minimise non-adherence to antiretroviral (ARV) treatment 
amongst HIV/AIDS adult patients at a hospital in Namibia thereby promoting successful 
outcomes in patients on ARV treatment. A quantitative cross-sectional descriptive study 
was conducted on a sample of 112 non-adherent adults. Data collection was through 
structured interviews and patients’ records review. Data analysis was by descriptive 
statistics. Rate of non-adherence was 36.7%. Characteristics common in the sample 
were, being a woman, age of 31-45 years, being unmarried, low educational status, lack 
of HIV status disclosure, feeling that taking ARVs reminded one of HIV and experience 
of  ARV side effects. Reasons for missed doses included forgetting, alcohol use, access 
to care, work commitments, lack of food, stress and travelling. Of the respondents, 86.6% 
had unsupressed viral loads. Recommendations include use of reminders, automated 
SMS, establishing treatment supporters and collaborative efforts in reducing active 
substance use  to improve adherence. 
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CHAPTER 1 
 
ORIENTATION TO THE STUDY 
 
1.1 INTRODUCTION 
 
The Human immunodeficiency virus (HIV) remains a global challenge. According to Joint 
United Nations Programme on HIV/AIDS (UNAIDS 2016:6), new infections among adults 
remained nearly static in 2015 at about 1.9 million [1.7 million–2.2 million]. By the end of 
2015, the total number of people living with HIV were 36.7 million [34.0 million–39.8 
million] (UNAIDS 2016:1). The UNAIDS Gap Report highlights that southern Africa is the 
worst affected region wordwide and is widely regarded as the 'epicentre' of the global HIV 
epidemic (UNAIDS 2014:6). According to World Health Organization (WHO), Swaziland 
is known to have the highest HIV prevalence worldwide at 27.4% while South Africa has 
the largest epidemic globally with 5.9 million people living with HIV in that country (WHO 
2013:[13]). HIV prevalence in Western and Eastern Africa are generally low to moderate. 
For example, Senegal has a prevalence of 0.5% while Kenya’s prevalence stands at 6% 
(UNAIDS 2014:6). Young women, children, sex workers, men who have sex with men 
and injection drug users have been identified as key risk groups in the HIV epidemic in 
sub-Saharan Africa.  
 
The WHO report on HIV treatment global update, impact and opportunities (WHO 
2013:[10]) notes that social behaviour, cultural practices, economics and other factors 
have been associated with the high HIV burden in sub-Saharan Africa. While 
internationally the first case of HIV was diagnosed in the early 1980s, in Namibia the first 
case was only reported in 1986 (Ministry of Health and Social Services (MoHSS) 2009:2). 
Since 1992, the MoHSS has conducted National HIV Sentinel Survey (NHSS) every 
second year among pregnant women seeking antenatal care services at the primary 
healthcare clinics (MoHSS 2014b:5). This data has been used by the MoHSS in 
approximating the HIV trends in Namibia. As observed from this data, Namibia has 
unfortunately become one of the countries with a high HIV prevalence in the world with 
13.1% of the adult population living with HIV in 2013 (MoHSS 2014b:3). The 2014 NHSS 
report describes  Namibia as a high, generalised and mature HIV prevalence country 
(MoHSS 2014b:5).  
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HIV is assumed to be primarily transmitted through heterosexual and mother-to-child 
transmission. It was estimated that over 234,508 people above the age of 15 years were 
living with HIV in Namibia in 2014. The same report notes that, the Government of the 
Republic of Namibia (GRN) has mounted an aggressive and tireless campaign against 
HIV and AIDS disease comprising of: surveillance, prevention, treatment, care and 
support, and impact mitigation. In the financial year 2013/14, from the total expenditure 
on all HIV programmes in Namibia, the GRN contributed the biggest and most remarkable 
portion of 64.0%. The remaining 36% was from other non-governmental partners 
including the President’s Emergency Plan for AIDS Relief (PEPFAR), Global Fund and 
other international and national organisations (MoHSS 2013b:4). 
 
The Namibia National Health Policy Framework 2010-2020 (MoHSS 2009:6) states that 
HIV/AIDS is Namibia’s major health problem and the nation’s number one health priority. 
As stipulated in the National Policy on HIV/AIDS (MoHSS 2007:2), the ministry  is offering 
continuum of HIV care to people living with HIV and their families, which is a 
comprehensive package of HIV prevention, diagnosis,  treatment and support services. 
HIV treatment can dramatically extend the lifespan of people living with HIV and 
effectively prevent HIV transmission (UNAIDS 2014:2).  Namibia’s anti retro-viral therapy 
(ART) roll out has been very successful, achieving more than 84% coverage against a 
national target of 90% (MoHSS 2014a:3). Key drivers of this succes has been centered 
on government commitment and collaborations with partners. According to the 2014 sero-
sentinal survey, the district in which the study was conducted had an HIV prevalence of 
10.6% (MoHSS 2014b:16). 
 
However, dispite the successful role out in Namibia, patients oftenly failed to meet the 
level of adherence required for successful ART. The challenge of non-adherence to ART 
treatment has also been noted at the study site. The importance of adherence in HIV 
treatment cannot be over-emphasised as the consequences of non-adherence to ARV 
treatment can be dire. In a study done in Nigeria, Uzochukwu, Onmujekwe, Onoka, Okoli, 
Uguru and Chukwuogo (2009:189) warn that outcomes of non-adherence to ARV 
medication include viral resistance, treatment failure, toxicities and waste of financial 
resources. As such, it is recommended that policy makers and programme managers 
need to address the factors responsible for non-adherence when scaling up subsidised 
ARV treatment programmes.  
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Ehlers and Tshisuyi (2015:[1]) reported that  there was a strong correlation between 
adherence and clinical outcomes. Therefore, there is need for healthcare workers to do 
in-depth analysis of factors influencing adherence if they intent to improve the ART 
adherence of their patients. Gill, Hamer, Simon, Theo and Sabin (2005:1243) proposed  
that given the large number of patients whose HIV infection will progress to AIDS if 
adherence is suboptimal, research is urgently needed to determine factors influencing 
adherence so that the most effective interventions to ensure adherence in African cohorts 
can be employed. Henceforth this study envisaged to identify factors associated with non-
adherence to ARV treatment in adult patients in a hospital in Namibia.  
 
 
Figure 1.1 Political map of Namibia 
(Source: Ministry of Health and Social Services 2015) 
 
Namibia has a surface area of approximately 824,116 square kilometres. With a 
population of 2.1 million the country  has the second lowest population density in the 
world at 2.5 inhabitants per square kilometre (Namibia Statistics Agency (NSA) 2013:3). 
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The nation is divided into 14 administrative regions where health services are delivered. 
The regions vary in population density,and are higher in the northern parts of the country 
(NSA 2013:3). The Namibia Demographic and Health Survey (MoHSS 2013a:2) states 
that Namibia is  ranked as a middle income country and has one of the most skewed 
distributions of income per capita in the world. The economy is largely dependent on 
mining, fishery, large-scale farming and high-end tourism. Namibia’s average spending 
on the health sector is above that of most countries in sub-Saharan Africa and some 
middle income countries. According to the report on “Namibia AIDS Response progress”, 
Namibia spends more than 6% of her gross domestic product (GDP) on health (MoHSS 
2013c:11).   
 
The study site was a district hospital in southern Namibia. It lies 500 km south of the 
capital Windhoek along the B1 route to South Africa. It is located in Keetmanshoop, the 
regional capital of the //Kharas Region, which has a population of approximately 36002 
people of whom 54% is urban population (NSA 2013:3). Majority of the inhabitants are 
Nama-Damara speaking people while other tribes from the north of the country have  
migrated to the district for various economic opportunities. Economic activities are 
centred on small livestock farming, agricultural activities at Naute Dam and the Neckartal 
Dam construction project. The Nama-Karoo vegetation around the study site supports 
goat and sheep husbandry but little crop farming is done due to erratic rainfall (NSA 
2013:6).  The construction of the Neckartal dam along Fish River 70 km outside the town 
has been the most significant contributor of migration into the district. Upon its completion 
this dam will be the largest in-land dam in Namibia and it is anticipated to boost and 
transform the economic landscape of the district. The MoHSS provides health services 
to the district through one district hospital, 2 health centres and five clinics. 
 
1.2 BACKGROUND INFORMATION 
 
Although there has been a general increase in access to HIV treatment and care across 
some African countries including Namibia, adherence to the medicines remains a 
challenge. Ehlers and Tshisuyi (2015:[1]) highlight that as ART is becoming increasingly 
available in developing countries, adherence challenges calls for even greater attention. 
 
In a Chinese study, Muessig, McLaughlin, Nie, Cai, Zheng, Yang and Tucker (2014:988) 
reported an 18.9% non-adherence rate among the study respondents. Reda and 
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Biadigilin (2012:4) are of the opinion that African HIV/AIDS patients have similar if not 
higher adherence levels compared to those of developed countries. Non-adherence is 
closely associated with treatment failure and AIDS related deaths even when the patient 
is on ARV treatment.  It is in this view that the Namibia ART guidelines (MoHSS 2014a:14) 
recommends that there should be on-going attention and reinforcement of adherence 
throughout the entire course of ART for a successful HIV programme. 
 
WHO (2003:[27]) classifies factors influencing patient adherence into socioeconomic 
factors, treatment related factors, patient-related factors, disease related factors and 
healthcare delivery system related factors. Concerning patient related factors Nuwagaba-
Biribonwoha, Pals, Kidder, Carpenter, Katuta, DeLuca, Bupamba, Maokola and 
Bachanas (2014:[123]) noted that patient characteristics associated with non-adherence 
include alcohol use, depressive symptoms, and younger age. Commenting on system 
related factors such as health facility operating hours and availability of ARV medicines 
in pharmacies, Wasti, Van Teijlingen, Simkhada, Randall, Baxter and Kirkpatrick 
(2012:75) highlighted that stock out of medicines  was a common reason for missing ARV 
medications resulting in patient non-adherence to ART. Patient-healthcare worker 
relationships have also been listed among factors influencing patient ability to take ARV 
medicines as agreed with clinicians (Abdissa 2013:120). De and Dalui (2012:251) report 
that bad attitude of healthcare workers was associated with patient non-adherence to 
ART. WHO (2003:]27]) also classified some of the factors as being related to the HIV 
disease itself. Kranzer, Lewis, Ford, Zeinecker, Orrell, Lawn, Bekker and Wood (2010:17) 
reported that previous illnesses or having other health conditions were positively 
associated with good adherence. Culture has also been observed to play a major role on 
peoples’ beliefs and view towards medical interventions (Tomori, Kennedy, Brahmbhartt, 
Wagman, Mbwando, Likindikoki & Kerrigan 2014:907). 
 
1.3 THE SOURCE TO THE RESEARCH PROBLEM 
 
Literature suggests several factors that could be associated with non-adherence to 
Antiretroviral treatment. Factors auch as long distances to health facilities, alcohol abuse, 
poverty and low educational level may predispose patients to non-adherence and these 
appeared to be influential in the study setting (Tabatabai, Namakhoma, Tweya, Phiri, 
Schnitzler & Neuhann and Glob Health Action 2014:[6]). //Kharas region in which the 
study site is located is the least densely populated region in Namibia with a density of 0.5 
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people per square kilometre (NSA 2013:32). The generally arid conditions experienced 
in the region and the lack of industrial activity have been linked with poverty in the district. 
The education status of the population is rather low when compared with other districts 
in the country. With such a high level of non-adherence, such as observed from the study 
site at 47%, the challenge of non-adherence to ARV treatment calls for more detailed 
asssessment in order to promote adhrence and improve health outcomes in the HIV 
programme. The high rates of non-adherence to ARVs at this site was a major factor in 
influencing choice of site for this research study. 
 
The clinic opens Monday to Friday every week 8-5 pm and it closes during 1-2 pm for 
lunch. Patients return to the clinic at varying intervals depending on discretion of the 
professional nurse or doctor as assessed by the adherence and clinical condition of the 
individual patient. The predominant return follow-up is usually 30 days with the maximum  
being 90 days. At every visit the patient is reviewed by a professional nurse and if required 
is referred to the doctor. After being reviewed during the follow up visits, patients collect 
their ARVs from the pharmacy which are dispensed by pharmacy professionals, either a 
pharmacist or pharmacist assistant. 
 
 According to  the EPMS. in January 2015 the study site  had 1289 adults receiving ARV 
medicines. On average,  the clinic serves about 250 to 400 patients in a month.  Table 
1.1. below shows the distrubution of patients at the study site according to adherence 
scores as observed from the EPMS during the period October to December 2014. A total 
of 933 patients received follow-up care at the study site. Of these patients 53% (n=530) 
achieved required adherence scores of more than or equal to 95% while approximately 
47% (n=403) were assessed as non-adherent during the healthcare workers adherence 
assessment. 
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Table 1.1 Distribution of patients at the study site according to adherence 
scores (Data from the study site electronic monitoring system (EPMS) 
January 2015) 
 
Month  
Adult patients adherence assessment scores 
Good (>95%) Fair (75-95%) Poor (<75%) 
October 156 75 20 
November 235 118 40 
December  139 102 48 
Quarter(Oct-Dec 2014) 530  295 108 
 
1.4 STATEMENT OF THE RESEARCH PROBLEM 
 
The GRN through the MoHSS provides free HIV care services including the ARVs. 
However, it is of concern that a recognisable number of patients do not take their 
medicines as prescribed by healthcare professionals. Although most patients attend their 
scheduled follow-up dates, a significant number were found not to be taking their ARVs 
as per their agreement with healthcare workers. At every follow-up visit the patient 
adherence is assessed by healthcare workers using the pill count method and verbal 
discussion with the patient. Based on the remaining pill count adherence assessment is 
calculated as medicines taken as a fraction of dispensed medicines. Namibia adopted 
the recommendations of WHO 2004 where good adherence is above 95%, fair is 85-95%, 
and poor is less than 85%.  Patient immunological markers like CD4 and viral load as 
reported in the patient records supplement this data on adherence assessment.  The 
individual patient adherence assessment scores are captured manually in the patient care 
booklet (PCB) and electronically in the electronic patient monitoring system (EPMS). As 
noted above in the last quarter of year 2014, the study site had a non-adherence rate of 
47%. The challenge of non-adherence to ARV treatment calls for attention if the HIV 
programme is to be successful. Studies have shown a correlation between higher levels 
of adherence and improved virological and clinical outcomes (MoHSS 2014a:15), while 
non-adherence to ARVs have been highly associated with poor ARV treatment outcomes, 
resistance and HIV related deaths (Okoronkwo, Okeke, Chinweuba & Iheanacho 
2013:[2]). 
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1.5 AIM OF THE STUDY 
 
The purpose and objectives of this study were as stipulated below.  
 
1.5.1 Research purpose 
 
The aim of this study was to minimize non-adherence to antiretroviral (ARV) treatment 
amongst HIV/AIDS adult patients at a hospital in Namibia thereby promoting successful 
outcomes in patients on ARV treatment. 
 
1.5.2 Research objectives 
 
The following objectives guided this study: 
 
 To identify non-adhering patients from the clinical visits and EPMS and confirm 
with patient care booklet in a hospital in Namibia. 
 To determine the factors associated with non-adherence in adult patients to ARV 
treatment. 
 To recommend to stakeholders methods to facilitate adherence in patients on 
ARVs. 
 
1.6 SIGNIFICANCE OF THE STUDY 
 
Determining the factors associated with non-adherence of patients to ARV medicines will 
assist healthcare workers in anticipating non-adherence and assist at promoting 
adherence for patients living with HIV. This information is of assistance to MoHSS in 
policy making and reviewing guidelines of HIV management. Home based care 
organisations taking care of HIV patients, non-governmental organisations (NGOs) and 
other partners working in the fight against HIV especially at the site of study will bethe  
beneficiaries of findings of this study. 
 
1.7 DEFINITIONS OF TERMS 
 
The following terms were used frequently in this study: 
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1.7.1 Adherence assessment 
 
The World Health Organization (WHO) describes adherence assessment as a state of 
the art measurement on the extent to which a person’s behaviour, taking medication, 
following a diet and or executing a lifestyle changes, corresponds with agreed 
recommendations from a healthcare provider (WHO 2003:[17]). This measurement may 
be based on subjective, objective or biochemical data.  
 
1.7.2 Adherence to antiretroviral therapy 
 
Adherence is the fact of behaving according to a particular rule or following a particular 
set of beliefs or fixed way of doing (Oxford Advanced Learner’s Dictionary of current 
English 2010, sv “adherence”). Reda and Biadgilign (2012:148) define adherence as 
taking medications or interventions correctly according to prescription. Sahay, Reddy and 
Dhayarkar (2011:836) comment that, “adherence is a patient's ability to follow a treatment 
plan, take medications at prescribed times and frequencies, and follow restrictions 
regarding food and other medications.” Adherence includes several operational subunits 
of definition. For example, adherence to dosage means number of pills taken as 
prescribed, adherence to schedule means taking pills consistently on time and finally 
dietary adherence is taking pills as prescribed with/ after/ or before meals (Sahay et al 
2011:836).  
 
1.7.3 Adult  
 
An adult is a fully grown person who is legally responsible for their actions(Oxford 
Advanced Learner’s Dictionary of current English 2010, sv “adult”). According to the 
Constitution of the Republic of Namibia, any persons 18 years or older can make their 
own decision individually as an adult (Ministry of Regional and Local Government and 
Housing 2002:13). In this research an adult is a person 21 years or older as he/she can 
make a consent to be a respondent in the research on his/her own. 
 
1.7.4 AIDS 
 
Acquired immunodeficiency syndrome (AIDS) is a term which applies to the most 
advanced stages of HIV infection. It is defined by the occurrence of any of more than 20 
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opportunistic infections or HIV-related cancers (WHO 2016b:[1]). The Centre for Disease 
control (CDC) defines AIDS as when the immune system of a person with HIV infection 
becomes severely compromised measured by CD4 count  or person becomes ill with an 
opportunistic infection (CDC 2015:2). 
 
1.7.5 ARVs  
 
Anti-retroviral medications (ARVs) are medications used to treat HIV. They fight HIV by 
stopping or interfering with the reproduction of the virus in the body, reducing the amount 
of virus in the body. There are different classes of ARVs and they act at different stages 
of the HIV life cycle (WHO 2016b:[3]). 
 
1.7.6 Health Belief Model  
 
A conceptual framework that describes a person’s health behaviour as an expression of 
the health beliefs. The model was designed to predict a person’s health behaviour, 
including the use of health services and to justify intervention to alter maladaptive health 
behaviour (Mosby’s Dictionary of Medicine, Nursing and Health Professions 2013, sv 
“Health Belief Model”). 
 
1.7.7 HIV 
 
Human immuno-deficiency virus is a viral infection which infects cells of the immune 
system, destroying or impairing their function (WHO 2016b:[1]).  
 
1.8 THEORETICAL FOUNDATIONS OF THE STUDY 
 
1.8.1 Research paradigm 
 
A paradigm is a world view, a general perspectives on the complexities of the world (Polit 
& Beck 2012:11). This study adopted the positivism paradigm. Polit and Beck (2012:12) 
describe the assumption of positivism paradigm also known as logical positivism as being 
that reality out there that can be studied and known. The ontologic assumption was that 
the real world of an HIV patient on ARV treatment has natural causes of how a patient 
takes his/her ARV treatment and those causes or factors are ensuing effects including 
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non-adherence and the outcomes of non-adherence thereafter. The epistemologic 
assumption of the research was that the principal investigator and the data collectors 
were independent  from the patients who became respondents. The data collectors had 
no influence upon respondents either in their choice to participate in the research or in 
the responses they would give. Realibility and validity of the data collection instrument 
was rigorously ensured because the axiologic assumption was to see objectivity in the 
study and avoid biases. The methodologic question persues to collect evidence using 
scientific methods. The researcher focused on objective and quantifiable data, therefore 
data could be presented  numerically. The sample was large enough and representative 
of patients attending the study site. The researcher was purely external without influence 
and used statistical analysis to make generalisations of the research results. In summary, 
the positivist paradigm used in this research assumed that when adults on ARVs are non-
adherent to their medicines there are factors which are influencing such a phenomena, 
and that it is not haphazard. The assumption of this study was that there are factors 
associated with non-adherence in adult patients on ARVs and these factors can be 
studied and be known.  
 
Polit and Beck (2012:13) highlight the following assumptions of the positivist paradigm 
which  this study also adopted: 
 
 There is a real natural world driven by real natural causes and ensuing effects. 
 The researcher is independent from those being researched, and findings will not 
be influenced by the researcher. 
 Seek objectivity hence forth need to rule out biases. 
 Theory has to be verified. 
 Concepts  should be specific and discreet. 
 There is a specific design. 
 Information should be quantifiable, able to be analysed. 
 Generalisations can be made on the findings. 
 
1.8.2 Theoretical framework 
 
A framework is the overall conceptual underpinnings of a study (Polit & Beck 2012:128). 
Miller and Hays (2000:177) point out that several conceptual frameworks have been 
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created to help understand and study adherence. Several social theories of health 
behaviour including the Health Belief Model (HBM) among others have been used to 
investigate adherence determinants. The HBM shown in Figure 1.2 below  was the theory 
of choice in this study due to its applicability to patient adherence and preventative health 
practices (Polit & Beck 2012:136). 
 
1.8.2.1 The Health Belief Model  
 
 
Figure 1.2 Health Belief Model 
 
(Source: Eller 2009:20) 
 
According to Smeltzer, Bare, Hinkle and Cheever (2010:50), the HBM was developed by 
Becker and colleagues in 1974. Smeltzer et al (2010:50) describe the four variables of 
the HBM as folows: 
 
 First variable is demographic and disease factors including patient characteristics 
such as gender, age, level of education, employment status severity of disease 
and duration of illness.  
 Second variable is barriers which are factors that leading to absence or difficulty 
in accessing the health aspect. Barriers to ART treatment adherence could include 
transport costs, side effects, lack of understanding among others.  
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 Resources is the third variable. These are factors enhancing the health behaviour 
for example family support in taking ART treatment could enhance adherence.  
 Fourth and last variable is the perceptual factors. These consists of how the person 
views his or her health status, self-efficacy and perceived demands of the illness. 
 
Alternatively Polit and Beck (2012:136) outline the four major components of HBM as 
follows: 
 
1.8.2.1.1 Perceived susceptibility  
 
This refers to how a person perceive himself or herself as being in danger of a health 
problem. In this study these were the perceptions of the HIV positive patient that the 
problem of the infection is relevant to him or her and trusts that the HIV diagnosis is 
correct. The assumption of the study was that patients whose perception of  their 
suspetibility of HIV disease progression to AIDS maybe suboptimal therefore leading to 
non-adherence to ARV treatment  
 
1.8.2.1.2 Perceived severity  
 
This construct focusses on how serious does the individal feel the health problem is. For 
this research it refered to the personal views of the HIV positive adult that the HIV 
diagnosis is a serious diagnosis with severe implications to health therefore requires 
appropriate action like adhereing to medicines. This concept have a direct bearing on 
how the patient will adhere to the ARV treatment. The lower the perception of severity the 
higher the non-adherence to ARV treatment. 
 
1.8.2.1.3  Perceived benefits and costs 
 
This component of the HBM focuses on the individual patient’s belief in a health behavior 
in this study meaning  ART treatment will treat the HIV infection. The individual patient 
needs to believe  that adherence to ART would reduce susceptibility to HIV disease 
progression and severity. This was the basis for questions in the questionnaire which 
inquired about how essential ART was to the individual patient. The perceived costs 
shows that theindividual’s belief that the materials, physical and psychological costs of 
adhering to ART are all outweighed the benefits. Related costs in adhering to ART 
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treatment includes transport costs to treatment facility, disclosure and lifestyle changes 
to accommodate living positively with the HIV infection.  
 
1.8.2.1.4 Motivation  
 
This is the willingness to comply to a health behavior in this study it meant to comply with 
ART treatment requirements. This component stresses that even if all components are in 
place, an individual needs motivation to take ARVs as prescribed is necessary, absence 
of which non-adherence to treatment sets in. This is influenced by availability of cocial 
support e.g. family members. 
 
1.8.2.1.5 Enabling or modifying factors 
 
Under this component the study was investigating variables that could be influencing 
adults not to adhere to ART. The modifying factors include patient satisfaction  and 
sociodemographic factors (Polit & Beck 2012:136). Therefore the data collection tool of 
the study inquired on how much respondents were satisfied with the healthcare workers 
and  convinience of the  clinic. Sociodemographic characteristics including gender, age 
religion and employement were also investigated as they were potential modifying 
characteristics.  
 
To further understand modifying and enabling factors for patient adherence to ART 
treatment, this research persued to understand factors associated with non-adherence. 
In this regard, Joubert and Ehrlich (2007:56) reported that David Werner a community 
development theorist and health activist believed that in order to have a critical 
understanding of health problems, a problem analysis tool like the “why” game should be 
used to determine contributing factors. According to the Werner problem analysis tool, 
factors related to any health problem can be classified under environmental factors, 
service related, disease related, socio-economic, cultural/religious and political factors. 
WHO (2003:[27]) states that the different dimensions affecting ARV treatment adherence 
are health system, condition-related factors, therapy-related factors, socioeconomic and 
patient-related factors. These agree with Chesney (2000:S173) who states that the 
principal factors associated with non-adherence appear to be the system of care, patient 
related, while other factors are inconvenient dosing frequency, dietary restrictions, pill 
burden and side effects and patient-healthcare provider relationships. Ehlers and 
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Tshisuyi (2015:[4]) re-iterate that barriers to adherence includes forgetfulness, 
transportation costs, loss of income due to absence from work during clinic visits. In a 
study conducted by Uzochukwu et al (2009:189) in Nigeria, they reported that reasons 
for non-adherence included physical discomfort (side effects); clinics out of stock of 
ARVs; forgetfulness and fear of social rejection among many other reasons. 
 
The researcher adopted the HBM  theory and used the Werner problem analysis tool to 
understand factors associated with non-adherence to ARV treatment in adults attending 
the study site. The framework had the following structure: patient related, system related, 
disease and treatment related, cultural and religious beliefs related factors that influence 
adherence to HIV treatment. These subtopics guided this research. 
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Figure 1.3 Conceptual framework of the study: factors associated with high rate 
of non-adherence to ARV treatment in adults 
(Source: Joubert & Ehrlich 2007:58) 
Diseases and treatment 
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1.9 RESEARCH DESIGN AND METHOD 
 
A quantitative descriptive study was conducted. This research design and method was 
explained in greater detail  in chapter three of this dessertation. 
 
1.10 SCOPE AND LIMITATION OF THE STUDY 
 
The study respondents were drawn from only one site at a hospital in Namibia. 
 
1.11 STRUCTURE OF THE DISSERTATION 
 
This dissertation consisted of five chapters. Each chapter had an introduction, body and 
conclusion. The chapters were outlined as follows: 
 
Chapter 1: Orientation of the study 
 
Aimed at giving the reader a comprehensive but brief overview of the dissertation. It 
highlighted on HIV at global, regional and country level. It also outlined the research 
problem, purpose, objectives, significance of the study, scope of study, theoretical 
grounding of the study, research design and method, and ethical considerations. 
 
Chapter 2: Literature review 
 
This chapter reviewed literature on the concepts of adherence and non-adherence to 
ARVs, adherence assessment and effects of non-adherence. Focus on non-adherence 
to ARVs globally, regionally, in Namibia and at study site was discussed. Detailed 
information about demographic factors, patient related factors, cultural and religious and 
health delivery system factors associated with non-adherence were discussed.  
 
Chapter 3: Research design and methodology 
 
The third chapter of this dissertation explained in detail the study design and data 
collection of the study. A thorough explanation of sampling methods and data collection 
for this study made up this chapter. 
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Chapter 4: Analysis presentation and description of the research findings 
 
The fourth chapter presents the study findings, analysis using statistical methods and 
summarised the findings.  
 
Chapter 5: Conclusions and recommendations 
 
The final chapter reported on conclusions and recommendations made from the study. 
 
1.12 CONCLUSION 
 
This chapter outlined a summarised insight into the study. It introduced the research 
problem, highlighted on the conceptual framework which was used in this study, the study 
design, and ethical considerations which were considered in this study.  
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
The second chapter of the study focussed on the literature that was accessed,reviewed 
and used by the researcher in this study. Aveyard (2010:5) defined literature review as a 
comprehensive study and interpretation of information which is associated with a 
particular topic. The researcher had a research question and undertook a thorough 
search of literature and analysed it. The key terms in this research were factors, non-
adherence and Anti-retroviral treatment. The aim of this chapter was to acquaint the 
reader on the work that has already been done in the area of non-adherence to HIV 
treatment. The literature review focussed on the period 2000–2016. 
 
2.2 THE HIV/AIDS DISEASE  
 
Engelkirk and Duben-Engelkirk (2015:318) describe HIV as a retrovirus which  means its 
genetic material changed from ribonucleic acid (RNA) into deoxyribonucleic acid (DNA) 
in order to replicate. The HIV virus targets the langerhans cells of foreskin and anogenital 
region, the CD4 lymphocytes (T-Helper cells), macrophages, monocytes  and glial cells. 
There are two types of HIV causing similar illnesses and driving the pandemic 
worldwide.HIV 1 is found worldwide and it is the main cause of the worldwide pandemic. 
HIV 2 is mainly found in West Africa, Mozambique and Angola. HIV 2 is less efficiently 
transmissible and rarely causes mother to child  transmission. It is also less aggressive 
with slower disease progression then HIV 1 and some ARV medicines are ineffective to 
the HIV 2 (Engelkirk & Duben-Engelkirk 2015:318).  
 
The Namibia Institute of Pathology (NIP) confirmed that the predominant strain found in 
Namibia is HIV-1 type C (MoHSS 2012:9). This is quite unfortunate because this HIV 1 
type C is known to be the most virulent subtype with higher multiplication rates and it is 
associated with faster disease progression in adults (MoHSS 2014c:8).  According to the 
Namibia 2014 sero-sentinel survey, 16.8% of the pregnant women attending anti-natal 
care at primary health clinics were HIV positive which shows that the HIV prevalence in 
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Namibia is high (MoHSS 2014b:3). The WHO report on HIV treatment global update, 
impact and opportunities (WHO 2013:[10]), noted that  the social behaviour, cultural 
practices, economics and other factors have been associated with the high HIV burden 
in the sub-Saharan African region including Namibia. The social behaviour and cultural 
practices include people generally lacking correct and consistent use of  condoms, 
inability to negotiate condom use, multiple and concurrent partnerships, high work-related 
migration and low rate of male circumcision.  
 
Economical factors believed to fuel the HIV disease are poverty in most of the low to 
medium countries, poor access to HIV related information on prevention and care, women 
of generally frail economic status and cross generational sexual relationships also known 
as the “sugar-daddy” phenomenon. Of note in Namibia is the virological factor as the HIV 
sub-type C has contributed to high prevalence in sub-Saharan Africa (WHO 2013:[10]). 
This sub-type is the most virulent and prevalent subtype of the HIV virus.Other factors 
associated with the high HIV prevalence in sub-Saharan Africa is that countries generally 
had delayed response towards the HIV pandemic and the high prevalence of ulcerative 
Sexually transmitted illnesses (STI) which fuels the HIV disease. Increased alcohol and 
substance abuse have also been linked to the high HIV burden. It has also been 
documented that in sub-Saharan Africa men preferring and sometimes even demanding 
dry sex increased the risk of HIV transmission (WHO 2013:[10]). 
 
2.3 HIV/AIDS TREATMENT 
 
Anti-retroviral medications (ARVs) are medications used to treat Human Immuno-
deficiency Virus (HIV). These medicines which suppress HIV replication are often called 
highly active antiretroviral therapy abbreviated “HAART”. There are different classes of 
ARVs and they act at different stages of the HIV life cycle (WHO 2016b:[1]). Each class 
works at a different stage of the life cycle of the HIV infection. Standard antiretroviral 
therapy (ART) consists of a combination of antiretroviral (ARV) drugs used to maximally 
suppress the HIV virus and stop the progression of HIV disease ti AIDS (WHO 2016b:[1]). 
 
The Namibia ART guideline (MoHSS 2014a:16) explains that there are six classes of 
antiretroviral medicines. There are nucleoside/nucleotide reverse transcriptase inhibitors 
(NRTIs) which are medications that inhibit the transcription of viral RNA into DNA, which 
is necessary for reproduction of the virus.  Examples are Tenofovir (TDF), Zidovudine 
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(AZT), Lamivudine (3TC), Abacavir (ABC) and Emtricitabine (FTC).  Non-nucleoside 
Reverse Transcriptase Inhibitors (NNRTIs) are another class which is chemically different 
that of NRTIs, but also inhibit transcription of viral RNA into DNA. Examples of medicines 
from this class are Nevirapine (NVP) and Efavirenz (EFV). A third class are the Protease 
Inhibitors (PIs). These medications act on the viral enzyme that cuts long chains of virally 
produced amino acids into smaller proteins. Class examples are Lopinavir (LPV), 
Indinavir (IDV), Saquinavir (SQV), ritonavir (RTV). There are also the  Integrase Strand 
Transfer Inhibitors (ISTIs) which prevent the newly synthesised viral DNA from being 
integrated into the host cell DNA. This class includes two medicines: Raltegravir (RAL) 
and Dolutegravir (DTG). A fifth class is that of the Entry Inhibitors, which consist of one 
CCR5 co-receptor antagonist which prevents the HIV virus from attaching to the host cell 
CD4 co-receptor CCR5. An example is  Maraviroc (MVR). The last class is called the 
Fusion Inhibitors, which block the HIV virus from being able to merge with the host CD4 
cell after binding (MoHSS 2014a:16). The only currently available fusion inhibitor is 
Enfuvirtide (ENF).  
 
2.4 ELIGIBILITY CRITERIA FOR STARTING ANTIRETROVIRAL TREATMENT IN 
NAMIBIA 
 
In Namibia before ARV treatment is initiated, HIV positive patients are assessed for 
eligibility to start the treatment. WHO (2007:[12]) classifies HIV-associated clinical 
disease as stage 1 (asymptomatic), stage 2 (mild symptoms), stage 3 (advanced 
symptoms) and stage 4 (severe symptoms) WHO. In Namibia clinicians are guided in 
initiating anti-retroviral treatment by the Namibian ART guideline. Persons falling in the 
following criteria are eligible to be initiated on ART (MoHSS 2014a:13): 
 
 CD4 count of less than 500 cells/mm3 regardless of WHO clinical stage. 
 WHO clinical stage 3 or 4 regardless of CD4 count. 
 All pregnant and breastfeeding women regardless of CD4 count or WHO clinical 
stage. 
 HIV-hepatitis B co-infection regardless of CD4 count or WHO clinical stage. 
 All HIV positive individuals in a sero-discordant sexual relationship regardless of 
CD4 count or WHO clinical stage so as to reduce the risk of HIV transmission to 
the negative partner. 
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 HIV positive sero-concordant couples currently intending to conceive a child, 
initiate ART in both partners regardless of CD4 count or WHO clinical stage. 
 All children less than 15 years of age regardless of CD4 count or WHO clinical 
stage. 
 
2.5 ART REGIMENS 
 
Recommended ART regimens consist of a combination of two or three NRTIs plus a 
NNRTI or PI (MoHSS 2014a:17). Namibia recommends three different lines of ARVs; 1st 
line, 2nd line and 3rd line. As shown in table 2.1 below, the current prefered 1st line 
regimen in Namibia is a once daily tablet containing 3 ARVs, that is two NRTIs, Tenofovir 
(TDF) and Emtricitabine (FTC), as well as one NNRTI which is Efavirenz (EFV). Due to 
side effects of EFV on the central nervous system it is advised for this once daily tablet 
to be taken at night and not during the day. There are alternative regimens to the prefered 
first line depending on the individual patient and contraindication. Second line regimens 
are selected medicines combined together for use where the first line of ARVs is found to 
be ineffective or failing. 
 
As shown in table 2.1 below, the current Namibian guideline recommends 
AZT1/TDF/3TC/LPV/r as a standard second line ARV treatment. However, if the patient 
has Hepatitis B co-infection the dose of Ritonavir is boosted from 100mg to 400mg. The 
third line regimens are ARVs used where ARV treatment failure happens while patient is 
on second line treatment. The guideline recommends that the medical practitiner  
prescribes such ARVs under the guidance and consultation of an HIV specialist. 
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Table 2.1 Namibia recommended 1st line regimen 
 
(Source: MoHSS 2014a:17) 
 
Patients who fail on the recommended regimens are evaluated for treatment failure.  
Figure 2.1 below of the Namibia ART guideline recommends that healthcare workers 
should do intensive counselling and rule out non-adherence before concluding treatment 
failure. Any viral load of above 1000 copies/mm3 is considered treatment failure as long 
as it is confirmed that the patient is adherent to the ARV medicines. Patients who are 
confirmed to have failed on first line regimen 1 are initiated on second line regimens as 
indicated in Table 2.2 that follows after the figure 2.1 below. 
 
1st line ART 
Preferred 1st line 
Regimens 
Alternative 1st line 
Regimens 
Adults (including adolescents ≥ 
10 years old and weigh at least 
35 kg), pregnant and 
breastfeeding women, adults with 
TB disease and adults with HBV 
co-infection 
TDF + FTC (or 3TC) + 
EFV 
(once daily FDC) 
AZT + 3TC + EFV 
AZT + 3TC + NVP 
TDF + FTC (or 3TC) + NVP 
ABC + 3TC + EFV (or NVP) 
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Figure 2.1 Algorithm for evaluating suspected ARV treatment failure 
(Source: MoHSS 2014a:20) 
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Table 2.2 Namibia recommended 2nd line ART regimen 
 
Target population Regimen Remarks 
HIV positive adults  
AZT/TDF/3TC/LPV/r  
Where standard first line regimens 
were used  
HIV positive pregnant and 
breastfeeding women  
HIV/HBV co-infection  
HIV/TB co-infection  AZT/TDF/3TC/LPV/RV Increase dose of RTV: i.e., LPV/r 
400mg/400mg 
(Source: MoHSS 2014a:17) 
 
2.6 ACCESS TO ANTIRETROVIRAL THERAPY 
 
By 2010 the estimated global coverage of antiretroviral therapy in low and middle income 
countries still remained less than 50% (WHO/UNAIDS/UNICEF 2011:90). 
 
2.6.1 Access to antiretroviral therapy globally 
 
The global coverage of antiretroviral therapy reached 46% at the end of 2015 UNIADS 
(2016:3). The same report noted that the global consensus is to achieve the 90–90–90 
treatment target by 2020. 90-90-90 means 90% of people living with HIV know their HIV 
status, 90% of the HIV-positive people are on anti-retroviral therapy and 90% of people 
on treatment have suppressed viral loads. This indicates that there is still more to be done 
to achieve this milestone. By end of 2015 about 54% of people living with HIV were still 
in need of treatment, and sadly most of them had never been tested for HIV and were 
unaware of their HIV status (UNIADS 2016:11). 
 
2.6.2 Access to antiretroviral therapy in sub-Saharan Africa 
 
There has been an increasing number of people living with HIV (PLHIV) in sub-Saharan 
Africa who are benefiting from the rapid scale-up of ARV treatment (Bezabhe, Chalmers, 
Berezniki, Peterson, Bimirew & Kassie 2014:[1]). It is reported that Botswana, Eritrea, 
Kenya, Malawi, Mozambique, Rwanda, South Africa, Swaziland, Uganda, the United 
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Republic of Tanzania, Zambia and Zimbabwe all increased treatment coverage by more 
than 25 percentage points between 2010 and 2015 (UNIADS 2016:3). The increase in 
access to treatment have brought up a 26% decline in AIDS-related deaths. An 
outstanding example is that of South Africa where nearly 3.4 million people are on 
treatment, which is more than any other country in the world (UNIADS 2016:3). It 
therefore can be concluded that although access to ARV treatment have significantly 
increased over the past five years, there is still more work needed for patients in sub-
Saharan Africa to access ART. 
 
2.6.3 Access to antiretroviral therapy in Namibia 
 
Namibia is has been internationally commended for having one of the most successful 
HIV care programmes worldwide. In 2014, MoHSS reported that ART roll out had been 
very successful, achieving more than 84% coverage against a national target of 90% 
(MoHSS 2014a:3). The provision of ARV treatment in state health facilities in Namibia 
started in 2003 followed up by a rapid scale-up of ART services. The total number of 
people receiving ART in Namibia increased from less than 100 in 2003 to 119,000 in 
2014, approximately 60% of whom were women (MoHSS 2014b:4). The MoHSS has 
decentralised ART services to all 35 districts of the nation, currently bringing the services 
to local primary healthcare clinics through the integrated management of adult illnesses 
(IMAI). In 2012 the MoHSS in its effort to decentralise ART services it started training 
registered  nurses to initiate and manage ART through the Nurse Initiated and 
management of antiretroviral therapy (NIMART) training (MoHSS 2012:1).  
 
2.7 NON-ADHERENCE TO ANTIRETROVIRAL TREATMENT  
 
In order to address the problem of non-adherence to ART in-depth, this subsection of the 
study first described what adherence is and the importance of adherence to ARV 
medicines. Thereafter, non-adherence is defined and its consequences thereof. 
 
2.7.1 Adherence  
 
Martin, Deborah, Calabresse, Wolters, Rogby, Brennan and Wood (2009:594) defined 
adherence as a percentage of prescribed medication doses taken over a given period of 
time. This definition is supported by Ingersoll and Cohen (2008:213) who describes 
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adherence as the level at which a patient’s taking of his/her medication corresponds with 
the prescription. Sahay et al (2011:836) are of the opinion that adherence is the patient’s 
ability to follow a treatment plan, take medications at prescribed times and frequencies, 
and follow restrictions regarding food and other medications. Adherence also includes 
several operational subunits of definition. For example, adherence to dosage means 
number of pills taken as prescribed, adherence to schedule means taking pills 
consistently on time and finally dietary adherence is taking pills as prescribed with/ after/ 
or before meal (Sahay et al 2011:836). 
 
2.7.2 Importance of adherence to antiretroviral treatment 
 
Literature has sufficient evidence that medication adherence of at least 95% is required 
in order to have sustainable viral suppression and improvement to clinical outcomes 
(Beer, Heffelfinger, Frazier, Mattson, Roter, Barash, Buskin, Rime & Valverde 2012:220). 
The great success story of HIV treatment is that the average life expectancy of people 
living with HIV, with effective adherence to ARV treatment  has now been proven to be 
approaching that of the negative population (WHO 2013:[43]). The MoHSS in its 2014 
ART Guideline notes that studies have proven a correlation between higher levels of 
adherence and improved virological and clinical outcomes (MoHSS 2014a:14). 
Nuwagaba-Biribonwoha et al (2014:[123]) are of the opinion that treatment efficacy relies 
on sustained adherence. They describe the importance of adherence to ARV medicines 
as being key to reducing morbidity and mortality of HIV-positive patients and significantly 
lowering the risk of HIV transmission to uninfected partners and children. In a study in 
Zambia, good adherence to ARVs has been linked to CD4 increases while  CD4 counts 
appeared to decrease in patients who poorly adhered to their ARV treatment (Chi, 
Cantrell, Zulu, Mulenga, Levy, Tambatamba, Reid, Mwanga, Mwinga, Bulterys, Sage & 
Stringer 2009:751). 
 
2.7.3 Non-adherence 
 
There are two types of non-adherence. The first is primary non-adherence, in which 
healthcare workers write prescriptions but the medication is never initiated. This is also 
called non-fulfilment adherence (Jimmy & Jose 2011:155). Reda and Biadgilign 
(2012:149) define non-adherence as failure to take medications or interventions correctly 
according to prescription.  
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2.7.4 Consequences of non-adherence to ARV treatment 
 
The potential burden of medication non-adherence outcomes on healthcare delivery 
makes it an important public health concern (National Council on Patient Information and 
Education 2007:[24]). Non-adherence to ARVs have been highly associated with poor 
ARV treatment outcomes, resistance and HIV related deaths (Okoronkwo et al 2013:[1]). 
Because of the negative outcomes associated with non-adherence, Nuwagaba-
Biribonwoha et al (2014:[11]) warn that patients with characteristics associated to non-
adherence need to be targeted for additional adherence counselling and support. In a 
study done in Nigeria, Uzochukwu et al (2009:189) cautioned that negative outcomes of 
non-adherence to ARV medication include viral resistance, treatment failure, toxicities 
and waste of financial resources. Gill et al (2005:1243) caution that even if  on ARV 
treatment, large numbers of patients with HIV infection will progress to AIDS if their 
adherence to ARVs is suboptimal. Inadequate suppression of viral replication by ART is 
predominantly a consequence of poor adherence to medicines further causing low 
efficacy of the antiretroviral regimens and sadly viral resistance to the ARV medicines 
(Reda & Biadgilign 2012:148). 
 
2.8 ASSESSING PATIENT ADHERENCE TO ARV TREATMENT 
 
Nachega, Mills and Schechter (2010:71) are of the opinion that it is paramount to be 
aware that there have not been any gold standard methods for measuring medication 
adherence. Some are direct methods such as biological markers and others are indirect 
methods such as self-report, patient interview, pill counts, pharmacy records, 
computerised medication caps and viral load monitoring (Reda & Biadgilign 2012:149). 
All of these methods of assessing adherence have their own strengths and weaknesses 
(Jimmy & Jose 2011:157). Direct approaches are one of the most accurate methods of 
measuring adherence but are expensive. Direct measures precisely inform patient’s 
adherence.  Indirect measures are subjective and their advantage is that they can provide 
explanations for patient's non-adherence. Lam and Fresco (2015:[1]) advice that since a 
perfect measure of adherence does not exist, a multi-measure approach seems to be 
currently the most appropriate practise.  
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2.8.1 Direct or objective methods 
 
2.8.1.1 Viral load assessment 
 
The Namibia ART guideline recommends healthcare workers to take blood samples from 
patients at 6 months after starting ART for laboratory assessment. After 6 months of 
adhering to effective ART, the viral load of the patient is expected to be undetectable. 
Viral load of more than 1000 copies per ml is an indication of non-adherence and should 
be closely monitored and  warrants a clinician to start investigating for treatment failure if 
non-adherence has been ruled out (MoHSS 2014a:14). In Namibia, including at the study 
site, after 6 months of initiating ART every patient’s viral load is assessed at the National 
Institute Laboratory (NIP). The turnaround time for the viral load result from NIP to the 
site is 4 working days. 
 
2.8.2 Indirect or subjective method  
 
2.8.2.1 Self-report 
 
Self-report is a method of measuring adherence in which the patient reports the number 
of doses missed over a given period (Nghoshi 2016:8).  Various studies indicate that self-
report adherence assessment method matches well with both viral load and clinical 
outcomes. Nieuwkerk and Oort (2005:445) suggest that although self-reports often 
overestimate adherence, the advantage is that it is inexpensive and fairly accurate for 
identifying patient adherence. While discussing with patient in adherence assessment, 
self-reports also help to determine reasons why the patient missed the ARV dose(s). Of 
the available methods to assess medication adherence, self-reports are arguably the 
most practical method for day to day use in a clinic (Nghoshi 2016:55). At the study site, 
self-reports are used to supplement the pill count method of assessing adherence.  
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2.8.2.2 Pill count 
 
Pill count or refill method of assessing adherence assumes that prescription-refilling 
patterns correspond to the patient medication-taking behaviour. This assumption has 
been considered as an acceptable estimate (Barner 2010:30). In a study conducted in 
South-Eastern Lousiana on adherence to hypertensive medicines using pill count and 
self-report methods, pill count was a better indicator in cardiovascular disease than self-
reports (Krousel-Wood, Holt & Joyce et al 2015:412). A strong positive association 
reported between ARV medicine adherence of more than 95% according to pill count and 
both virologic and immunologic failure has been proved (El-Khatib, Katzenstein, Marrone, 
Laher, Mohapi, Petzold et al 2011:[3]). At the study site, healthcare workers 
predominantly used pill count supplemented by patient self-report to assess ARV 
medication adherence. This is done in a private room in the clinic  where a lay counsellor 
counts the remaining number of ARV tablets. The adherence score is then calculated as 
number of tablets taken as a fraction of dispensed ARVs. 
 
2.8.3 Electronic patient monitoring system (EPMS) 
 
Electronic prescription refill records requires a centralised computerised system along 
with a consistency among prescribers and dispensers to collect a complete dataset over 
that designated period. The disadvantage of this method is that it does not give many 
clues to the researcher or the health professionals concerning the barriers involved in the 
detected non-adherence in terms of individual patients (Krousel-Wood et al 2015:412). In 
Namibia, including at the study site, the EPMS automatically calculates the adherence of 
the patient to ARVs as it dispenses the new prescription. Other features of the EPMS is 
to report the patients who were due to come for ARV follow-up and they didn’t turn up. 
This facility is used by the healthcare workers to follow-up the patient before the patient 
becomes an ART interrupter or worse still totally defaults the ART treatment.  
 
2.9 THE PROBLEM OF NON-ADHERENCE TO ANTIRETROVIRAL THERAPY 
 
While more persons are being initiated on ART yearly across the globe not all are able to 
adhere to the medicines. Some interrupt the treatment while others stop the ART 
altogether. The challenge of ART adherence has been found to vary across countries due 
to various reasons.  
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2.9.1 Non-adherence in developed countries 
 
Globally, various studies have reported on adherence levels of patients to ARV treatment. 
Achappa, Madi, Bhaskaran, Ramapuram, Rao and Mahalingam (2013:222) in a study in 
India, report suboptimal adherence in respondents with  76% achieving the required 
adherence rate. While in Guangzhou China, a study among 721 adults on ARV treatment 
by Muessig et al (2014:988) reaveled that 18.9% reported recent non-adherence and 
6.8% reported treatment interruption. Non-adherence varies across nations with China 
approximately 20% and India with the highest non-adherence averaging 32%. 
 
2.9.2 Non-adherence in Africa  
 
Abdissa (2013:134) reported that the non-adherence rate among respondents in a study 
conducted in Ethopia was found to be 20.0%. In a study conducted across 3 African 
countries (Kenya, Tanzania and Namibia) by the Centre for Disease Control (CDC) in 
2014, they reported that concerns have been raised about suboptimal ART adherence 
among patients enrolled in HIV clinical care in Africa. In this CDC study, 14% reported 
missing ≥1 dose of ARVs in past 30 days which shows non-adherence rate of 14% 
(Nuwagaba-Biribonwoha et al 2014:[9]). This agrees with findings from a study conducted 
in Uganda by Senkomago, Guwatudde, Breda and Khoshnood (2011:1246) who 
highlighted that according to pill count adherence assessment, 13.6% of the patients were 
non-adherent. In spite of the findings highlighted above, Reda and Biadgilign (2012:148) 
maintain that against researchers’ expectations, sub-Saharan African patients were found 
to have similar or higher adherence levels as compared to those of developed countries. 
 
2.9.3 Non-adherence in Namibia 
 
As highlighted above, the study by CDC showed non-adherence rate of 14% in Namibia 
(Nuwagaba-Biribonwoha et-al 2014:[9]). A recent study in the northern parts of Namibia 
revealed a non-adherence rate of 27% measured by pill count and 30% as per patient 
self-reporting (Nghoshi 2016:ii). 
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2.9.4 Non-adherence at the study site  
 
Against the documented statistics of non-adherence rates of approximately 20% in 
developed countries, sub-Saharan Africa and even Namibian ranging from 14%-30% 
non-adherence, the study site had abnormally high levels of non-adherence. According 
to EPMS, in the quarter October to December 2014, 933 patients attended the hospital 
for their follow-up care. Of these patients 439 (47%) had an adherence score of less than 
95% which is the minimum score regarded as good adherence. This resulted in a non-
adherence level of 47% at the study site.  
 
2.10 FACTORS ASSOCIATED WITH NON-ADHERENCE TO ANTIRETROVIRAL 
THERAPY IN ADULT PATIENTS 
 
Bolsewicz, Debattista, Vallely, Whittaker and Fitzgerald (2015:1429) suggest that the 
understanding of the context around patient's use of ARV treatment  and reasons for 
treatment interruption and non-adherence remains poor consequently calling for research 
to be done in this scope. The WHO (2003:[27]) classifies the factors influencing the ability 
of a patient to take their ARVs as agreed together with healthcare workers into five 
categories. The five categories are socioeconomic factors, treatment related factors, 
patient-related factors, disease related factors and healthcare delivery system related 
factors.  
 
2.10.1 Patient-related factors  
 
Smeltzer et al (2010:50) report that the first variable of the Health Belief Model is 
Demographic factors like gender, age, level of education and employment status.  
 
Reda and Biadgilign (2012:149) report that barriers to ART adherence include factors 
related to patients and their families. Patient characteristics associated with non-
adherence include alcohol use, depressive symptoms, and younger age (Nuwagaba-
Biribonwoha et al 2014:[10]). Other personal factors like low education and living alone 
were also associated with non-adherence (Muessig et al 2014:988). Some healthcare 
workers were of the opinion that lifestyle factors, such as homelessness, substance 
abuse, lack of education, and unstable mental state are predictors of non-adherence and 
some actually go on to withhold ARV treatment  from such  patients. In a study conducted 
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in Botswana, approximately 40% of the respondents admitted missing a dose because of 
alcohol consumption (Kip, Ehlers & Van Der Wal 2009:149). Other studies have yielded 
different results on age as an influencing factor on adherence. Abdissa (2013:65) reported 
that there was no statistically significant association found between the age of 
respondents and their adherence to antiretroviral therapy. In another study in America, 
Beer et al (2012:218) reported that younger age and excessive intake of alcohol and 
related substances were associated with non-adherence. Reporting  on patient related 
factors associated with non-adherence, Gari, Doig-Acuňa, Smail, Malungo, Martin-Hilber 
and Merten (2013:1) concluded that the factors associated with non-adherence are 
similar  in both developed and developing countries. These included stigma and 
discrimination, alcohol and drug abuse, depression and low self-efficacy. One of the major 
reasons cited by patients for non-adherence was simply forgetting to take their 
medications (Gari et al 2013:4). These findings were similar to a study in Nigeria where 
49.6% of patients mentioned forgetfulness as one of the major non-intentional reasons 
for not taking their ARV treatment correctly (Adisa, Alutundu & Fakeye 2009:165). Due to 
the influence of personal factors on adherence of patients to ARV treatment, the Namibian 
ART guideline (MoHSS 2014a:14) advices healthcare workers to consider the following 
social aspects that support better adherence to treatment; such as not abusing alcohol or 
being ready to stop alcohol abuse, not having unstable psychiatric disorders and being 
committed to lifelong ART treatment with strict adherence to treatment. However, the 
same guideline points out that no patient should be denied ART services due to failure to 
meet the above stipulated considerations. 
 
2.10.1.1 Patient social support 
 
Family support very crucial in fostering adherence. Some patients lack social support 
because they have not disclosed their status to significant others. Achappa et al 
(2013:222) contend that fear of being stigmatised has been associated with non-
adherence. Li, Li, Lee, Wen, Lin, Wan and Jiraphongsa (2010:212) highlighted that poor 
family communication was associated with non-adherence. According to  Franke, Murray, 
Munoz, Hernandez-Diaz, Sebastian, Atwood, Caldas, Bayona, Shin (2011:[1483]) 
disclosing to at least one family member about one’s positive HIV status was associated 
with good adherence. The MoHSS (2014a:16) notes that it is desirable for all patients to 
have a treatment supporter. They define a treatment supporter as someone at home, in 
the community, or at the workplace, who can accompany the patient to visits and assist 
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the patient daily to adhere to ART. Notwithstanding, MoHSS comments that absence of 
a treatment supporter should not be a reason to deny treatment to a patient (MoHSS 
2014a:16). Abdissa (2013:112) reported a statistically significant association between 
availability of social support in taking ARV treatment and adherence to ARV treatment 
(P=0.023). At the study site, although not compulsory, patients are encouraged to 
disclose their HIV status to a significant person who would become their treatment 
supporter through positive living. Within the community in which the study site is locate, 
they are also support groups which support PLWHIV run by organisations such as 
Catholic AIDS Action.  
 
2.10.2 Health delivery system related factors 
 
The MoHSS recognises that the healthcare system may influence the adherence of 
patients to ARV treatment (MoHSS 2014a:10). The Namibia ART guideline recommends 
that healthcare workers need to be alert to such factors such as educating clients, proper 
dosing,  managing side effects, access to care and the patient-healthcare provider 
relationship (MoHSS 2014a:10). 
 
2.10.2.1 Health facility operating hours and ARV medicine stock outs  
 
Wasti et al (2012:75) highlight that running out of pills was a reason for missing ARV 
medications. The WHO recently conducted studies in different African settings  where it 
cited the problem of long waiting times at the health facilities as one of the major 
challenges to adherence (WHO 2016a:[25]). In Tanzania, the mean time spent at the 
clinic averaged six hours. About 50% (12/28) of the healthcare workers interviewed in 
Tanzania also noted long patient waiting times as a barrier to adherence. In Botswana, 
most respondents reported spending about four hours at the clinic to receive HIV care. In 
Uganda, the average waiting time for ARV users was about five hours in government 
facilities and one hour in private facilities.   
 
Extrapolation of these findings shows that ARV patients may need to miss one working 
day per month in order to get their HIV care. This may pose problems for some patients 
whose employers are unaware of their HIV care and to those employers who simply do 
not support the employees need for care (WHO 2016a:[25]). As with other public facilities 
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in Namibia, the study site opens weekdays, Monday to Friday from 8 am to 5 pm and is 
closed during lunch hour, 1-2 pm, public holidays and weekends.  
 
2.10.2.2 Patient-healthcare worker relationships  
 
In relationship to HIV care, Stigma Index surveys have been conducted in more than 65 
countries (UNIAIDS 2016:10). In twenty-two of these countries, more than 10% of people 
living with HIV reported they had been denied healthcare because they were HIV positive. 
In some cases,  the service rendered by healthcare workers in ART clinics was found to 
be below the expectation of patients and influences patient adherence to medicines. 
Flickinger, Saha, Moore and Beach (2013:366) reported that patients kept follow-up 
appointments better if the healthcare workers treated them with dignity and respect, 
listened carefully to them, explained in ways patient could understand, and above all 
treated them as human beings. Similar findings were recorded by Boyer, Clerc, Bonono, 
Marcellin, Bile and Ventelou (2011:1383) who noted that inadequate communication with 
healthcare workers was one of the reasons for non-adherence and treatment interruption. 
De and Dalui (2012:251) concur that bad attitude of healthcare workers was associated 
with patient non-adherence to ART. A significant relationship between perception of study 
respondents on patient-provider relationship and their adherence to antiretroviral 
treatment (t=2.551, P=0.011) was reported by Abdissa (2013:120). Mills, Nachega, 
Buchan, Orbinski, Attaran, Singh, Rachlis, Wu, Cooper, Thabane, Wilson, Guyatt and 
Bangsbe (2006:688) are of the opinion that healthcare workers need to utilise information 
on factors associated with non-adherence and engage in dialogue with patients in order 
to facilitate adherence.  
 
2.10.2.3 Access to the clinic  
 
The study site is the only one in the district serving a total population of 36001 people 
whom are scattered across the semi-arid desert area in southern Namibia. Distance to 
the health facility from patients’ homes varies from a few hundreds of metres for those 
living near the hospital to around 200km for those staying in villages and on farms.  A 
study conducted in Malawi revealed that among the reasons for interrupting ARV 
treatment by patients was transport costs to the clinic (Tabatabai et al 2014:[6]). The cost 
of accessing ARV clinics is also mentioned among reasons for interruption and non-
adherence in Addis Ababa. Biadgilign, Deribew, Amberbir, Deribe and Sahara (2009:148) 
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noted that cost and access to transportation were associated with non-adherence. 
Similarly findings were reported in Uganda by Senkomago et al (2011:1246) who 
observed  that transportation costs accounted for 7.8% of reasons why patients were non-
adherent to their ARV medicines.  In another study in Philadelphia, patients discussed 18 
barriers or facilitators to retention in care and ART adherence. Among the eleven most 
common factors that came up included co-location of services and service delivery factors 
such as access to care (Holtzman, Shea, Glanz, Jacobs, Gross, Hines, Mounzer, Samuel, 
Metlay & Yehia 2015:817). 
 
2.10.3 Disease and treatment related 
 
The WHO (2003: [27]) acknowledges that some factors influencing patients’ adherence 
are related to the HIV infection and the ARV treatment itself.  
 
2.10.3.1 Disease related  
 
The effects of the disease state of a patient on adherence could be two way. In a study 
in South Africa, Kranzer et al (2010:17) reported that previous illnesses or having other 
health conditions were positively associated with good adherence. The MoHSS also 
agrees that some patients who initiate ART with CD4 of above 350 may not feel sick and 
as such may not fully understand the consequences of non-adherence (MoHSS 
2014a:13). Therefore, they point out that healthcare workers should thoroughly counsel 
such patients beforehand. On the other hand, some patients who are too sick may lose 
hope in ARVs while still others maybe  too sick to take ARVs resulting in the patients 
being non-adherent.  
 
2.10.3.2 Treatment related 
 
Uzochukwu et al (2009:189) revealed physical discomfort from side effects of ARVs and 
non-availability of drugs at treatment sites among the reasons for non-adherence. 
Patients who had a CD4 of over 200 cells/ml, after being on ART for less than 15 months 
were found to be more non-adherent (Charurat, Oyegunle, Benjamin, Habib, Eze, Ele, 
Ibanga, Ajayi, Eng, Mondal, Gebi, Iwu, Etiebet, Abimiku, Dakum, Farley & Blatter 
2010:[3]). Abdissa (2013:98) pointed out that respondents who had changed their HIV 
  
37 
medication had suboptimal adherence as compared to those who had not changed ARV 
medication. 
 
2.10.4 Cultural and religious factors  
 
Culture is defined as values, norms, habits and ways of life characteristic of a coherent 
social group. On the other hand religion can be understood as a set of beliefs adhered to 
by the members of a community, involving symbols regarded with a sense of awe or 
wonder, together with ritual practices (Giddens & Sutton 2013:1054). These two aspects 
influence daily decisions of human beings including their views and perceptions to 
interventions such as medicines like ART.  
 
2.10.4.1 Cultural factors  
 
Beliefs of patients to ART is well-documented to have impacted on adherence. Gari et al 
(2013:7) reported that poor beliefs in the benefits of ARVs were associated with non-
adherence to ART. Some cultures do not approve of ARVs thereby influencing patients 
not to take their ARV treatment as agreed with healthcare workers. Wasti et al (2012:75) 
indicated that fear of disclosure of one’s HIV status to the community has been highly 
associated with non-adherence. Experience of discrimination among patients was also 
associated with poor adherence in low income countries (Charurat et al 2010:[5]). Culture 
plays a major role in people’s beliefs. In fact, Tomori et al (2014:907) concluded that 
numerous socio-cultural barriers inhibit retention in HIV care and  promote non-
adherence. The study site is situated in southern Namibia where the Nama culture is 
more prevalent. Cultural diversity is enhanced by migrants from the northern parts of the 
country. 
 
2.10.4.2 Religious factors 
 
In a study conducted in Nigeria by Charurat et al (2010:[6]), they reported that religion 
had influence on ability of patient to take medicines. of note was that being Muslim was 
associated with non-adherence to ARV treatment. Tomori et al (2014:907) advocate that 
healthcare workers should develop partnerships with alternative healers in order to 
reduce non-adherence due to cultural and religious beliefs. Tabatabai et al (2014:[6]) also 
reiterates that religious belief or perceived stigma were some of the factors associated 
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with non-adherence in a study in Malawi. In rural South Africa, Loeliger, Niccolai, 
Mtungwa, Moll and Shenoi (2016:982) highlight that among the  key themes  for non-
adherence included tension between ART and alternative medicine. The community in 
which their study was conducted had various religions but predominantly Christianity.  
 
2.11 CONCLUSION  
 
This chapter reviewed literature on HIV globally, in sub-Saharan Africa, Namibia and at 
the study site. Literature on ARV treatment, adherence, and implications of non-
adherence were also discussed. It concluded by focussing on factors associated with 
non-adherence to ARV treatment. The next chapter discussed the methodologies used 
in the research. 
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CHAPTER 3 
 
RESEARCH DESIGN AND METHODOLOGY 
 
3.1 INTRODUCTION 
 
The previous chapter dealt with literature reviewed related to the study. This chapter of 
the dissertation explained in detail the study design and outlined data collection of the 
study. Description of sampling and data collection methods are well-defined including 
ethical considerations pertaining to the methods used. It completes by explaining how 
internal and external validity were ensured in this study.  
 
3.2 RESEARCH DESIGN 
 
Polit and Beck (2012:741) define a research design as the overall plan for addressing a 
research question laying out specifications in order to enhance the study integrity. On the 
same note Burns and Grove (2011:253) put it forward as a blueprint of conducting a study.  
 
The research design of this study was a cross-sectional descriptive design. Cross-
sectional studies are carried out at one time point over a short period (Polit & Beck 
2012:741). The purpose is to estimate the prevalence of the outcome of interest or 
sometimes to investigate associations between risk factors and the outcome of interest. 
However, cross-sectional designs are limited by the fact that they are carried out at one 
time point and give no indication of the sequence of events. According to Punch 
(2005:28), quantitative researchers collect facts and study the relationship of one set of 
facts to another,using numerical data, typically structured and predetermined research 
questions, conceptual frameworks and designs while qualitative researchers  
perspectives are more concerned about understanding individual’s perceptions of the 
world. De Vos, Strydom, Fouché and Delport (2011:156) noted that non-experimental 
studies measure relevant variables at a specific time and there is no manipulation of 
variables and do not include a control group.   
This research design was applicable as it met the objectives of the study in which the 
researcher sought to identify non-adhering adult patients and most importantly being able 
to determine the factors associated with non-adherence.  
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The independent variable is the presumed source of influence which in this study were 
the factors associated with non-adherence. These factors were classified as patient 
related, system related, disease and treatment related, and cultural and religious beliefs 
related factors. The dependent variable was the non-adherence to ARV medicines. 
 
3.3 RESEARCH METHODOLOGY 
 
According to Polit and Beck (2012:12), a research method is a technique used by 
researchers to structure a study, to collect information relevant to the research questions 
and analyse it. Under the research methodology the researcher explained what was the 
population and sampling of this study, sampling method used, size of sample, the context, 
data collection procedures and how data was analysed. 
 
3.3.1 Population and sampling 
 
This subsection of the chapter explains the population, target population, sampling 
procedures and the ethical considretaions observed during sampling. 
 
3.3.1.1 Population  
 
Polit and Beck (2012:59) described population as, “all the individuals or objects with 
common, defining characteristics.” In this study, the population refered to HIV positive 
adults receiving HIV care at a hospital in Namibia. In January 2015 the total number of 
adults receiving HIV care at the hospital was 3568. This number included those receiving 
ARV (1289) and those not yet on ARVs (2279). 
 
3.3.1.1.1 Target population  
 
Babbie (2009:89) defines target population as a complete set of persons or objects which 
possesses some common characteristics of interest to the researcher. In this study the 
target population were HIV positive adults 21 years and older on anti-retroviral treatment 
at the study site located in a hospital in Namibia. According to the EPMS by the end of 
December 2014, the facility ART register had a total number of 1289 adult patients on 
ARV treatment. Of the 1289 patients who were on ARV treatment, 933 patients came to 
 
  
41 
the hospital for their follow-up care and ARV refill in the period of October to December 
2014. All 933 patients that came to the facility were all assessd for adherence to their 
ARV medication. The outcome was that 439 (47%) were assessed as being non-adherent 
to their ARVs. Therefore the  the estimate population of non-adherent adult patients was 
439. 
 
3.3.1.2 Sampling 
 
Bless, Smith and Sithole (2013:161) define sampling as a technical accounting device to 
rationalise the collection of information, to choose an appropriate way in which to restrict 
the set of objects, persons or events from which the actual information will be drawn. Polit 
and Beck (2012:59) describe sampling as the process of selecting cases to represent an 
entire population so that inferences about the population may be made. According to 
Bless et al (2013:163), the main advantages of sampling include; less time consuming, 
less costly, and the fact that sometimes sampling maybe the only practical method, when 
the population is too large. 
 
3.3.1.2.1 Sampling plan 
 
A sampling plan specifies how the sample will be selected and recruited and how many 
subjects it will be (Polit & Beck 2012:59). Four steps should be followed when a 
quantitative researcher is sampling; identify the population, specify the eligibility criteria, 
specify the sampling plan and then recruit the sample (Polit & Beck 2012:286). The 
researcher followed these steps as follows: 
 
 Identify the population: In this study the researcher identified the population as HIV 
positive adults on Anti-retroviral treatment, 21 years and older at the study site. In 
January 2015 this population was 1289 adults. 
 Specify the eligibility criteria: To be a respondents, the individual had  to be aged  
21 years and above, receiving ARV treatment and care at the selected hospital for 
a minimum duration of 3 months and non-adherent to the medicines.All persons 
less than 21 years old, on ARV treatement for less than 3 months and adherent to 
medicines were excluded in the research. 
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3.3.1.2.2 Sampling method 
 
Census and multi-stage sampling method was used in this study.  
 
A census is  a survey covering an entire community (Polit & Beck 2012:275). All patients 
who attended the ARV clinic during the data collection period became part of the entire 
community of the HIV positive patients receiving care at the facility  .All the members in 
this census could laiter be part of the study if they were eligible and consenting to be 
respondents. 
 
Multi-stage sampling is a sampling strategy that proceeds through a set of of stages from 
larger to smaller sampling unit (Polit & Beck 2012:275). Possible respondents were to 
selected in successive steps. It has been documented that approaching of possible 
respondents is increasingly an important issue in sampling. There are mixed views about 
the appropriateness of approaching someone in the waiting room (Bedford, Wilson & 
Ritchie 2015:87). Firstly the Principal investigator and data collectors was stationed at the 
study site and approached possible respondents for participation in the study during 
individualised service  in the ARV pill count room. The researcher worked together with 
the lay counsellors in the ARV clinic to identify possible respondents meeting eligibility 
criteria.  
 
Two methods were used to identify respondents. The principal method used to identify 
patients with non-adherence was according to the pill count in the pill count room. Lay 
counsellors did pill count in a private room and documented it before the registered nurse 
reviewed the patient for the follow-up care. The researcher was situated in the pill count 
room together with the lay counsellor. In this private room the counsellors counted 
remaining ARV tablets as a method of assessing individual patient adherence. 
 
In this multistage sampling , all patients who were on single dose ARV regimens and had 
missed more than 1 dose in a period of 30 days were assessed as non-adherent. 
Secondly  patients on two doses per day ART regimens who had  missed more than 3 
doses in a period of 30 days were also  assessed as non-adherent.Both of the above 
stated two groups of patients adherence scores were below required 95% therefore 
regarded as non-adherent.  
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From the pill count room the researcher identified patients meeting the inclusion criteria. 
The researcher again went through the information brochure with the individual patient 
and requested for the patient participation in the study.  
 
The second method of identifying non-adherent patients was through review of patient 
records, that is all patients who on their last visit to the ARV clinic had adherence score 
of less than 95% documented in their patient care booklet (PCB). The researcher then 
individually contacted the patients telephonically if they would want to participate in the 
research. This second method of identifying respondents was meant to supplement those 
identified during clinic visits as they were not enough to make the required sample size. 
 
Lastly but very important , respondents who verbally consented also signed the written 
consent form and their names, home address, convenient time for interviewing was 
recorded down for the interview to be done later at the patients homes.However, most 
respondents prefered to have the interview done in a private room at the clinic. Most 
respondents were uncomfortable with meeting data collectors at their homes or any other 
alternative place. Altogether 112 adults gave a written consent to participate in the study 
and they made up the study sample of this study. 
 
 Achieving the required sample size  
 
The study adopted the influential factors in making a research enjoyable, convenient and 
non-threatening to respondents (Polit & Beck 2012:287). 
 
Predominantly the researcher approached possible respondents face to face than by 
telephone call but did not use letters or emails. A few respondents were approached 
telephonically for the sample size to be met. 
 
The data collectors were very courteous, pleasant and enthusiastic about the study which 
helped in recruiting the required sample size. 
 
Data collectors did not force patients to become respondents but they were patient to 
come back later if patient wished so. 
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Data collectors  provided detailed explanation on the benefits of the study and possible 
patient outcomes to the community and respondents. This is believed to have helped in 
better recruitment of respondents. 
 
The study had endorsement by the senior medical officer in charge of the hospital and 
sister in charge of the clinic which gave prospective respondents confidence in 
participating in the research. 
 
Prospective participants were given assurance that there information was confidentially 
kept. 
 
3.3.1.3 Ethical issues related to sampling 
 
To ensure that during this research ethical aspects were observed, the study strictly 
adhered to the following basic principles in its sampling: 
 
3.3.1.3.1 Principle of respect to persons 
 
Payne and Payne (2006:206) advocate that a researcher should always be aware of the 
right to autonomy that every human being has. Thus participation in this research was 
purely voluntary and individuals were not penalised or prejudiced for their decisions.  
Respondents who opted to participate in this research had a right to withdraw at any time 
in the study. The respondents had freedom from coercion of any nature. No incentives 
were given in this study to prevent financial coercion. Polit and Beck (2012:154) re-iterate 
on the importance of self-determination where it is the respondents voluntarily decision 
to take part in the research without risk of prejudicial treatment. These authors further 
underline the crucial component of the right to full disclosure. Full disclosure means the 
researcher fully described the nature of the investigation, client’s right to refuse 
participation, and the researcher’s responsibility, as well as possible risks and benefits.   
 
3.3.1.3.2 Principle of justice 
 
This is the broad principle of the Belmont report which focuses on two important aspects, 
right to fair treatment and right to privacy. 
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 Right to fair treatment 
 
Respondents were selected based on study requirements not vulnerability. Requirements 
included adults on ARV treatment at the selected hospital and on treatment for a minimum 
of 3 months consecutively.  Fair treatment principle also require that researchers treat 
people who decline to participate in a non-prejudicial manner (Polit & Beck 2012:155).  
 
3.3.1.4 Sample 
 
A sample is a subset of the whole population which is actually investigated by the 
researcher and in the case of quantitative research whose characteristics will be 
generalised to the entire population (Bless et al 2013:162). Jane and Jane (2009:157) 
define a sample as a subset of the population that is selected to represent the population.   
 
Polit and Beck (2012:422) point out that to determine a sample size a procedure called 
power analysis should be done. 
 
 Power analysis  
 
The four components of power analysis are significance criterion (α), sample size (N), 
effect size (ES) and power (Polit & Beck 2012:422). Significance criterion states that all 
things being equal the more the stringent the study critereon the lower the power. As 
sample size increases the power increases. The effect size is an estimate of the strength 
of the relationship between dependent and independent variable. 
 
The following values were used to calculate sample size. Population (N) of 134 non-
adherent adults, 95% confidence interval significance level of 0.05, an expected 
frequency of 0.47 which was from the problem statement of 47% of adults receiving ARV 
treatment at the study site in the last quarter of 2014 were non-adherent and a power 
level of 0.8. The values were computed into an electronic sample size calulator (Raosoft 
2004). The required minimum sample size was calculated to be 100. In order to be able 
to  discuss the study findings in terms of percentages, a minimum of 100 partcipants are 
recommnended (UNISA 2015:87). Therefore the minimum  sample size for the study was 
100. However twelve  more partcicipants volunteered to participate and the final number 
of partcipants for the study was 112.      
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3.3.1.4.1 Factors which affected the sample size of the study  
 
 Effect size  
 
This is the strength of relationships among research variables (Polit & Beck 2012:285). 
In this study the dependent variable was non-adherence and the independent variable 
were the factors associated with non-adherence. The researcher expected a moderate to 
strong relationship to exist between non-adherence and the associated factors, 
consequently a relatively small sample was considered adequate to reveal the 
relationship statistically. Polit and Beck (2012:285) proposed that if there is a reason to 
expect independent and dependent variables to be strongly related then a relatively 
smaller sample maybe enough to statistically ascertain the relationship between 
variables. 
 
 Homogeneity of the population  
 
If the population is generally homogenous then a small sample may be adequate (Polit & 
Beck 2012:285).  Furthermore, the larger the variance of the variable the larger the 
sample required. In this study there were vast variation of the rate of non-adherence 
among the respondents. All adults who had an adherence score less than 95% were 
classified as non-adherent such that the variance from 0-94% was wide posing the need 
for a larger sample in this study. This determinant of sample size required the sample to 
be large. 
 
 Cooperation and attrition  
 
According to Polit and Beck (2012:285), researchers should expect some degree of 
respondent loss and thus should recruit accordingly. They point out that not everyone 
invited in a study will agree to participate. After the required sample size had been 
ascertained, the study issued out 12 questionnaires to cater for dropouts and incomplete 
questionnaires. 
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 Subgroups analysis  
 
Respondents in this study were non-adherent adults 21 years or older, who were on ARVs 
for a minimum of 3 months at the Hospital. The wide age range as well as wide variation 
in duration on ARVs required the sample size of this study to be relatively large for it to 
represent the population well. 
 
 Sensitivity of the measures 
 
Polit and Beck (2012:286) warn researchers that if measuring tools are imprecise and 
prone to errors, then such researchers should make their samples larger in order to 
adequately test hypothesis. The researcher of this study maximally ensured the validity 
and reliability of the instrument, pre-tested it to ascertain that the tool was precise and not 
susceptible to errors. This allowed the sample size in this study to be relatively smaller 
yet still adequate to provide representation of the population. 
 
3.3.1.4.2 Size of the population (N) 
 
In this study the number of adult ARV patients who had non-adherence in the quarter of 
October to December 2014 was 403 giving an average of 134 non-adherent adult patients 
per month. As a result, population size for the study was estimated at 134.  
 
3.3.2 Data collection 
 
3.3.2.1 Data collection approach and method 
 
The data collection approach chosen was that of structured interviews supplemented with 
review of records method. Bell and Waters (2014:282) define a structured interview as a 
standardised interview which is a quantitative research method with the aim that each 
interview is conducted with exactly the same questions in the same order across 
respondents. Patient data was collected using patient responses during interview and 
patient records. The patients who were identified as non-adherent from the pill count 
room, and who verbally consented to participate in the research, after signing the consent 
form formed the sample. These respondents informed the researchers on the times they 
preferred to be interviewed at their convenience of which the majority opted to be 
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interviewed in private room at the clinic.. Joubert and Ehrlich (2007:108) also agreed that 
structured interviews follow a clearly structured format which prevents interviewer from 
interpreting questions in their own way. Joubert and Ehrlich (2007:108) further point out 
that the advantage of structured interviews is that it allows standardisation and increases 
reliability of information obtained.  
 
Bless et al (2013:76) describe structured interviews as having the following 
characteristics; uses an interview schedule like a questionnaire in which the researcher 
uses a list of set questions on every respondent, the interview schedule is designed and 
piloted well before main interview with respondents. 
 
Advantage of structured interview allows the researcher to organise and analyse his/her 
findings relatively easily. Other advantages of structured interviews also include higher 
response and quality information as compared to other methods like telephonic or postal 
interviews. Furthermore, in structured interviews same questions are used in same order 
making it is easier to compare responses from one subject to the other. Disadvantages 
of structured interviews are that they do not allow scope for in-depth interviewing which 
means researcher cannot follow-up subsequent questions, for example, if researcher 
wants to find out why people feel the way they do (Bless et al 2013:76). Secondly by its 
design, structured interviews cannot cater  for spontaneous responses from respondents, 
for exapmle, off the cuff  responses that respondents may want to offer during the 
interview. Other disadvantages include its time consuming, expensive, and the fact that 
physical confrontation may interfere with data (Jourbert & Ehrlich 2007:108). 
 
To reach the required sample size the principal investigator and data collectors  identified 
possible respondents from the review of patient data as per their patient care booklet 
(PCB). Respondents’ clinical records were accessed to access data about individual 
patient and the data was recorded on a check list which correlated with the questionnaire. 
Review of records is known to be quick and cost effective, allows historical comparison 
and data cannot be influenced by the researcher. However, reviewing records has 
challenges of incomplete data and data being recorded by different people (Jourbert & 
Ehrlich 2007:108). Records have adherence and/or non-adherence history of the 
individual patient which was important to the researcher. Further information reviewed in 
the records included the attendances of appointments dates, adherence assessment 
scores where non-adherence are identified, ARV regimen of the particular patient, 
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duration on ARV treatment, and blood results of patients including viral load. The 
researcher used both the electronic patient monitoring system (EPMS) and paper based 
data to document patient data.  
 
3.3.2.2 Development and testing of the data collection instrument 
 
As per data from literature review following the conceptual framework of factors 
influencing non-adherence of individuals, a structured questionnaire was compiled firstly 
in the English language (see Annexure G). Some questions were compiled based on 
findings from literature reviewed on factors associated with non-adherence while others 
were derived from the Namibia HIV patient care booklet (PCB) in which patient 
information is entered on every follow-up visit to the clinic. One medical officer, two 
nurses, one pharmacist and one lay counsellor all of who had experience of working in 
the ARV clinic gave assistance in the development of the questionnaire. Phraising of 
some questions was adopted  from the tools used in two different studies in Ethiopia by 
Tsega, Srikanth and Shewamene (2015:375) and Abdissa (2013:60).  Finally as this was 
a quantitative research, a statistician finalised the questionnaire. When the English 
questionnaire was ready, the researcher employed language experts, in the form of 
secondary level subject teachers from the Namibian Ministry of Education, Arts and 
Culture, to translate the English questionnaire into Afrikaans (Annexure I)  and 
Oshiwambo (Annexure H) which were among the common languages that are widely 
spoken by the respondents.   
 
The subsections of the questionnaire were as follows:  
 
Section 1: Socio-demographic and socio-economic. The first section of the questionnaire 
had a set of 8 questions which collected information on socio-demographic information of 
the respondent. These included age, sex, race, preferred language, marital status, level 
of education and employment status. 
 
Section 2: Patient-related factors. This comprised of 6 questions seeking to understand 
individual markers in a patient that could be associated with non-adherence. Questions 
focussed on duration on ARV therapy, emotional status, alcohol consumption and 
forgetting to take ARVs. 
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Section 3: System-related factors. A set of 8 questions which focused on healthcare 
delivery system and patient perceptions of it. The focus here was on service system 
operating hours, professional relationships, distance of clinic from patient’s residence and 
pharmacy stock outs. 
 
Section 4: Disease- and treatment-related factors. Six question were employed to elicit 
data about the HIV/AIDS disease and the ARV treatment of the respondent. This part of 
the questionnaire asked on side effects of ARVs on the patient, dose of ARVs and health 
status of the patient. 
 
Section 5: Cultural and religious factors that could be related non-adherence. Questions 
explored whether taking ARVs offended patient’s cultural and religious beliefs and if the 
patient believed HIV could be treated by religious or cultural methods. 
 
The questionnaire was piloted on 10% (10 respondents) of the sample size. Changes 
were made on the questionnaire from the feedback given during piloting. Polit and Beck 
(2012:195) describe that piloting is a trial run or small scale version of the study which is 
meant to test the proposed methods before they are used at a larger scale. Among other 
things, this helped the researcher to determine required time for the interview. Average 
time taken to conduct the interview was 10-15 minutes. Pre-testing also granted an 
opportunity to identify vague questions in the questionnaire which respondents could not 
clearly understand. Some questions which were found repetative where removed from 
the questionnaire. Other changes included some questions being removed as they were 
too long and terms were changed to make it easier for partcipants to clearly understand. 
 
3.3.2.3 Characteristics of the data collection instrument 
 
According to Jourbert and Ehrlich (2007:107), a questionnaire is a list of questions which 
are answered by a respondent and which give indirect measures of the variables under 
investigation. Bless et al (2013:82) notes that there are 3 types of questionnaire. 
 
1. Attitudinal questions which gather data on how people think, feel or behave and  it 
can be scored. 
2. Gather information which report on particular things e.g. yes or no and tick boxes. 
Such questions cannot be scored. 
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3. Mixed questionnaires which have both attitudinal and gather information 
questions. 
 
Some questionnaires like the one in this study used both attitudinal and gathering data 
questions. The study questionnaire was predominantly attitudinal as it asked respondents 
on how they think, feel and behave and they could be scored. It also had questions which 
simply gathered data by ticking boxes.  The questions were structured because they were 
predetermined, definite and they followed the same order for all respondents. The 
researcher did not construct new questions during data collection as all questions were 
prepared in advance including the possible responses. 
 
3.3.2.4 Data collection process 
 
After securing ethical clearance (Annexure A) with the UNISA Department of Health 
Studies, an approval (Annexure B) with the Namibia Ministry of Health and Social 
Services Research Committee was applied for and approval was granted as shown in 
Annexure C. A letter for permission to collect data from the study site was also submitted 
to the senior medical officer of the hospital and the sister in charge of the ARV clinic (see 
annexures for approval letters and application letters to the hospital senior medical officer 
and sister-in-charge). In all cases permission was granted. 
 
The principal investigator identified three data collectors but only two were available 
during data collection. Both were third year nursing students. The principal investigator 
used assessments of students from their progress files to confirm their professional 
conduct and academic performance. This was also supported with students’ evaluation 
feedback from clinical area and lecturers’ feedback on the two students. This background 
helped the researcher to train them on ethically and academically sound data collection. 
The two data collectors were comfortable in using all the three languages on the 
questionnaires, English, Afrikaans and Oshiwambo. The data collectors underwent two 
days training, on 27 and 28 July 2016, conducted the principal researcher on data 
collection using the three questionnaires. Training emphasised on the four principles of 
ethical considerations and how to prevent bias. The data collectors also signed a 
confidentiality binding form (see Annexure D). Data collection commenced on the 3rd of 
August 2016.  
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All respondents who gave verbal and written consent agreed with the data colectors  on 
comfortable time and place for data collection to occur. The consent form is depicted in 
Annexure E. Noteworthy, most respondents were not comfotable with data collectors 
coming to their homes and instead prefered for the interview to be done at the clinic in a 
private room. About 73.3% (n=82) of respondents were interviwed at the clinic while 
26.7% where interviwed at places of their choice other than the clinic. Eacn respondent’s 
interview took approximately 10-15 minutes. 
 
3.3.2.5 Ethical issues related to data collection 
 
Firstly, permission to carry out the study was requested from the UNISA Department of 
Health Studies. When the ethical clearance had been provided (see Annexure A), 
approval was also sought from the Namibia Health Research Ethics Committee(See 
Annexure B). Aproval to conduct study was granted by the Namibia Health Research 
Ethics Committee (see annexure C ). Then application was submitted to the senior 
medical officer of the selected Hospital and the sister-in-charge of the ARV clinic 
requesting permission to conduct the study at the particular site. The study site authorities 
gave verbal approval to  for data collection of the study.  Individual patients volunteered 
to participate in this research. Verbal consent was sought from patient after which the 
patient signed a consent form agreeing to participate in the study (see Annexure F). 
 
3.3.2.5.1 Principle of beneficence 
 
Polit and Beck (2012:152) state that beneficence imposes a duty on researchers to 
minimise harm and maximise benefits. They are of the opinion that researchers have an 
obligation to avoid, prevent or minimise harm to respondents. Questions were structured 
to collect precise data yet not causing emotional harm or distress to the respondents. 
Respondents did not incur costs as a result of their participation in this study. Polit and 
Beck (2012:152) says that protection of respondents should be holistic so as to ensure 
freedom from discomfort or harm physically, spiritually, emotionally, economically, 
socially and legally. Questions and interviews were also structured in a way not to 
undermine patient’s spiritual, cultural or social beliefs. Respondents were free not to 
answer questions they felt uncomfortable to answer. As Polit and Beck (2012:153) note, 
protecting respondents from physical harm is straightforward but psychological 
consequences maybe subtle hence calling for closer attention. There was no covert data 
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collection, meaning no data was collected without patient knowledge and consent. The 
researcher and data collectors pledged that they would not be deception prior to 
commencent of the study. All necessary information relating to the study was provided to 
the respondents.  
 
3.3.2.5.2 Privacy and confidentiality  
 
To maintain privacy, patients were only approached to participate in this research in the 
pill count room where there was privacy and individualised care. Patients who agreed to 
participate in the research were interviewed in private at a place most convinient to the 
respondents. Information collected during data collection was kept in strict confidentiality. 
Both paper based and electronic based data did not have any markers which could 
identify the respondents. Data collectors signed confidentiality forms which bound them 
to maintain strict confidentiality concerning all information  gathered during this study. 
 
3.3.3 Data analysis  
 
Completed paper questionnaires were kept in a locked secure place which only the 
principle researcher could access. Before electronic data capturing, data cleaning and 
coding was done. Coding is the process of transforming data into symbols often numbers 
(Polit & Beck 2012:473).  Electronic data collected for this study was kept in a password 
protected computer. Only the principal research had access to this computer. The 
services of a statistician were also employed. Data was entered into a computer package 
called Statistical Package for Social Sciences (SPSS version 20). Analysis was by 
descriptive statistics. Descriptive statistics describe and summarise data using means 
and percentages while inferential statistics permits inferences to be made about whether 
results observed in the sample can be generalised to the larger population (Polit & Beck 
2012:725). Measures of association between exposure and outcome are used to 
summarise information gathered in a study (Joubert & Ehrlich 2007:148). Exposure for 
this study referred to factors associated with non-adherence and the outcome was non-
adherence. In this study descriptive methods were used to evaluate  association.  
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3.4 INTERNAL AND EXTERNAL VALIDITY OF THE STUDY 
 
Validity is the design of research to provide credible conclusions; whether the evidence 
can bear the weight of the interpretation put on it (Sapford & Jupp 2006:1). Joubert and 
Ehrlich (2007:117) note that validity describes the extent to which the measurement 
instrument measures what it is intended to measure. Validity can be internal or external. 
 
Internal validity is the extent to which changes in the dependent variable are indeed due 
to the independent variable (De Vos et al 2011:153). Internal validity allows researcher to 
answer the research question convincingly (Bless et al 2013:157). 
 
External validity is the degree to which results can be generalised (De Vos et al 
2011:153). External validity refers to what extent the results obtained in this study apply 
to the population being studied and to other contexts different from those of this specific 
study (Bless et al 2013:157). To ensure external validity the principal investigator and 
data collectors had to act in a way which did not interfere with results (De Vos et al 
2011:155).  
 
According to Polit and Beck (2012:336), the four important facets of validity are face 
validity, content, criterion related and construct related validity. Instruments can be 
validated using any of the four facets. In this particular study face, content and construct 
were used to ensure validity.  
 
3.4.1 Face validity  
 
Face validity refers to whether the instrument appears to be measuring the target 
construct (Polit & Beck 2012:336). For the face value of the questionnaire it was assessed 
by 5 healthcare workers trained and working in HIV care. These 5 healthcare workers 
were 1 medical officer, 2 registered nurses, 1 pharmacist and 1 lay counsellor. They gave 
their inputs and helped to make the questionnaire clear and respondent friendly yet 
measuring what they were intended to measure. 
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3.4.2 Content validity  
 
This examines the extent to which measurement includes all the major elements relevant 
to the construct being measured (Burns & Grove 2011:335). This description of content 
validity is reiterated by Polit and Beck (2012:336) who note that content validity is the 
degree to which an instrument has appropriate sample items for the construct being 
measured and adequately covers the construct domain. The construct in this study were 
factors associated with non-adherence. To cover this construct the following elements 
were assessed; patient-related factors, socio-economic factors, disease and treatment 
related factors and finally cultural and religious related factors.  In this study, content 
validity was ensured by a thorough literature review and review of the instrument by five 
expert healthcare workers. The instrument was reviewed against the Namibian ART 
guidelines by the healthcare workers which provided content and construct validity. 
 
3.4.3 Construct validity  
 
According to Burns and Grove (2011:335), construct validity includes content and 
predictive validity. It is concerned with validity of inferences from the observed persons, 
the settings, cause and effect relationships involved in the study and the constructs that 
these instances may be representing (Polit & Beck 2012:237). 
 
3.5 RELIABILITY  
 
Reliability is defined as the extent to which an instrument consistently measures a 
concept (Burns & Grove 2011:546). The same concept of consistence is re-iterated by 
Polit and Beck (2012:331) who describe reliability as the degree of consistence or 
dependability with which an instrument measures an attribute. In other words, reliability 
focuses on level of similarity of results obtained when the measurement is repeated could 
be on the same subject or group (Joubert & Ehrlich 2007:117). In this study reliability was 
ensured first by engaging healthcare workers  involved with HIV care critiquing the 
instrument. The data collection tool was also translated from English to Afrikaans and 
Oshiwambo to ensure clear understanding and avoid misinterpretation of questions. The 
statistician’s input provided addition information to ensure the reliability of the instrument. 
Pre-testing of the instrument and piloting also maximised on reliability of the instrument 
as feedback was inco-operated before instrument was used for this study. The commonly 
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used method to assess internal consistency is coefficient alpha. Previous studies which 
investigated factors associated with patient’s ability to take ARV medicines as agreed 
with healthcare workers had variable reliability coefficients (Cronbach’s alpha). Abdissa 
(2013:60) in a study on determinant factors affecting adherence the instrument yielded a 
Cronbach alpha of 0.75 to 0.82. A reliability coefficient of at least 0.80 for all well-
developed tools and 0.70 for a newly developed tool is considered acceptable. Questions 
which were from previously used tools used in this study were from two different studies 
in Ethiopia  by Tsega et al (2015:375) and Abdissa (2013:60) of which yielded alpha 
coeficient above 0.70. 
 
3.6 CONCLUSION 
 
This chapter outlined the research methods used in this study. It described the sampling 
methods and highlighted ethical issues related to sampling and data collection in this 
study. It concluded by outlining data analysis, internal and external validity. Following is 
chapter provides a detailed lay-out of the research findings. 
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CHAPTER 4 
 
ANALYSIS, PRESENTATION AND DESCRIPTION OF THE RESEARCH 
FINDINGS 
 
4.1 INTRODUCTION 
 
This chapter presented and discussed the research findings from the data that was 
collected. The overall purpose of this study was to minimise non-adherence to 
antiretroviral (ARV) treatment amongst HIV/AIDS adult patients at a hospital in Namibia 
thereby promoting successful outcomes in patients on ARV treatment.  
 
The objectives of this study were: 
 
 To identify non-adhering patients from the clinical visits and EPMS and to confirm 
with the patient care booklet. 
 To determine the factors associated with non-adherence in adult patients to ARV 
treatment. 
 To recommend to stakeholders methods to facilitate adherence in patients on 
ARVs 
 
4.2 DATA MANAGEMENT AND ANALYSIS  
 
Data collection was conducted from 3rd of August until the 7th of September 2016. The 
principal investigator and two trained data collectors conducted structured interviews 
using a questionnaire. The total number of respondents interviewed was 112 which made 
up the study sample. The venue for interviews depended upon individual respondent 
preferences. Most respondents were comfortable being interviewed in a private room at 
the clinic than at their homes. The questionnaires did not have any identifiers or markers 
and only sequential numbers were used for identification. Therefore, all the data was 
anonymous and was collected in strict confidentiality. Data was kept in a lockable 
cupboard while the electronic data was kept in a password locked computer.  
 
  
58 
Data was cleaned and entered into a database on SPSS version 20.0. Descriptive 
statistics were used to analyse the data. The data was presented in form of frequency 
distribution using bar graphs, tables, pie charts and percentages.  
 
4.3 RESEARCH RESULTS  
 
Data analysis was done according to objectives as outlined in chapter one. 
 
4.3.1 Identify non-adhering patients from the clinical visits and EPMS and confirm 
with patient care booklet 
 
In the period of data collection 392 adult patients on ART at the site attended the clinic 
for their follow-up HIV care and refill of ARV treatment. All patients who came for ARV 
follow-up were assessed for adherence to their medication using the pill count method.  
From the healthcare workers, adherence assessment using the pill count method in the 
pill count room, 144 patients had an adherence score of less than 95%. All the patients 
with adherence score of less than 95% were identified as non-adherent.  Therefore the 
rate of non-adherence among patients at the study site in this period was found to be 
36.7%. Of the 144 non-adherent  patients,  fourteen (14) did not meet the inclusion criteria 
as eight (8) were on ARV treatment for a duration of less than 3 months while six (6) were 
less than 21 years of age.  
 
From 130 eligible adult patients who were approached to participate in this study, 94 
consented verbally and also signed the consent to participate in the study, giving a 
response rate was 73%. To meet the required sample size of minimum of 100 
respondents, the study needed more 6 respondents. To cater for a possible low response 
rate, twenty-five more non-adherent patients were identified from the EPMS and 
confirmed with the patient care booklet. These patients were contacted telephonically and 
18 expressed willingness consent to participate in the study giving a response rate of 
72%. All 18 additional patients attended the interviews which resulted in a total of 112 
respondents for the study.  
 
The non-adherence rate of 36.7% found in this study was significantly higher than that 
reported in a study in Northern Namibia of 22% measured by pill count (Nghoshi 2016: 
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ii). In another study in Ethiopia, Negash (2011:64) noted that 26.5% of the respondents 
had sub optimal adherence. 
 
4.3.2 Determine the factors associated with non-adherence in adult patients to 
ARV treatment 
 
The following was discussed under the subtopics of demographic sample characteristics, 
patient related factors, system related factors, cultural and religious factors. 
 
4.3.2.1 Demographic sample characteristics  
 
In this section, the research results pertaining to respondents’ sex, age, ethnicity, religion, 
marital status, level of education, living condition, source of support and employment 
status were presented. The results are presented from the table over leaf. 
 
4.3.2.1.1 Distribution of respondents by sex (N=112) 
 
 
Figure 4.1 Distribution of respondents by sex 
 
Of the 112 respondents in this study 56.3% (n=63) were women and 43.8% (n=49) were 
men as shown in in figure 4.1 above. This is in line with the general population of patients 
receiving HIV care in Namibia including at the study site where 60% of patients in HIV 
care are women (MoHSS 2014b:4). More females could imply that although more females 
attended follow-up visits for refills, female were also more non-adherent. Although the 
study did not compare equal number of women versus men, research findings are similar 
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to from other studies (Tsega et al 2015:375; Amsalu, Wanzahun, Mohammed & Tariku 
2014:75). Beer et al (2012:218) concur that females tended to be more non-adherent 
than males. Uzochukwu et al (2009:192) also re-iterated that being female was 
significantly associated with non-adherence. However, some studies have yielded no 
significant relationship between sex and non-adherence (Abdissa 2013:65). Others 
showed higher incidence of non-adherence among men than women. Nghoshi (2016:29) 
reported an overall higher incidence of non-adherence among men then females in a 
study in northern Namibia.   
 
4.3.2.1.2 Age of respondents (N=112, Total=100%) 
 
 
Figure 4.2 Age distribution of respondents 
 
Respondents were classified in age groups which share similar developmental 
characteristics along life span. This was in line with contributions provided by the 
statistician. Those respondents in age group 21-30 years are young adults’ who oftenly 
are pursuing careers and ambitions, those in age group 31-45 years mainly contribute to 
the working force, those in age group 46-64 years are mature adults approaching 
retirement and those 65 years and above make up the retired age group. Figure 4.2 above 
showed that the highest number of respondents were found in the age group 31 -45 
(54.5%) followed by 46 -64 years (27.7%) and 21-30 years (16.1%) while the least was 
the above 65 years (1.8%). This concedes with findings reported by Tsega et al 
(2015:373) who noted that the likelihood of ART non-adherence in the age group 31–45 
years and 18–30 years was 1.51 and 0.63 times that of the age group 46–64 years. The 
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significant association between younger age and non-adherence is further supported by 
Nuwagaba-Biribonwoha et al (2014: [10]) and Beer et al (2012:218). However, Abdissa 
(2013:65) highlighted that there was no statistically significant association between the 
age of respondents and their adherence in a study conducted in Ethiopia.   
 
4.3.2.1.3 Ethnicity of respondents (N=112, Total=100%) 
 
 
Figure 4.3 Distribution of respondents by ethnicity 
 
Figure 4.3 above shows that the study sample had equal numbers of Oshiwambo (47.3%) 
and Nama-Damara (47.3%) respondents while 4.7% were Caprivians and Okavango and 
only 0.9% were Otjiherero. As study site is located in Southern Namibia, the Nama-
Damara ethnic group predominates. According to the Namibia Demographic Health 
Survey, 56% of the population speak Oshiwambo, 13% speak Damara/Nama, while 
about 10% speak Afrikaans, 10%Herero and 10% Kwangali (MoHSS 2013a:7). Previous 
studies conducted on adherence in Namibia are silent on the relationship between 
ethnicity and level of adherence to ARV treatment. In view of this observation, 
respondents at the study site were not equally distributed across ethnic groups. 
Noteworthy, this study may not conclude that specific ethnic groups are more non-
adherent than others. 
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4.3.2.1.4 Religion of respondents (N=112) 
 
 
Figure 4.4 Distribution of respondents by religion 
 
Figure 4.4 above depicts the distribution of respondents by religion. Catholics were 26.8% 
(n=30), Orthodox were 56.3% (n=63) while the remainder of 17% were Protestant. None 
were from the Islam, neither Hindu nor the African traditional religions. The 2013 DHS 
(MoHSS 2013a:23) highlighted that 44% of the population belong to the Evangelical 
Lutheran Church of Namibia which is Orthodox , 13% were Protestant and approximately 
26% were Roman Catholic. While the analysis showed general distribution of the various 
religious groups in this geographical location, this does not imply that respondents who 
were orthodox were most non-adherent. Other studies did not also yield any statistical 
significance between religion and level of adherence (Abdissa 2013:73; De & Dalui 
2012:251).  
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4.3.2.1.5 Marital status (N=112) 
 
 
Figure 4.5 Respondents marital status 
 
As outlined in figure 4.5 above, the majority of the respondents 71.4% (n=80) were 
unmarried, 22.3% (n=25) were married while the remainder was either separated/ 
divorced (4.5%) or widowed (1.8%). According the DHS of 2013, approximately only 15-
18% of Namibian adults are married (MoHSS 2013a:7). Findings of unmarried people 
being more non-adherent have also been reported in Zambia (Sasaki, Kakimoto, and 
Dube et al 2012:11). Elsewhere, association between marital status and adherence levels 
were not established (Abdissa 2013:70; Negash 2011:67).  
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4.3.2.1.6 Level of education of respondents (N=112, Total=100%) 
 
 
Figure 4.6 Respondents highest level of education 
 
Figure 4.6 presented highest level of education. The results showed that most of the non-
adherent respondents had only attained basic education or less.  The majority (65.2%) of 
respondents had attained only basic level basic education, 21.4% (n=24) had elementary 
education, 8% had a diploma or higher qualification while 5.4% were illiterate. These 
findings are consistent with the general education status in Namibia where only 10% of 
adults have received higher than secondary education and about  8% have never 
attended school (MoHSS 2013a:7). The relationship between low education status and 
non-adherence have been documented before (Campos, Guimarães & Remien 
2010:293; Muessig et al 2014:988). However, some studies did not yield any association 
between education level and adherence levels. (Negash 2009:51; Abdissa 2013:71).  
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4.3.2.1.7 Respondents living condition (N=112, Total=100%) 
 
 
Figure 4.7 Living conditions of the respondents 
 
Figure 4.7 depicted the living conditions of the respondents. The majority of the 
respondents 70.5% (n=79) were living with family, 14.3% lived alone, 9.8% were living 
with others while the remaining 5.4% lived with a friend.  
 
4.3.2.1.8 Respondents source of support  
 
Table 4.1 Distribution of respondents by source of support (N=112, Total=100%) 
 
Source of support  Frequency Percentage 
Self-support 65 58.0 
Families  36 32.1 
NGOs 7 6.3 
No support  4 3.6 
Total  112 100.0 
 
Table 4.1 above shows the source of support of the respondents. 58% (n=65) of the 
respondents were self-supporting, 32% received support from family, 6.3% received 
support through donor-funded groups and notably only 3.4% of respondents had no 
support at all. Although 70.5% of respondents lived with their family, only 32% received 
support from family. Abdissa (2013:112) noted that there was a significant association 
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between availability of social support in taking ARV treatment and adherence to 
treatment. In Thailand, Li et al (2010:212) highlighted that poor family communication was 
associated with non-adherence. Seven (4.9%) respondents attributed lack of food for not 
taking their ARVs while another 7 (4.9%) respondents reported that they did not have taxi 
money to come to the clinic as their reasons for non-adherence.  
 
4.3.2.1.9 Respondents employment status (N=112, Total=100%) 
 
 
Figure 4.8 Employment status of the respondents 
 
As shown in figure 4.8, 49.1% of the sample was employed while the remaining 50.9% 
was unemployed.  In this study, both employment and its lack therefore were observed 
to contribute to non-adherence. Some respondents highlighted that work commitments 
kept them busy and contribute to them missing ARV doses. Notably, 7(4.9%) respondents 
indicated having not got time off work to take their ARVs.  In Ethiopia, one study reported 
that the likelihood of ART non-adherence in employed patients was 0.41 times that of the 
unemployed patients (Tsega et al 2015:376). Nghoshi (2016:39), however, noted that 
employed respondents had a higher rate of adherence compared to pensioners and 
unemployed respondents combined in a study in Northern Namibia.  
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4.3.2.2 Patient related factors  
 
This subsection presented study outcomes on aspects that pertain to the patients 
themselves. These included respondents’ beliefs in ART, community disclosure, use of 
active substances, patient emotional status and whether taking ARVs reminded the 
respondents of the HIV infection.  
 
4.3.2.2.1 Respondents responses on ART is essential for HIV patient (N=112) 
 
 
Figure 4.9 Respondents responses to ART is essential for the HIV patient 
 
Majority of the respondents, 58.9% (n=66), strongly agreed that ART is essential for the 
HIV patient, 38.4% simply agreed while only 1.8% were uncertain and 1 (0.9%) 
respondent disagreed. 97.3% of respondents either strongly agreed and agreed that ART 
is essential for their care. This result suggested that although respondents were non-
adherent to their medicines, they were aware ART was vital in HIV care. This may be an 
indication of the importance of successful health education on the importance of ART 
treatment to patients.  Similar findings have been reported were approximately 97% 
respondents agreed and strongly agreed that the use of ART was essential to their life 
(Tsega et al 2015:376).  Other studies have also reported that poor beliefs in the benefits 
of ARVs were associated with non-adherence (Gari et al 2013:7). 
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4.3.2.2.2 Respondents comfort in taking ART in the presence of others (N=112, 
Total=100%) 
 
 
Figure 4.10 Comfort of respondents in taking ARVs in the presence of others 
 
Approximately 52.7% (n=59) respondents were comfortable taking their ARV treatment 
in the presence of others, while 9 (8%) were undetermined as depicted in figure 4.9 
above. Only 39.3% (n=44) expressed discomfort with taking ARVs in the presence of 
others. The study findings revealed that patients sometimes miss their doses because of 
discomfort with taking ARVs in the presence of others.  
 
4.3.2.2.3 Respondents use of active substances (N=112) 
 
 
Figure 4.11 Distribution of respondents by use of active substances 
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In this study, 45.5% (n=51) of respondents were using active substances while the 
remainder 54.5% (n=61) were non-users. Among the respondents using active 
substances, 22(43%) cited alcohol use as the reason for missed doses. The number of 
respondents using active substances in this study was double that reported in Ethiopia 
where only 22.5% respondents were active substance users (Tsega et al 2015:375). 
These results suggest that active substance use may contribute to non- adherence. The 
association between active substance use and non-adherence were also documented in 
America, South Africa and Ethiopia respectively (Beer et al 2012:220; Kip et al 2009:149; 
Negash 2011:69).  
 
4.3.2.2.4 Respondents frequency in use of active substances in the past one month 
(N=112) 
 
 
Figure 4.12 Distribution of respondents by frequency in use of active substances 
in the past 1 month 
 
Of the 51 respondents who were using active substances, 60.7% (n=68) reported not 
using active substances in the past 1 month, 32.1% took 1-2 times a week, 7(6.3%)  took 
3-4 times a week and only 1 (0.9%) respondent took 4-7 times a week. These findings 
concur with findings that use of alcohol in the past one month was significantly associated 
with the risk of non-adherence (Achappa et al 2013:222; Do, Dunne, Kato, Pham & 
Nguyen 2013:5).
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4.3.2.2.5 Respondents disclosure of HIV status to the community (N=112) 
 
 
Figure 4.13 Distribution of respondents by disclosure of HIV status to 
community 
 
Figure 4.11 above shows the findings pertaining to respondents disclosing their HIV 
status to the community. Only 30.4% (n=34) had disclosed their HIV status to the 
community while the majority 69.6% (n=78) had not disclosed. This is contrary to findings 
from Ethiopia where 70.9% disclosed their HIV status to community (Tsega et al 
2015:376). The low community disclosure could also be a contributing factor to 
respondents feeling uncomfortable to take ARVs in the presence of others. These 
findings support previous findings which have revealed that lack of community disclosure 
was highly associated with non-adherence (Franke et al 2011:1483; Wasti et al 2012:75). 
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4.3.2.2.6 Emotional status of respondents in the past 1 month (N=112) 
 
 
Figure 4.14 Emotional statuses of respondents in the past 1 month 
 
Concerning the emotional status of the respondents in the past 1 month, 37.5% (n=42) 
reported being generally happy, 41% (n=46) were neutral, 17% (n=19) were somehow 
depressed and 4.5% (n=5) were very depressed. In total 21.5% of respondents were 
depressed in the past one month. It is of note that when asked for reason for missed dose 
a total of 6 (4.2%) respondents cited stress as their reason for missed doses. The 
association between emotional status particularly depression and non-adherence were 
documented by Negash (2013:66) in Ethiopia. 
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4.3.2.2.7 Respondents responses on whether taking ARVs remind them of the HIV 
infection (N=112) 
 
 
Figure 4.15 Respondents responses on taking ARVs remind them of the HIV 
infection 
 
Figure 4.13 shows that 40.2% (n=45) respondents were of the opinion that taking ARVs 
did not remind them of the HIV infection, a 59.8% (n=50) thought it somehow reminded 
them and 15.2% (n=17) thought it strongly reminded them of the HIV infection. As such, 
taking ARVs reminded some of the respondents about the HIV infection which could be 
a contributing factor to them missing the doses in a bid to forget about the infection. 
 
4.3.2.3 System related factors  
 
In this section respondents were asked about how convenient they found the ART clinic, 
their satisfaction with the healthcare workers and if they had ever found the pharmacy 
out of stock of their ARVs.  
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4.3.2.3.1 Convenience of the ART clinic to respondents (N=112) 
 
 
Figure 4.16 Distribution of respondents on convenience of clinic 
 
As shown in figure 4.14, 50% (n=56) found the clinic convenient, 34% were undetermined 
and the remaining 22% found the clinic inconvenient. Some respondents positively 
commented on the nurses and community counsellors’ behavior. However, other 
respondents’ were mainly dissatisfaction with the distance of clinic from their homes. 
Other respondents 8(7%) were of the opinion that MoHSS should build more ARV clinics 
within the district. Ten (7%) respondents cited transport challenges as reason for missing 
doses. This included 7 (4.9%) respondents who reported that they did not have tax money 
to come to the clinic and 3 others who failed to get transport from farms were they work 
to the clinic for follow-up care. Similar findings have been reported in Uganda, where 
transportation costs accounted for 7.8% of reasons why patients were non-adherent 
(Senkomago et al 2011:1246). The association between transport challenges and non-
adherence were also reported by Biadgilign et al 2009:148; Tabatabai et al 2014: [6]). 
 
In this study some respondents felt the healthcare workers could be more efficient in their 
work. This inconvenience experienced by respondents in accessing their HIV care at the 
clinic may have been associated with non-adherence at the study site. 
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4.3.2.3.2 Respondents satisfaction with the healthcare workers (N=112) 
 
 
Figure 4.17 Respondents satisfaction with the healthcare workers 
 
Findings revealed that 73.2% (n=82) of the respondents were satisfied, 17% (n=19) were 
undetermined and the remaining 9.8% were dissatisfied with the healthcare workers. 
Fourteen (12.5%) respondents were satisfied with the care they received from the nurses. 
However, the patient satisfaction with healthcare workers in this study was much lower 
than that reported in Northern Namibia where 95% of the respondents were satisfied with 
the services of healthcare workers (Nghoshi 2016:47). Although the satisfaction in this 
study was higher than in other studies, attention should still be given to the 27% who 
were not satisfied with the services of healthcare workers (Tsega et al 2015:376). These 
findings agree those reported by Boyer et al (2011:1383) who highlighted that poor 
communication with healthcare workers was one of the reasons for non-adherence and 
treatment interruption by patients. The research findings point out that patient–healthcare 
worker relationship is an associated factor to non-adherence. Other studies also revealed 
a significant relationship between perception of study respondents on patient-healthcare 
worker relationship and their adherence to antiretroviral treatment (Abdissa 2013:120; De 
& Dalui 2012:251)  
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4.3.2.3.3 Responses on if respondents have ever found the pharmacy out stork of your 
ARVs (N=112) 
 
 
Figure 4.18 Respondents have ever found the pharmacy out stork of your ARVs 
 
A resounding 96.4% had never found the pharmacy out of stock of ARVs due timely 
supply of ARVs at health facilities across the country. Only 4 (3.6%) respondents had 
ever found the pharmacy out of stock of their ARVs, It can be concluded in this study that 
non-adherence is not related to medicine supply at the pharmacy at this study site. Similar 
findings are reported by Abdissa (2013:128) where the majority (94.2%) of the 
respondents had not encountered problems in refilling their ARV drugs at the pharmacy. 
On the contrary, in Nigeria Uzochukwu et al (2009:192) reported that non-availability of 
drugs at treatment sites was one the reasons for non-adherence.  
 
4.3.2.4 Disease and treatment related factors  
 
The focus of questions in this section was to gather data on attributes pertaining to the 
ARV medicines themselves and the HIV disease which could be associated to the non-
adherence in the study respondents. 
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4.3.2.4.1 Respondents duration on ARV treatment (N=112) 
 
 
Figure 4.19 Respondents duration on ARV treatment 
 
In this study 10.7% (n=12) were on ARV treatment for 3-12 months, 24.1% (n=27) were 
on treatment for 1-3 years and the majority 65.2% (n=73) were on ARVs for more than 3 
years. Most of the non-adherent patients were found in the duration of more than 3 years 
on ARV treatment. It is noteworthy that on being asked for reason for missed dose 3 
(2.1%) respondents highlighted that they got tired of taking the ARV medicines. These 
findings are similar to those of Venkatesh, Pathmanathan and Brownlee (2010:799) who 
found that respondents on ARV treatment for more than 2 years were more likely to be 
non-adherent than respondents who had been on treatment for less than 2years. Gari et 
al (2013:7) also reported that taking ART for more than two years was positively 
associated with adherence in high income countries. However, other studies have not 
yielded any statistically significant association between duration on treatment and 
adherence to ART (Drachler, Drachler, Teixeira & De Carvalho Leite 2016:[2]; Abdissa 
2013:130). 
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4.3.2.4.2 Respondents responses on whether they have you ever experienced any side 
effects to ARVs (N=112) 
 
 
Figure 4.20 Distribution of respondents who have experienced  
ARV side effects 
 
Study results as depicted in figure 4.17 show that 42.9% (n=48) had not experienced side 
effects of ARVS while the majority 57.1% (n=64) had at one time suffered from ARV side 
effects.  Respondents who experienced ARV side effects were more than double those 
reported by Nghoshi (2016:42) who found only 20% of respondents in a study in Northern 
Namibia reported experiencing side effects of ARVs. This was also higher than that 
reported from Ethiopia where 53% of respondents had experienced side effects (Tsega 
et al 2015:375). About 3 (2.1%) respondents commented that ARV side effects were the 
reason for missing doses. As observed in this study, experiencing side effects was 
associated with non-adherence at the study site. In their study, Uzochukwu et al 
(2009:192) also documented physical side effects of ARVs among reasons for non-
adherence.  
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4.3.2.4.3 Distribution of respondents who have special instructions regarding ARVs and 
food (N=112) 
 
 
Figure 4.21 Distribution of respondents who have special instructions regarding 
ARVs and food 
 
Pertaining to instructions regarding ARVs and food, 53.6% (n=60) responded “yes” to 
having special instructions relating to ARVs and food while 46.4% (n=52) who did not 
have any special instructions. The currently recommended ARV regimen in Namibia of 
TDF/3TC/EFV which the majority of respondents were on has no documented food 
restrictions as outlined in the ART guideline. Seven (4.9%) respondents commented that 
not having food to take with the ARVs as the reason for missed dose. These findings are 
similar to those reported by Nghoshi (2016:42) where 7% of study respondents 
complained of dietary requirements. 
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4.3.2.4.4 Respondents general health status been in past 1 months (N=112) 
 
 
Figure 4.22 Distribution of respondents by their health status in  
the past 1 month 
 
Findings of the study showed that 57.1% (n=64) of the respondents although non-
adherent were healthy in the past 1 month, 25% (n=28) were somewhat healthy while 
17% were sick and 2.7% (n=3) were very sick. The results show that about one fifth of 
the sample had been sick in the past one month whilst the 80% were healthy. In South 
Africa and Ethiopia, studies have proven a statistically significant association between 
adherence to ART and illness in the past one month (Kranzer et al 2010:17; Abdissa 
2013:88). Charurat et al (2010:[5]) also highlighted that patients who had other health 
conditions were positively associated with good adherence while those with CD4 of more 
than 200 cells/ml were found to be more non-adherent. Sickness was observed to be also 
a barrier to adherence. It was also noted in this study that 4 (3.5%) respondents 
responded that the reason for missed dose was due to feeling too sick to come to the 
clinic.  
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4.3.2.5 Cultural and religious beliefs related factors 
 
Data presented in this subsection is on respondents’ cultural and religious beliefs towards 
HIV and ART treatment.  
 
4.3.2.5.1 Responses of respondents on whether taking ARV medicines offend any of 
your cultural beliefs (N=112) 
 
 
Figure 4.23 Distribution of respondents’ responses on whether  
taking ARV medicines offend their cultural beliefs 
 
As shown in figure 4.17 above, 98% (n=110) of the respondents were of the opinion that 
taking ARV medicines did not offend any of their cultural beliefs. Only 1(0.9%) respondent 
responded that taking the ARV medicines offended their cultural beliefs. The results 
revealed that the non-adherence reported at the study site was not related to patients’ 
feelings on whether ARV treatment offended their cultural beliefs.    
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4.3.2.5.2 Respondents responses on whether HIV infection can be treated by cultural 
methods without ARV medicines (N=112) 
 
 
Figure 4.24 Respondents responses on whether HIV infection can be treated  
by cultural methods without ARV medicines 
 
Figure 4.20 shows that 93% (n=83) were of the opinion that HIV cannot be treated by 
cultural methods, 17% (n=16) did not know and none of the respondents felt the infection 
can be treated by cultural methods. The results showed that the respondents did not 
believe cultural methods were an alternative therapy to ARV treatment.  In another study 
in Northern Namibian, 11% of respondents reported taking other traditional treatments 
together with ART (Nghoshi 2016:42). 
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4.3.2.5.3 Distribution of respondents on whether taking ARV medicines offend any of 
their religious beliefs (N=112) 
 
 
Figure 4.25 Distribution of respondents on whether taking ARV medicines offend 
any of their religious beliefs 
 
In this study 94.6% (n=106) respondents were of the opinion that their religion was not 
offended by taking ARVs, 4.5% (n=5) did not know and 0.9% (n=1) was offended. The 
results of this study did not reveal ARVs offending respondents’ religious beliefs as an 
associated factor to non-adherence. 
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4.3.2.5.4 Respondents responses to whether they think HIV infection can be treated by 
religious methods without ARV medicines (N=112) 
 
 
Figure 4.26 Respondents responses on whether they think HIV infection can be 
treated by religious methods without ARV medicines 
 
All the 112 respondents practiced the Christian religion (26.8% Catholics, 56.3% 
Orthodox and 17% protestant). Findings of this study revealed that 70.5% (n=79) 
commented that HIV cannot be treated by religious methods, 14.3% (n=16) did not know 
and a notable 15.2% (n=17) believed that HIV can be treated by religious methods without 
ARVs. Similar findings were reported in rural South Africa by Loeliger et al (2016:982) 
highlighted that among reasons for non-adherence was tension between ART and 
alternative therapies which included religion.  
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4.3.2.6 Independent  variable  
 
4.3.2.6.1 Study respondents adherence score (N=112) 
 
 
Figure 4.27 Respondents adherence score 
 
Only non-adherent patients were eligible to be part of this study. The adherence scores 
in this study according to pill count was 61% (n=68) of the respondents had fair adherence 
of 75-95% while 39% (n=44) respondents had adherence score less than 75% which is 
regarded as poor adherence. The sample size had a rate of non-adherence of 36.7%. 
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4.3.2.6.2 Respondents’ viral load (N=112) 
 
 
Figure 4.28 Respondents viral load 
 
Although all respondents in this study were assessed as non-adherent it is noteworthy 
that a significant 13.4% (n=15) had non-detectable viral load. A possible explanation was 
that blood for viral load testing was drawn one to two months prior to participating in the 
study when the patients were still adherent, while adherence in this study focused on only 
the previous one month. Another possibility for the non-detectable viral load could be that 
the adherence assessment by pill count method was different to that shown by the 
biological markers which revealed maximum viral suppression. 41.6% (n=46) 
respondents had viral load below 1000 copies per ml while a worrisome 45.6% (n=51) 
respondents had more than 1000 copies per ml of blood which is regarded as treatment 
failure. The study showed a total of 86.6% of the respondents had unsuppressed viral 
load as all respondents in this research were non-adherent. On the contrary, in a study 
in Myanmar, 94% of patients had an undetectable viral load and only 4% had ART failure 
(Kaleebu, Kirungi, Watera, Asio, Lyagoba, Lutalo, Kapaata, Nanyonga, Parry, Magambo, 
and Nazziwa 2015: [1]). It was further reported that 84.7% of respondents on first and 
second line treatment in the Myanmar study had viral load below 1000 copies/ml (Kaleebu 
et al 2015: [1]). 
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4.3.2.6.3 Respondents WHO clinical stage (N=112) 
 
 
Figure 4.29 Respondents WHO clinical stage 
 
Figure 4.29 illustrates that 51% (n=57) of the respondents were asymptomatic and in 
WHO clinical stage 1. 25% (n=28) respondents had a WHO stage 2 defining condition 
while the remaining 24% (n=27) where stage 3 and 4. In this study the number of 
asymptomatic respondents (51%) was almost equal to that of symptomatic respondents 
(49%). These results are similar to those reported in Zambia where WHO clinical stage 
was not predictive of non-adherence (Chi et al 2009:751). Other studies did yield a 
relationship between WHO clinical stage and adherence. Abdissa (2013:63) documented 
a statistically significant association between WHO clinical stage before initiation of 
antiretroviral therapy and combined adherence to ART. Conversely, Negash (2011:57) 
reported that the level of adherence to treatment was inversely proportional to the WHO 
clinical stage 
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4.3.2.7 Respondents responses to the open-ended questions 
 
At the end of the interview respondents were asked if they had any additional comments 
they wished to say. Below is a brief description of the responses. 
 
4.3.2.7.1 Respondents’ responses on the reason/s for ARV missed dose (N=142, 
Total=100%) 
 
All the 112 respondents in the study were asked for the reasons for missed dose. Some 
respondents mentioned more than one reason. The total number of reasons mentioned 
by the 112 respondents was 142. However, some reasons were recurring among 
respondents and were summarised together. For presentation purposes the reasons 
were classified into the categories of socio-demographic, patient-related, service system 
related, disease and treatment related and cultural and religious factors.    
  
Table 4.2 Summary of the reasons shared by respondents for missing dose/s (N=142, Total=100%) 
 
Section  Main theme  
Number of times 
reason is 
mentioned  (n) 
Percentage (%) Examples of respondents responses  
Socio-demographic and 
economic characteristics  
Due to travelling 
 
6 4.2%  I went for travel and slept on the way 
 I travelled to the North and ran out of ARVs  
Work commitments   
 
14 9.9%  Morning parade prolonged beyond 8 o clock 
which is my time for taking ARVs 
 Left early for work when l was supposed to take 
the treatment at  0700hr 
Transport problems 10 7.0% 
 
 I did not get a hike to come to the clinic  
 I did not have tax money  
Lack of food  7 4.9%  When l don’t have food I don’t take ARVs 
Social  relationships  
 
2 1.4%  Family problems, my daughter was sick and 
spent more time on my child and forgot myself. 
 My boyfriend is positive but not on the 
medicines and he is refusing to use condoms 
what is the need for me to take ARVs 
Patient related factors  Forgot 31 21.8%  Forgot to take treatment on time l was watching 
TV 
Alcohol use 22 15.5%  When l drink during the weekend l don’t take 
ARVs 
Due to stress 6 4.2%  I forgot to take my medicines due to stress 
caused by my boyfriend 
Tired of taking the 
medicines 
3 2.1%  Sometimes l just get tired of these tablets l know 
it’s not good  
8
8
 
  
Section  Main theme  
Number of times 
reason is 
mentioned  (n) 
Percentage (%) Examples of respondents responses  
Not at home during 
time of taking 
medicines  
2 1.4%  I went to overnight at relatives  
 I was not at home did not take my medicines 
Others  
 
3 2.1%  I got confused about time 
 I moved from one family house to another and 
it was difficult for me to take the medicines. 
 Over slept 
System related  Access to treatment  
 
14 9.9%  Patient was in prison in South Africa  
 I was out of town and forgot my passport so l 
was refused medicines 
 I was on the farm, the clinic is too far from our 
farm 
Service at the clinic  
 
7 4.9%  Clinic is closed in the time am free, open the 
clinic at 7 before l stat work and during lunch 
hour also  
 The waiting time at the clinic is too long  
 The que was too long and l went back home 
 I just don’t like the way we receive our 
medicines at the pharmacy  there is no privacy 
at all 
Heath care provider – 
patient relationship  
2 1.4%  Missed the treatment due to poor treatment 
from the nurse at the ARV clinic which cause 
me to walk away without taking the medicines 
for almost a whole month  
 Community counsellors and nurses are 
sometimes rude it discourages to come to the 
clinic  
  
8
9
 
  
Section  Main theme  
Number of times 
reason is 
mentioned  (n) 
Percentage (%) Examples of respondents responses  
Disease and treatment 
related  
Disease 5 3.5%  I was too sick to come to the clinic  
ARV treatment  
 
6 4.2%  The size of the pill was too big and l stopped 
taking them  
 The medicines were making me sick  
 The medicines were giving me headache and 
itching and l sometimes did not take 
Cultural and religious  
 
Religion 2 1.4%  The truth is l don’t believe in ARVs , I believe 
God is the healer nurses must stop forcing us 
to take ARVs 
 My faith healed me  
Total  142 100%  9
0
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The reasons frequently mentioned by patients for missed doses included; forgetting 
21.8% (n=31), alcohol use 15.5% (n=22), challenges in access treatment 9.9% (n=14), 
work commitments 9.9%, transport problems to health facility 7% (n=10), lack of food 
4.9% (n=7), stress 4.2% (n=6), need for travelling to receive HIV care 4.2% (n=6). Other 
reasons also cited were due to the ARV treatment itself giving patient discomfort which 
included side effects 4.2% (n=6), HIV infection related sicknesses 3.5% (n=5), tiredness 
after taking ARVs 2.1% (n=3), social relationships  1.4%(n=2), healthcare provider–
patient relationships 1.4% and religious beliefs accounting for 1.4%. These reasons for 
missed dose were similar to those reported from northern Namibia by Nghoshi (2016:43) 
who observed that the majority of the respondents 57 (20%) simply forgot, 32 (11%) 
indicated they had travelled away from home, while 26 (9%) attributed missing their 
dose(s) to alcohol use. In another study in Ethiopia, respondents cited missing their doses 
due to forgetfulness 29 (43.3%), missing appointment 14 (20.9%), having run out of 
medicines 9 (13.4%), depression, anger, or despair 4 (6.0%), side effects 2 (3.0%), and 
2 (3.0%) of respondents did not think that ARV medicines were important (Tsega et al 
2015:376). 
 
4.3.2.7.2 Additional comments by respondents  
 
In this part of the questionnaire, respondents were asked for any other comment before 
the interview was concluded. The reasons were classified according to the sections of 
factors associated with non-adherence from which main themes were created. Of the 112 
respondents, 64 (57.1%) responded had no comments to say, 48 (42.8%) respondents 
gave some comments and 82% of the comments expressed dissatisfaction with the 
service delivery system. Main themes derived were that patients are dissatisfied with long 
waiting times at the clinic and pharmacy, poor attitude of lay-counsellors and short 
duration of prescriptions. Respondents suggested solutions included keeping the clinic 
and pharmacy services running during lunch hour, increasing number of staff, bringing all 
ART services under one roof and decentralising ART services to other primary healthcare 
facilities. The comments are summarised in Table 4.3 below.  
 
  
Table 4.3 Respondents responses on any additional comments (N=48, Total=100%) 
Section  Frequency  Example of respondents responses  
Socio-demographic and economic characteristics  1/48=2.1% Government to provide houses and blankets for unemployed people on 
treatment  
Patient-related factors  0/48=0% None 
System-related Comments expressing 
satisfaction with the system  
5/48=10.4% Nurses must continue with their good job   
Continue with the good job  
Staff are very helpful 
 Comments expressing 
dissatisfaction with the system 
39/48=81.2% Staff are nice but too slow 
The ARV clinic healthcare worker must also dispense the medication at the 
ARV clinic and not the pharmacy to reduce the time   
Ministry must dispense ARVs at all the other clinics like other medicines  
Please give all the services at one point 
Community counsellor must improve her attitude 
I don’t like the fact that we are isolated and privately treated at the pharmacy 
Counsellors are rude to us  
Clinic must not close for lunch hour pharmacy also   
Drs and nurses are too few  
When we want to be helped in the North the ques are too long and the people 
also refuse to help us 
Drs must come and see us at our clinic when we go to see Dr at OPD the que 
is too long 
When we (ARV patients) go to the pharmacy our passports are served last 
even after those who came after us 
Ques are very slow and long 
The time spend at pharmacy is too long 
Disease and treatment-related  1/48=2.1% They must make an injection to give us only once a month because we forget 
Cultural and religious  2/48=4.2% Nurses must stop forcing us to take ARVs especially when l believe 
God is the healer not people or medicines  
9
2
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A few of the comments given by respondents in this study were similar to those reported 
in other studies. Nghoshi (2016:48) noted that the slow pace of service providers or long 
waiting period were among the reasons why respondents were not satisfied with the 
quality of health services. The majority of the respondents’ comments are particular to 
the study setting which made these research findings more relevant and informative for 
this study site. 
 
4.4 OVERVIEW OF RESEARCH FINDINGS  
 
The rate of non-adherence at the study site was 36.7%. The sample had 112 respondents 
who were all assessed as non-adherent according to pill count. There were more women 
(56.3%) than men (43.8%) in the sample. The results showed that the age group of 31-
45 years was the most non-adherent (54.5%), the majority of the respondents (71.4%) 
were unmarried, more than 70% attained basic education or less and 45.5% of 
respondents used active substances. While 78% had not disclosed their HIV status to the 
community, approximately (60%) felt taking ARV treatment reminded them of the HIV 
treatment. Most of the respondents (57.1%) had experienced side effects of ARVs, 46.2% 
had special instructions regarding their ARV treatment and food and a recognisable 
15.2% believed HIV infection could be treated by religious methods alone without ARV 
treatment. 28% of the respondents were dissatisfied with the healthcare providers.  
 
Among the main reasons for missed dose was forgetfulness 21.8%, alcohol use 15.5%, 
challenges in accessing treatment 9.9%, work commitments 9.9%, transport problems to 
health facility 7%, lack of food 4.9%, stress 4.2%, due to travelling 4.2% and 4.2% of the 
respondents missed doses due to side effects.  Social relationships, healthcare provider-
patient relationships and religious beliefs contributed 1.4% each for the reasons for 
missed doses. In general, the majority 67% (n=47) of reasons mentioned were under 
patient related factors, followed by socio-demographic factors 27.5% (n=27), 16.2% were 
system related, 7.7% were disease and treatment reasons and lastly 1.4% were religious 
reasons.  86.6% of respondents had unsuppressed viral load while 24% of the 
respondents had a clinical condition which placed them in WHO stage 3 or 4. 
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4.5 CONCLUSION 
 
This chapter presented the study results. Data was presented in graphs, pie charts and 
tables. The findings were presented according to the questionnaire which was used in 
data collection under the subsections of sample characteristics, patient related factors, 
system related factors, cultural and related factors. The chapter concluded by narrating 
the main themes which came out from respondents on reason for missed doses and other 
additional comments. The next and final chapter presented summarised study findings, 
recommendations and conclusions of the study.  
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CHAPTER 5 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 INTRODUCTION 
 
This final chapter of the study gave the summary of the outcomes of this research together 
with their interpretation. The chapter outlined the findings pertaining to the level of 
adherence and factors associated with non-adherence to Anti-retroviral treatment in 
adults at the study site.  Conclusions, recommendations, contributions of the study and 
its limitations were also outlined in this chapter. Finally, the chapter presented the 
concluding remarks for the study.  
 
5.2 RESEARCH DESIGN AND METHOD 
 
This study was a quantitative research design and descriptive non-experimental in nature. 
The study population was HIV positive adults receiving HIV care at a hospital in Namibia. 
Target population was HIV positive adults 21 years and older on ARV treatment for 
minimum duration of 3 months.  A cross-sectional study was carried out on a sample of 
112 adults. Data was collected from the 3rd of August until 7th September through face to 
face structured interviews. Respondents were selected using census and multi-stage 
sampling. Adult patients who attended the study site during the data collection period 
were all assessed for their adherence using the pill count method. All adult patients who 
had an adherence score of less than 95%, were 21 years and older and were on ARV 
treatment for 3 months or more were eligible to participate in the study. The principal 
investigator and data collectors approached such patients for participation and only those 
who gave verbal consent and written consent were included in the study. Ninety-four 
respondents were identified using this method of identifying non-adherent patients using 
the follow-up visit adherence score from pill count assessment. Eighteen more 
respondents were identified using electronic (EPMS) and confirmed using paper records 
(Patient care booklet). These were approached telephonically and also gave written 
consent to participate in the study. Although the study required only a minimum of 100 
respondents, the final number of respondents was 112. Most respondents preferred to be 
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interviewed at the clinic, in a private area in the pill counting room, instead of at their 
homes or at any other place.  
 
5.3 SUMMARY AND INTERPRETATION OF THE RESEARCH FINDINGS  
 
The interpretation of the research findings were presented in relation to the Health Belief 
Model theory and the conceptual framework of the study on factors associated with non-
adherence.  As discussed in chapter 1 the HBM theory used in this study assumed that 
the patient’s ability to adhere to ART was strongly dependent on a number of concepts. 
The concepts were how the patient views his risk of being non-adherent to ARVs, how 
serious is the problem of non-adherence, beliefs on the importance of adhering to ARVs, 
the cost of being adherent to the medicines, strategies to enhance adherence and lastly 
the individual patient ability to actually take the ARV medicines as prescribed. The data 
collection tool inquired on these concepts whose findings are interpreted in summary. 
 
5.3.1 Non-adherence at the study site 
 
This study concluded that there was an abnormally high non-adherence (36.7%) at the 
study site warranting corrective interventions. The non-adherence was correlating with a 
very high number of patients (86.6%) with unsupressed viral loads. The study results 
concur with those in another study that showed viral loads are strongly dependent on 
patient adherence (El-Khatib et al 2011:[3]). However, it is noteworthy that 66.3% of the 
adult patients at the study site were found to be adherent to their medicines according to 
pill count method. According to the Health Belief Model such non-adherence resulted 
from low perception of patient susceptibility where patients feel they are not prone to 
missing ARV doses or interrupting treatment. Additionally, patients could view non-
adherence as being better than completely stopping who and therefore perceive the 
problem of non-adherence lightly. Patients who perceive the benefits of ART lowly, 
experience barriers to adherence, have low patient self-efficacy and have minimal 
strategies to enhance adherence are most likely to be non-adherent. These factors which 
were investigated in this study are discussed below.   
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5.3.2 Factors associated with non-adherence  
 
The concepts of the HBM were synced into the WHO (2003: [27]) categorisation of factors 
that influence patient adherence. These modifying factors which have a bearing on the 
constructs of the Health Belief Model were discussed under socioeconomic, treatment 
related factors, patient-related factors, disease related factors and healthcare delivery 
system related factors. This study added an additional class of cultural and religious 
related factors 
 
5.3.2.1 Socio-demographic and economic characteristics  
 
The study findings showed that females, adults in age group of 31-45 and unmarried were 
found to be more non-adherent to ARV medicines. Most of these non-adherent 
respondents were also of low educational status. These aspects were highlighted as 
barriers to adherence in this study. These findings are all similar to those reported in 
previous studies by Tsega et al (2015:373) and Nuwagaba-Biribonwoha et al (2014: [10]). 
In contrast, on the sex attribute, Nghoshi (2016:29) reported men were more non-
adherent than women. In another study, Abdissa (2013:65) reported no association 
between age and non-adherence. Non-adherence among females could be related to 
females in most African settings being burdened with household chores which may result 
in them forgetting their ARVs (Ipinge 2009:15).  
 
Most adults in the age group of 31-45 years are actively employed which could have 
increased their chances of missing doses through work commitments, being away from 
home or being unable to collect their medicines from the clinic. As reported by Sasaki et 
al (2012:8), unmarried people were more non-adherent than the married. Similar finding 
were observed in this study which may be due to unmarried respondents not having 
treatment support as in the case of married couples supporting each other. Although it is 
often expected for families to support their members on ARV treatment, this study showed 
that the 70.5% of the non-adherent respondents were actually living with their families. 
Lack of family disclosure by respondents was shown to contribute to non-adherence as 
respondents could not receive family support to adhere to their ARV treatment. 
Alternatively, family members may not have been knowledgeable on how to support their 
relatives on ARV treatment. 
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5.3.2.2 Patient-related factors  
 
The results revealed that although respondents were non-adherent, 97% valued ART as 
essential for their HIV care. This shows that the study site had successful ways of 
educating the patients on the importance of ARVs and HIV care. As such, the non-
adherence experienced at this study site may not be attributed to the lack of 
understanding of the value of ARV treatment as only 1(0.9%) respondent disagreed that 
ART was essential. Despite successful patient education, a notable 45.5% of 
respondents were into active substances use and 43% of substance users highlighted 
they had missed an ARV dose at least once due to active substance use. This is almost 
double that reported in Tsega et al (2015:375) where only 22.5% in the study respondents 
used active substances.  Beer et al (2012:220) also found active substance influenced 
patient adherence. 
 
The study findings also showed that 39.3% of respondents were uncomfortable with 
taking ARVs in the presence of others while 70% had not disclosed their HIV status to 
the community. The study pointed out that most of the non-adherent respondents had 
never disclosed their HIV status to the community. This level of non-disclosure was higher 
than that reported in Tsega et al (2015:376) were 29.5% of respondents had not 
disclosed. In the 2013 DHS (MoHSS 2013a:178), only 28% of women and 26% of men 
aged 15-49 years had a complete acceptance attitude of those living with HIV/AIDS. This 
was of concern because stigma among those living with HIV also prevented their 
adherence to ART. It was observed that lack of disclosure to community was an 
associated factor to non-adherence in this study. Wasti et al (2012:75) also noted lack of 
community disclosure as being associated with non-adherence.  
 
Findings of depression being associated with non-adherence were reported in Negash 
(2013:66). This study also highlighted that 22% of the non-adherent adults were 
depressed and 6 (4.2%) respondents highlighted stress as reason for missing ARV 
doses. While this study cannot conclude depression as an associated factor to non-
adherence, it should however be noted that stress and its management thereof is vital to 
patients on HIV care.  
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Interestingly, among other patient related factors was that 60% of respondents responded 
that taking the ARV medicines reminded them of the HIV infection. This may act as a 
trigger towards depression among HIV patients. Negative outcomes of being reminded of 
HIV infection could be feelings of anger, self-blame, anxiety about their long-term health, 
the burden of taking ARV medicines their whole life and the possible restrictions the 
infection may bring in their lives. The study results suggest that some patients may avoid 
taking the ARVs in order to avoid being reminded of the HIV infection.  
 
5.3.2.3 System related factors 
 
Insightful findings were revealed in this study with regards to the service delivery system. 
Only half (50%) of the respondents found the clinic convenient for their care while the 
remainder were either undetermined (30.4%) or found it inconvenient altogether (19.6%). 
Respondents mentioned several reasons which are related to the service system for 
missing doses. These barriers to adherence as highlighted in this study included 
transportation costs to the clinic, unfriendly service hours, and high healthcare worker–
patient ratios and the resultant long waiting hours. Senkomago et al (2011:1246) and 
Tabatabai et al (2014: [6]) both concluded that poor service delivery attributes were 
associated with non-adherence. As reported in the Presidential Commission of Enquiry 
(MoHSS 2013a:9), the public health sector suffers from inadequate numbers of staff, 
availability of equipment, materials, medicines and appropriate technologies. These items 
are often inadequate due to limited funding, poor management processes and together 
have been attributed to poor service delivery which in turn has been associated with non-
adherence. 
 
Healthcare workers are pivotal to patients’ perceptions of service delivery. Respondents’ 
satisfaction with healthcare workers was 73.2% which was much lower than from similar 
studies conducted in Namibia were 95% of respondents were satisfied with their 
healthcare workers (Nghoshi 2016:47). Of the 9.8% of respondents who not satisfied with 
healthcare workers, some noted the rudeness of lay- counsellors as a reason for their 
dissatisfaction. While professional healthcare workers such as nurses are taught ethics 
of professional practice, lay counsellors are only receive limited training on ethics and 
counselling. This lack of professional training could have contributed to the perceived low 
satisfaction as indicated by the respondents and may have been the possible reason why 
lay counsellors are often found rude or unprofessional by patients.  
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Concerning the availability of free ARV medicines across the country, 96.4% had never 
found the pharmacy out of stock of their treatment. In this study only 4(3.6%) respondents 
had ever found the pharmacy out of stock of their ARVs. The National Drug Policy 
advocates for the constant availability of safe and efficacious medicines across the 
Namibian population (MoHSS1998:4). As ARVs are among the medicines that are 
provided for free to state facilities in Namibia, this is evidence of a functional and efficient 
supply chain from the central medical stores to the district hospitals and ultimately to the 
patients. 
 
5.3.2.4 Disease and treatment related factors  
 
The category with the highest number (65.2%) of non-adherent respondents was that of 
those on treatment for more than 3 years. As the number of patients on ART is cumulative 
over time, more respondents in this study had been on ART for more than 3 years. This 
is a positive indication that patients are being retained in care. However, if patients were 
defaulting or dropping off from treatment, the number of patients on treatment would 
stagnant. Like many other chronic conditions, over time some patients get tired of taking 
the ARV medicines and their adherence may reduce.  
 
ARV side effects range from minor nausea, vomiting, skin rash to severe liver damage or 
life threatening Steven Johnson Syndrome (MoHSS 2014a:15). In this research it was 
worrisome to note that 57.1% of respondents were having or had previously suffered from 
ARV side effects resulting in them missing doses. This study suggested that side effects 
were associated with non-adherence. 
 
Although only 53.6% of respondents had special instructions regarding ARVs and food, 
the majority of respondents believed that they could not take their ARVs when they have 
not eaten. This belief is contrary to Namibian ART guideline which discourages patients 
from missing their ARVs because they do not have any food (MoHSS 2014a:15). 
 
While non-adherent respondents would be expected to be sick and with higher WHO 
clinical stage, only 20% of the respondents reported being sick in the past one month.  
The results of non-adherence are cumulative over time, thus respondents who were non-
adherent during the data collection period might still have been healthy, but with continual 
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non-adherence, a depleted immune system and rising risk of opportunistic infections 
would eventually become sick patients with time. 
 
5.3.2.5 Cultural and religious beliefs related factors  
 
The study results showed that non-adherence at the study site may not be attributed to 
respondents’ cultural beliefs. Only 1(0.9%) respondent responded that taking the ARV 
medicines offended their cultural beliefs. Of all the 112 respondents none believed that 
the HIV infection can be treated by cultural methods. Concerning respondents’ religious 
beliefs and ARVs, 15.2% were of the opinion that HIV could be treated by religious 
methods without ARVs. Loeliger et al (2016:982) also highlighted the tension between 
ARV treatment and alternative therapies. Such beliefs present healthcare workers with a 
challenge to promote and foster adherence to ART among patients. In an era where some 
churches offer miracles of different forms, it appears HIV patients have not been spared 
and are sometimes advised to stop taking the ARVs as a sign of their healing resulting in 
non-adherence of the part of the patients.  
 
5.3.2.6 Patient adherence 
 
The eligibility criterion for this study was that only adults with adherence score of less 
than 95% were regarded as non-adherence and included in the study. From this study, 
36.7% of the adults attending the clinic for follow care were non-adherent. Of these 
respondents, 61% had fair adherence while 39% had poor adherence. This is of concern 
as consequences of non-adherence include poor clinical outcomes, virological failure and 
oftenly resistance (Ehlers &Tshisuyi 2015: [1]). The study confirmed that non-adherence 
was prevalent at the study site and appropriate corrective measures are required. 
 
 
 
5.3.2.7 Patient last viral load  
 
It was noteworthy that 86.6% respondents in this study had unsuppressed viral load while 
only 13.4% had non-detectable viral loads, also known as maximum viral suppression. 
The viral loads support the pill count adherence method as the viral loads depict the 
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adherence level in patients. This is a public threat as resistant HIV strains could result 
due to the non-adherence (Ehlers &Tshisuyi 2015: [1]).    
 
5.3.2.8 Patient WHO clinical stage  
 
WHO clinical staging classifies HIV patients according to HIV defining illnesses. In this 
study the number of asymptomatic respondents in stage 1 was 51% almost proportional 
those who were symptomatic, stages 2, 3 and 4 at 49%. Of the symptomatic respondents, 
24% were in stage 3 and 4 which agrees with the observation that 20% of the respondents 
had been sick in the past 1 month. As noted above, respondents’ non-adherence may 
not have had immediate negative outcomes but the consequences of continual non-
adherence are likely to be more prominent over time. In this study, the respondents viral 
load were already showing non-adherence although the majority of the patients were still 
not sick and in mainly stage 1 or 2.   
 
5.3.2.9 Reasons for missing ARV medicines  
 
Respondents cited a various reasons for missing their ARVs. Reasons ranged from those 
related to the patients themselves, their socio-demographics circumstances, system of 
care, the treatment and other religious and cultural factors. Reasons mentioned in the 
order of most common to least commonly were; forgetfulness (21.8%), alcohol use 
(15.5%), challenges in accessing treatment (9.9%), work commitments (9.9%), transport 
problems to health facility (7%), lack of food (4.9%), stress (4.2%) and  travelling (4.2%). 
A notable 4.2% of the respondents mentioned discomfort due to ARVs including the side 
effects as reason for missed dose. In Uzochukwu (2009:192), HIV infection related 
sicknesses constituted 3.5% of reasons for missed dose, while 2.1% simply got tired of 
taking ARVs and missed their doses. Lastly social relationships, healthcare provider–
patient relationships and religious beliefs each made up 1.4% of the reasons for missed 
dose. In Gari et al (2013:7) they also noted that poor beliefs in ARVs and belief in 
alternative treatments was associated with non-adherence. The majority of the reasons 
were patient related reasons, for example alcohol use, followed by socio-demographic, 
system of care, disease and treatment and lastly religious reasons. Some of the reasons 
mentioned in this study, for example forgetfulness, transport problems and work 
commitments are similar to those reported in other studies (Tsega et al 2015:375; 
Nghoshi 2016:43; Abdissa 2013:156). However, while lack of food was mentioned in this 
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study, in another study conducted in Northern Namibia, lack of food was not revealed as 
a reason for missed doses. Due to the Savanna climate in Northern Namibia, crop farming 
of staple foods like sorghum is possible which helps to enhance food security in most 
households. In contrast southern Namibia is predominantly semi-arid to desert which 
does not support crop farming but mainly small livestock husbandry (NSA 2013:13). Of 
note also is that, more than half of the respondents in this study were unemployed, which 
may have impacted on food insecurity among some respondents. As the study site serves 
a very vast geographic area, is also not surprising that some patients found it very difficult 
accessing the health facility?  
 
5.3.2.10 Patient comments  
 
The majority of the respondents’ comments were directed towards the service delivery 
system. Main themes derived from the comments included; patients’ satisfaction with the 
services they received from the nurses; although acknowledging inadequacy of nursing 
staff. Some respondents expressed the need for more nurses to be allocated to the 
division. Another commonly mentioned suggestion was need for decentralisation of ART 
services so that service can be nearer to the people. Other respondents suggested that 
the duration of ARV prescription should be increased for up to 6 months to frequent visits 
the clinic for refill. Another noteworthy suggestion was towards the integration of ART with 
other services, including the dispensing of medicines and reviews by a medical officer.  
 
5.3 RECOMMENDATIONS  
 
The findings from this study culminated in the following the recommendations. These 
recommendations are presented according to the constructs of the Health Belief Model 
and aimed towards promoting adherence. Proposed strategies to minimise non-
adherence at the study site are as follows: 
 
5.3.1 Perceived susceptibility 
 
Patients on long term therapy including ART maybe susceptible to missing doses at some 
point in time as observed in this study or interrupting treatment completely. Healthcare 
workers are recommended to appropriately educate patients on the disease process of 
HIV and explain the need consistently attaining levels adherence greater than 95%. There 
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is need for patients to understand that not only interrupting treatment for a longer period 
has negative results on their health but missing doses can also be detrimental.  
 
5.3.2 Perceived severity 
 
The results showed that 86.6% of respondents had unsuppressed viral loads. Where 
applicable, healthcare workers should use results of viral loads to explain resistance at 
appropriate levels of understanding of patients as a way to promote understanding of the 
consequences of non-adherence. The concept of resistance should be emphasised in 
explaining severity of non-adherence to ART treatment. 
 
5.3.3 Perceived benefits 
 
Healthcare workers are advised to plot patients’ biological markers including CD4 and 
viral loads on a graph to explain benefits of adherence to patients. This has potential of 
improving patients’ perception of benefits of adherence to ART including the clinical 
outcomes.  
The study recommends the clinic management promotes recruitment and the active 
involvement of “expert patients”. This is an HIV positive patient who is attending that 
facility and has disclosed their HIV status and living positively. They are trained to 
motivating other patients and explaining benefits of adhering to treatment and practising 
healthy lifestyle while on ART treatment.  
 
5.3.4 Perceived barriers 
 
Use of active substances came out in the research as barrier to adherence. A multi-
disciplinary approach is required to help patients to reduce or stop active substance 
use.As travelling contributed 4.2% of reasons for missed doses, improved linkages of 
patient referral are required Healthcare workers need to strengthen patients’ referral 
system across the different levels of HIV care so as to make it easier for patients to access 
continuing care. 
Lack of transport to health facilities accounted for 7% of reasons for missed doses in this 
study. To improve access to ART services for patients in remote areas, ART can be 
integrated into existing outreach programmes. Work commitments contributed to 9.9% of 
reasons for missed dose in this study. It is proposed that HIV programs in the workplace 
  
105 
be intensified so as to increase awareness among employers on the need for treatment 
support of employees as well as to reduce stigma which is often experienced at 
workplaces. 
 
Lack of food contributed to 4.9% of reasons for missed doses. The MoHSS needs to 
strengthen collaborative efforts with other non-governmental organisations on supportive 
care for ARV patients such as by providing food support.  
 
Healthcare workers particularly lay counsellors need to be trained in basic communication 
skills and counselling techniques. Among the patient comments were statements of 
dissatisfaction with attitude of lay counsellors. 
 
Adequate staff should be provided to the ART clinic as well as other department that 
provide supportive HIV care to patient. 
 
The ARV clinic and the pharmacy staff should consider taking turns to go for lunch rather 
than closing the services during lunch hour.  
 
5.3.5 Cues to action 
 
Patients should be encouraged to identify treatment supporters of their choice which can 
provide motivation and remind patients to take treatment. 
 
The MoHSS is recommended to adopt the use of Automated Short Message Service 
(SMS) as a way of reminding patients their ARVs. The Automated SMS from a 
telecommunications service provider can be linked to the Electronic Patient Monitoring 
System. The EPMS will automatically send SMSs which are directed to individuals with 
only their initials to take their ARVs when the scheduled time arrives. Project proposals 
to local service providers (such as Telecom and MTC Namibia) can be submitted on the 
desired services for consideration by the relevant MoHSS management. 
 
Healthcare workers need to work with patients and significant others to structure 
reminders around individual patient daily routine so that patients remember to take their 
ARVs as forgetting remains a major barrier to patient adherence.  
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5.3.6 Self-efficacy 
 
Healthcare workers should strengthen health education how to manage in case of missed 
doses. This helps to minimise non-adherence and missed doses. 
 
Fifty-seven percent of respondents in this study had experienced side effects. There is 
need to anticipate and discuss potential side effects, the time they maybe experienced 
and importantly how to handle them. Some minor side effects may be managed using 
home remedies while some need intervention of healthcare workers. As such, patients 
need to be empowered on their roles during HIV care  
 
As recommended above the expert patient can also assist by helping other patients’ build-
up their self-esteem to enhance successfully adherence to ART treatment. 
 
5.4 CONTRIBUTIONS OF THE STUDY  
 
The need remains for patients on ARV treatment to adhere to their treatment, yet until 
recently, there was limited data that identified the factors associated and the reasons for 
non-adherence in Namibia. Using scientific methods of research, this study has provided 
information about the level of non-adherence at a particular hospital in Namibia. The 
research investigated factors that affect patients’ ability to adhere to ARV treatment. 
Documenting the factors associated with non-adherence by patients to ARV treatment 
provides a foundation to healthcare workers to anticipate causes of non-adherence and 
aim at preventing or minimising it before it causes significant negative outcomes among 
the susceptible group of patients. The study also provided a platform for patients to give 
feedback about the quality of care the patients are receiving and provide suggestions of 
improvement. Findings of this study are vital in policy making and review of guidelines on 
HIV management in adults. This information will also assist MoHSS and other 
stakeholders in decision-making and with setting-up strategies that can improve HIV care 
services. Finally the study allowed the principal investigator to engage vital stakeholders 
on mapping strategies to promote adherence among ART patients at the study site and 
other sites nationwide. The stakeholders meeting deliberated on innovative initiatives 
including the use of the automated SMS as reminders among others strategies.  
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5.5 LIMITATIONS OF THE STUDY  
 
Although research methods used in this study ensured ethically and scientifically 
soundness, the study had limitations. Therefore the study findings should be viewed in 
the light of the following limitations 
 
The respondents were only drawn from only one health facility which is a district hospital 
in a country with 35 districts. It would be desirable to include more districts across the 
nation. This limits the study results to be generalised for the whole population.  
 
The adherence assessment used in this research was according to pill count. For lack of 
gold standard methods of measuring adherence, the pill count is widely used regardless 
of its limitations. 
 
The study was conducted at a specific point in time hence cannot provide information 
about patient adherence over a period of time. 
 
5.6 CONCLUDING REMARKS  
 
The rate of non-adherence in this study of 36.7% using the pill count method was much 
higher than most studies from both high and low income settings. Characteristics that 
were associated with non-adherence included; being female, age group of 31-45years, 
unmarried, lack of HIV disclosure to community, feeling that taking ARVs reminds one of 
the HIV infection and experiencing side effects of ARVs. Reasons for non-adherence 
were outlined by the patients themselves.  Forgetfulness, alcohol use, work commitments, 
transport problems, lack of food, stress and travelling were the most commonly mentioned 
reasons for missing ARV doses. Majority of respondents had unsuppressed viral loads. 
In line with these conclusions, the following recommendations mentioned below were 
made Non-adherence among patients on ART was determined and factors associated 
with the non-adherence at the study site identified. Very significant was the feedback from 
the patients through the comments they gave and these have been shared with the 
hospital management in the stakeholders meeting. Despite the limitations of this study 
particularly the use of respondents from only one site, this study has provided the study 
site with an in-depth knowledge on the HIV care services they are providing. The 
stakeholders’ meeting was a hallmark for strategic initiatives in preventing and combating 
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non-adherence amongst patients at the study site. This study investigated the problem of 
non-adherence at the site and as Mark Levy stated “a problem well stated is half solved”. 
It is trusted that the findings of this study have significantly contributed in solving the 
problem on non-adherence experienced among HIV patients.   
  
109 
LIST OF REFERENCES 
 
Abdissa, AE. 2013. Determinant factors affecting adherence to antiretroviral therapy 
among HIV infected patients in Addis Ababa.  
From: 
http://uir.unisa.ac.za/bitstream/handle/10500/13959/dissertation_abelti_ae.pdf?sequenc
e=1 (accessed 25 March 2016). 
 
Achappa, B, Madi, D, Bhaskaran, U, Ramapuram, JT, Rao, S & Mahalingam, S. 2013. 
Adherence to antiretroviral therapy among people living with HIV. North American Journal 
of Medical Science 5(3):220-223. From: https://www.najms.org (accessed 24 June 2016).  
 
Adisa, R, Alutundu, MB & Fakeye, TO. 2009. Factors contributing to non-adherence to 
oral hypoglycemic medications among ambulatory type 2 diabetes patients in 
Southwestern Nigeria. Pharmacy Practice (Granada) 7(3):163-169.  
From: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139048/pdf/pharmpract-07-
163.pdf (accessed 24 June 2016). 
 
Amsalu, A, Wanzahun, G, Mohammed, T & Tariku, D. 2014. Factors associated with 
antiretroviral treatment adherence among adult patients in Wolaita Soddo Hospital, 
Wolaita Zone, Southern Ethiopia. Science Journal of Public Health 2(2):69-77. From: 
http://article.sciencepublishinggroup.com/pdf/10.11648.j.sjph.20140202.15.pdf  
(accessed 24 June 2016). 
 
Aveyard, H. 2010. Doing a literature review in health and social care: A practical guide. 
2nd edition. Maidenhead: Open University Press. 
 
Babbie, E. 2009. The practice of social research. 12th edition. Belmont, CA: Wadsworth. 
 
Barner, J. 2010. Medication adherence: Focus on secondary database analysis. ISPOR 
Student Forum. 
 
  
  
110 
Beer, L, Heffelfinger, J, Frazier, C, Mattson, C, Roter, B, Barash, E, Buskin, S, Rime, T & 
Valverde, E. 2012. Use of and adherence to antiretroviral tharapy in a large U.S. sample 
of HIV-infected adults in care, 2007-2008. The Open AIDS Journal 6 (suppl 1:M21):213-
223. From: http://benthamopen.com/contents/pdf/TOAIDJ/TOAIDJ-6-213.pdf (accessed 
22 November 2015).  
 
Bedford, T, Wilson, S & Ritchie, O. 2015. Identfying and recruiting partcipants for health 
research. London: OPM Group. 
 
Bell, J & Waters, S. 2014. Doing your research project a guide for first-time researchers.  
6th edition. England: Open University Press.  
 
Bezabhe, WM, Chalmers, L, Bereznicki, LR, Peterson, GM, Bimirew, MA & Kassie, DM. 
2014. Barriers and facilitators of adherence to antiretroviral drug therapy and retention in 
care among adult HIV-positive patients: a qualitative study from Ethiopia. PLOS ONE 
9(5):e97353. From: http://dx.doi.org/10.1371/journal.pone.0097353 (accessed 21 
November 2015). 
 
Biadgilign, S, Deribew, A, Amberbir, A, Deribe, K & Sahara, J. 2009. Barriers and 
facilitators to antiretroviral medication adherence among HIV-infected paediatric patients 
in Ethiopia: A qualitative study. SAHARA-J: Journal of Social Aspects of HIV/AIDS 
6(4):148-154.  
From: http://www.tandfonline.com/doi/pdf/10.1080/17290376.2009.9724943 (accessed 
25 May 2016).  
 
Bless, C, Smith, CG & Sithole, SL. 2013. Fundamentals of social research methods an 
African perspective. 5th edition. Cape Town: Juta. 
 
Bolsewicz, K, Debattista, J, Vallely A, Whittaker, A, Fitzgerald, L. 2015. Factors 
associated with antiretroviral treatment uptake and adherence: a review. Perspectives 
from Australia, Canada, and the United Kingdom. AIDS Care 27(12):1429-1438. From: 
http://www.tandfonline.com/doi/abs/10.1080/09540121.2015.1114992 (accessed 22 
June 2016).   
 
  
111 
Boyer, S, Clerc, I, Bonono, CR, Marcellin, F, Bile, PC & Ventelou, B. 2011. Non-
adherence to antiretroviral treatment and unplanned treatment interruption among people 
living with HIV/AIDS in Cameroon: Individual and healthcare supply-related factors. 
Social Science and Medicine,72(8):1383-1392.  
From: http://dx.doi.org/10.1016/j.socscimed.2011.02.030 (accessed 16 June 2016).  
 
Burns, N & Grove, SK. 2011. Understanding nursing research building an evidence-
based practice. United States of America: Saunders. 
 
Campos, LN, Guimarães, MDC & Remien, RH. 2010. Anxiety and depression symptoms 
as risk factors for non-adherence to antiretroviral therapy in Brazil. National Institute of 
Health. From https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859347/ (accessed 16 
June 2016). 
 
Centre for Disease Control and Prevention. 2015. Terms, definitions and calculations HIV 
surveillance Publications.  
From: www.cdc.gov/hiv/statistics/surveillance/terms.html (accessed 29 June 2016). 
 
Charurat, M, Oyegunle, M, Benjamin, R, Habib, A, Eze, E, Ele, P, Ibanga, I, Ajayi, S, Eng, 
M, Mondal, P, Gebi, U, Iwu, E, Etiebet, MA, Abimiku, A, Dakum, P, Farley, J & Blattner, 
W. 2010. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy 
program in Nigeria: a longitudinal analysis for risk factors. PLoS One 5 (5):e10584. From: 
http://dx.doi.org/10.1371/journal.pone.0010584 (accessed 26 June 2016).  
 
Chesney, MA. 2000. Factors affecting adherence to antiretroviral therapy. Clinical 
Infectious Disease 30(Suppl 2):S171-S176.  
From: http://cid.oxfordjournals.org/content/30/Supplement_2/S171.full.pdf+html 
(accessed 26 June 2016).  
 
  
  
112 
Chi, BH, Cantrell, RA, Zulu, I, Mulenga, LB, Levy, JW, Tambatamba, BC, Reid, S, 
Mwanago, A, Mwinga, A, Bulterys, M, Sage, MS & Stringer, JS. 2009. Adherence to first-
line antiretroviral therapy affects non-virologic outcomes among patients on treatment for 
more than 12 months in Lusaka, Zambia. International Journal of Epidemiology 
38(3):746-756.  
From: http://ije.oxfordjournals.org/content/38/3/746.full.pdf+html (accessed 26 June 
2016). 
 
De, AK & Dalui, A. 2012. Assessment of factors influencing adherence to anti-retroviral 
therapy for human immunodeficiency virus positive mothers and their infected children. 
Indian Journal of Medical Science 66(11):247-259. From: http://www.indianjmedsci.org 
(accessed 24 May 2015).  
 
De Vos, AS, Strydom, H, Fouché, CB & Delport, CSL.  2011. Research at grass roots: for 
the social sciences and human service professions. 3rd edition. Pretoria: Van Schaik. 
 
Do, HM, Dunne, MP, Kato, M, Pham, CV & Nguyen, KV. 2013. Factors associated with 
suboptimal adherence to antiretroviral therapy in Viet Nam: A cross-sectional study using 
audio computer-assisted self-interview  (ACASI). BMC Infectious Diseases, 13(1):1-9. 
From: http://www.biomedcentral.com/1471-2334/13/154 (accessed 16 August 2016).   
 
Drachler, M de L, Drachler, CW, Teixeira, LB & De Carvalho Leite, JC. 2016. The scale 
of self-efficacy expectations of adherence to antiretroviral treatment: A Tool for identifying 
risk for non-adherence to treatment for HIV. PLoS ONE 11(2):e0147443. From: 
http://doi.org/10.1371/journal.pone.0147443 (accessed 22 July 2016).  
 
Ehlers, VJ & Tshisuyi, ET. 2015. Adherence to antiretroviral treatment by adults in a rural 
area of Botswana. Curationis 38(1), Art. #1255, 8 pages.  
From: http://dx.doi.org/10.4102/curationis.v38i1.1255 (accessed 15 June 2015).  
 
Eller, LS. 2009. Adherence, resistance and antiretroviral therapy. New Jersey, New York: 
AIDS Education and Training Centre.  
From: https://aidsetc.org/sites/default/files/resources_files/nynj-nurse-mod2-09.ppt 
(accessed 16 August 2016). 
 
  
113 
El-Khatib, Z, Katzenstein, D, Marrone, G, Laher, F, Mohapi, L, Petzold, M, Morris, L, Anna 
Mia Ekstrom, AM. 2011. Adherence to drug-refill is a useful early warning indicator of 
virologic and immunologic failure among HIV patients on first-line ART in South Africa. 
PLoS ONE 6(3):e17518.  
From: http://dx.doi.org/10.1371/journal.pone.0017518 (accessed 30 June 2016).  
 
Engelkirk, PG & Duben-Engelkirk, J. 2015. Burton’s Microbiology for the health sciences. 
10th edition. Hong Kong: Wolters Kluwer/Lippincott Williams and Wilkins. 
 
Flickinger, TE, Saha, S, Moore, R & Beach, MC. 2013. Higher quality communication and 
relationships are associated with improved patient engagement in HIV care. Journal of 
Acquired Immune Deficiency Syndrome 63(3):362-366.  
From: https://dx.doi.org/10.1097%2FQAI.0b013e318295b86a (accessed 30 June 2016). 
 
Franke, MF, Murray, MB, Muñoz, M, Hernández-Díaz, S, Sebastián, JL, Atwood, S, 
Caldas, A, Bayona, J & Shin, SS. 2011. Food insufficiency is a risk factor for suboptimal 
antiretroviral therapy adherence among HIV-infected adults in urban Peru. PubMed 
Central.  
From: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377162/pdf/nihms377933.pdf 
(accessed 30 June 2016). 
 
Gari, S, Doig-Acuňa, C, Smail, T, Malungo, JRS, Martin-Hilber, A & Merten, S. 2013. 
Access to HIV/AIDS care: a systematic review of socio-cultural determinants in low and 
high income countries. BMC Health Services Research 13(198):1-13.  
From: http://www.biomedcentral.com/1472-6963/13/198 (accessed 24 June 2016).  
 
Giddens, A & Sutton, PW.  2013. Sociology. 7th edition. Malden, USA: Polity Press. 
 
Gill, CJ, Hamer, DH, Simon, JL, Theo, DM & Sabin, LL. 2005. No room for complacency 
about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS 19(12):1243-1249.  
From: 
http://journals.lww.com/aidsonline/Fulltext/2005/08120/No_room_for_complacency_abo
ut_adherence_to.1.aspx (accessed 24 June 2016). 
 
  
114 
Holtzman, CW, Shea, JA, Glanz, K, Jacobs, LM, Gross, R, Hines, J, Mounzer, K, Samuel, 
R, Metlay, JP & Yehia, BR. 2015. Mapping patient-identified barriers and facilitators to 
retention in HIV care and antiretroviral therapy adherence to Andersen's Behavioral 
Model. National Health Institute. 
From: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400221/ (accessed 24 June 
2016). 
 
Ingersoll, KS & Cohen, J. 2008. The impact of medication regimen factors on adherence 
to chronic treatment: a review of literature. PubMed Central. 
From: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868342/ (accessed 12 October 
2015).  
 
Ipinge, S. 2009. HIV/AIDS in the Namibian context. Windhoek: University of Namibia. 
 
Ritchie, J & Lewis, J. 2009. Qualitative research practice. A guide for social science 
students and researchers. Pretoria: Van Schaik. 
 
Jimmy, B & Jose, J. 2011. Patient medication adherence: Measures in daily practice. 
Oman Medical Journal 26(3):155-159  
From: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191684/pdf/OMJ-D-10-00107.pdf 
(accessed 12 October 2015). 
 
Joint United Nations Programme on HIV/AIDS. 2014. Fast-track ending the AIDS 
epidemic by 2030. Geneva, Switzerland: UNAIDS. 
 
Joint United Nations Programme on HIV/AIDS. 2016. Report on the global AIDS 
epidemic. Geneva, Switzerland: UNAIDS. 
 
Joubert, G & Ehrlich, R. 2007. Epidemiology a research manual for South Africa. 2nd 
Edition. Cape Town: Oxford University Press. 
 
  
  
115 
Kaleebu, P, Kirungi, W, Watera, C, Asio, J, Lyagoba, F, Lutalo T, Kapaata, A.A., 
Nanyonga, F., Parry, C.M., Magambo, B. and Nazziwa, J. 2015. Virological response and 
antiretroviral drug resistance emerging during antiretroviral therapy at three treatment 
centers in Uganda. PLoS ONE 10(12):e0145536.  
From: http://dx.doi.org/10.1371/journal.pone.0145536 (accessed 22 June 2016).  
 
Kip, E, Ehlers, VJ & Van Der Wal, DM. 2009. Patients adherence to anti-retroviral therapy 
in Botswana. Journal of Nursing Scholarship 41(2):149-157.  
From: http://onlinelibrary.wiley.com/doi/10.1111/j.1547-5069.2009.01266.x/ful 
(accessed 22 June 2016). 
 
Kranzer, K, Lewis, JJ, Ford, N, Zeinecker, J, Orrell, C, Lawn, SD, Bekker, LG & Wood, R. 
2010. Treatment interruption in a primary care antiretroviral therapy program in South 
Africa: cohort analysis of trends and risk factors. PubMed Central:17. From: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024539/ (accessed 3 June 2016). 
 
Krousel-Wood, M, Holt, E, Joyce, C, Ruiz, R, Dornelles, A, Webber, LS, Morisky, DE, 
Frohlich, ED, Re, RN, He, J and Whelton, PK. 2015. Differences in cardiovascular 
disease risk when antihypertensive medication adherence is assessed by pharmacy fill 
versus self-report: The cohort study of medication adherence among older adults 
(CoSMO). Europe PubMed Central:412.  
From: https://www.europepmc.org/articles/pmc4514519 (accessed 3 June 2016). 
 
Lam, WY & Fresco, P. 2015. Medication adherence measures: An Overview. BioMed 
Research International. From: http://dx.doi.org/10.1155/2015/217047 (accessed 3 June 
2016). 
 
Li, L, Li, L, Lee, SJ, Wen, Y, Lin, C, Wan, D & Jiraphongsa, C. 2010. Antiretroviral therapy 
adherence among patients living with HIV/AIDS in Thailand. PubMed Central. From: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947817/pdf/nihms236945.pdf 
(accessed 3 June 2016). 
 
  
  
116 
Loeliger, KB, Niccolai, LM, Mtungwa, LN, Moll, A & Shenoi, SV. 2016. Antiretroviral 
therapy initiation and adherence in rural South Africa: community health workers' 
perspectives on barriers and facilitators. PubMed Central.  
From: http://dx.doi.org/10.1080/09540121.2016.1164292 (accessed 24 June 2016) 
 
Martin, S, Deborah, KE, Calabresse, S, Wolters, PL, Rogby, G, Brennan, T & Wood, LV. 
2009. A comparison of adherence assessment methods utilized in the United States: 
perspectives of researchers, HIV-infected children, and their care givers. AIDS Patient 
Care and STDs 23(8):593-601. From: https://dx.doi.org/10.1089/apc.2009.0021 
(accessed 24 June 2016). 
 
Miller, LG & Hays, RD. 2000.  Adherence to combination antiretroviral therapy: Synthesis 
of the literature and clinical implications. AIDS READER-NEW YORK 10(3):177-185. 
From: https://www.ncbi.nlm.nih.gov/labs/articles/10758022/ (accessed 24 June 2016) 
 
Mills, EJ, Nachega, JB, Buchan, I, Orbinski, J, Attaran, A, Singh, S, Rachlis, B, Wu, P, 
Cooper, C, Thabane, L, Wilson, K, Guyatt, GH & Bangsberg, DR. 2006. Adherence to 
antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 
296(6):679-690. From: http://jama.ama-assn.org/cgi/content/full/296/6/679 (Accessed 12 
April 2015) 
 
MOHSS see Ministry of Health and Social Services. 
 
Ministry of Health and Social Services. 1998. National drug policy for Namibia. Windhoek: 
GRN Printers. 
 
Ministry of Health and Social Services 2007. Namibia policy on HIV/AIDS. Windhoek: 
GRN Printers.  
 
Ministry of Health and Social Services. 2009. Namibia National Health Policy Framework 
2010-2020. Windhoek. Namibia.  
 
Ministry of Health and Social Services. 2012. Nurse initiated and management of 
antiretroviral therapy training manual.Windhoek. Namibia. 
 
  
117 
Ministry of Health and Social Services. 2013a. The Namibia Demographic Health Survey 
2013. Windhoek. Namibia. And Rockville, Maryland, USA: MoHSS and ICF International.  
 
Ministry of Health and Social Services. 2013b. Ministry of Health and Social Services 
annual report 2012/2013.Windhoek. Namibia. 
 
Ministry of Health and Social Services. 2013c. Namibia AIDS response progress. 
Windhoek. Namibia. 
 
Ministry of Health and Social Services. 2014a. National guidelines for antiretroviral 
therapy. Windhoek. Namibia. 
 
Ministry of Health and Social Services. 2014b. Namibia HIV sero-sentinel survey. 
Windhoek. Namibia. 
 
Ministry of Health and Social Services. 2014c. Training for clinicians on the use of the 
Namibian guidelines for antiretroviral therapy. 4th edition. Windhoek. Namibia. 
 
Ministry of Health and Social Services. 2015. THE NAMIBIA AIDS RESPONSE 
PROGRESS REPORT 2015 Reporting Period: 2013-2014. Directorate of Special 
Programmes Division Expanded National HIV/AIDS Coordination Subdivision: Response 
Monitoring and Evaluation. Windhoek. Namibia. 
 
Ministry of Regional and Local Government and Housing. 2002. The Constitution of 
Namibia. Windhoek. Namibia. 
 
Mosby’s Dictionary of Medicine, Nursing and Health Professions 2013, Sv “Health Belief 
Model”. 9th Edition. St. Louis, Mo, Mosby/Elsevier 
 
  
  
118 
Muessig, KE, McLaughlin, MM, Nie, JM, Cai, W, Zheng, H, Yang, L & Tucker, JD. 2014. 
Suboptimal antiretroviral therapy adherence among HIV-infected adults in Guangzhou, 
China. AIDS care-psychological and socio-medical aspects of AIDS/HIV. PubMed 
Central. From: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024070/ (accessed 25 
June 2016). 
 
Nachega, JB, Mills, EJ & Schechter, M. 2010. Antiretroviral therapy adherence and 
retention in care in middle-income and low-income countries: current status of knowledge 
and research priorities. Current Opinion in HIV and AIDS 5(1):70-77. From: 
http://www.ceatenf.ufc.br/ceatenf_arquivos/Artigos/Antiretroviral%20therapy%20adhere
nce%20and%20retention%20in%20care%20in.pdf (accessed 29 June 2016). 
 
NSA see Namibia Statistics Agency. 
 
Namibia Statistics Agency. 2013. Namibia 2011 population and housing census main 
report. Windhoek. Namibia. 
 
Enhancing prescription medicine adherence: A national action plan. 2007. National 
Council on Patient Information and Education.  
From: 
http://www.talkaboutrx.org/documents/enhancing_prescription_medicine_adherence.pdf
(accessed 25 June 2016). 
 
Nghoshi, SS. 2016. Assessment of determinants and levels of adherence to antiretroviral 
therapy in HIV-infected people in Opuwo district, Kunene region, Namibia. Windhoek: 
University of Namibia.  
From: repository.unam.edu.na/handle/11070/1101 (accessed 30 June 2016) 
 
Nieuwkerk, PT & Oort, FJ. 2005. Self-reported adherence to antiretroviral therapy for HIV-
1 infection and virologic treatment response: A meta-analysis. Journal of Acquired 
Immune Deficiency Syndromes 38(4):445-448. 
 
  
  
119 
Nuwagaba-Biribonwoha, H, Pals, S, Kidder, D, Carpenter, D, Katuta, F, DeLuca, N, 
Bupamba, M, Maokola, W & Bachanas, P. 2014. Factors Associated with Non-
Adherenceto Antiretroviral Therapy among Patients Attending HIV Care and Treatment 
Clinics in Kenya, Namibia, and Tanzania. PowerPoint presentation. Center of Disease 
Control. From: www.iapac.org/AdherenceConference/presentations/ADH7_80082.pdf 
(accessed 25 June 2016). 
 
Oxford Advanced Learner’s Dictionary of Current English. 2010. Sv “adherence” ‘adult”  
8th edition Oxford: Oxford University Press.  
 
Okoronkwo, I, Okeke, U, Chinweuba, A & Iheanacho, P. 2013. Nonadherence factors and 
sociodemographic characteristics of HIV-infected adults receiving antiretroviral therapy 
in Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. Hindawi Publishing 
Corporation. From: https://www.hindawi.com/journals/isrn/2013/843794/ (accessed 06 
June 2016).  
 
Payne, G & Payne, J. 2006. Key concept in social research. California: Sage. 
 
Polit, DF & Beck, CT. 2012. Nursing research: generating and assessing evidence for 
nursing practice. 9th edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & 
Wilkins. 
 
Punch, KF. 2005. Introduction to social research: quantitative and qualitative approaches. 
2nd edition. London: SAGE. 
 
Raosoft. 2004. Sample size calculator by Raosoft.  
From: www.raosoft.com/samplesize.html (accessed 28 June 2016).  
 
Reda, AA & Biadgilign, S. 2012. Determinants of adherence to antiretroviral therapy 
among HIV-Infected patients in Africa. Hindawi Publishing Corporation: AIDS Research 
and Treatment. From: https://www.hindawi.com/journals/art/2012/574656/ (accessed 17 
April 2015). 
 
  
  
120 
Sasaki, Y, Kakimoto, K, Dube, C, Sikazwe, I, Moyo, C, Syakantu, G, Komada, K, Miyano, 
S, Ishikawa, N, Kita, K and Kai, I. 2012. Adherence to antiretroviral therapy (ART) during 
the early months of treatment in rural Zambia: influence of demographic characteristics 
and social surroundings of patients. BioMed Central:8-11. 
From: https://ann-clinmicrob.biomedcentral.com/articles/10.1186/1476-0711-11-34 
(accessed 17 August 2016). 
 
Sahay, S, Reddy, KS & Dhayarkar, S. 2011. Optimizing adherence to antiretroviral 
therapy. The Indian Journal of Medical Research 134(6):835-849.  
From: http://www.ijmr.org.in/temp/IndianJMedRes1346835-4779805_011939.pdf 
(accessed 15 April 2015). 
 
Sapford, R & Jupp, V. 2006.Data collection and analysis. 2nd edition. London: SAGE. 
 
Senkomago, V, Guwatudde, D, Breda, M & Khoshnood, K. 2011. Barriers to antiretroviral 
adherence in HIV-positive patients receiving free medication in Kayunga, Uganda. Taylor 
& Francis Online.  
From: http://www.tandfonline.com/doi/abs/10.1080/09540121.2011.564112 (accessed 
20 May 2016). 
 
Smeltzer, SCO, Hinkle, JL, Cheever, KH & Bare, B. G. 2013. Brunner and Suddarth's 
textbook of medical-surgical nursing. 13th edition. North American Edition, Combined 
Volume edition.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 
 
Tabatabai, J, Namakhoma, I, Tweya, H, Phiri, S, Schnitzler, P, Neuhann, F and Glob 
Health Action. 2014. Understanding reasons for treatment interruption amongst patients 
on antiretroviral therapy--a qualitative study at the Lighthouse Clinic, Lilongwe, Malawi. 
PubMed Central.  
From: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185090/pdf/GHA-7-24795.pdf 
(accessed 15 June 2016). 
 
  
  
121 
Tomori, C, Kennedy, CE, Brahmbhatt, H, Wagman, JA, Mbwambo, JK & Likindikoki, S, 
Kerrigan, DL. 2014. Barriers and facilitators of retention in HIV care and treatment 
services in Iringa, Tanzania: the importance of socioeconomic and sociocultural factors. 
Taylor & Francis Online.  
From: http://www.tandfonline.com/doi/abs/10.1080/09540121.2011.564112 (accessed 
26 June 2016). 
 
Tsega, B, Srikanth, BA & Shewamene, Z. 2015. Determinants of non-adherence to 
antiretroviral therapy in adult hospitalized patients, Northwest Ethiopia. Patient 
Preference and Adherence 9:373-380.  
From: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356699/pdf/ppa-9-373.pdf 
(accessed 12 July 2016). 
 
UNAIDS see Joint United Nations Programme on HIV/AIDS. 
 
University of South Africa.  Department of Health Studies.  2015. General tutorial letter 
for proposal: Tutorial Letter 301/0/2015. Pretoria: Unisa. 
 
Uzochukwu, BS, Onmujekwe, OE, Onoka, AC, Okoli, C, Uguru, NP & Chukwuogo, OI. 
2009. Determinants of non-adherence to subsidized anti-retroviral treatment in southeast 
Nigeria. Health Policy and Planning 24(3):189-196.  
From: http://heapol.oxfordjournals.org/content/24/3/189.full.pdf+html (accessed 12 July 
2016). 
 
Venkatesh, KK, Srikrishnan, AK, Mayer, KH, Kumarasamy, N, Raminani, S, Thamburaj, 
E, Prasad, L, Triche, EW, Solomon, S & Safren, SA. 2010. Predictors of non-adherence 
to highly active antiretroviral therapy among HIV infected south Indians in clinical care : 
Implications for developing adherence interventions in resource-limited settings. AIDS 
Patient Care and STDs 24(1):795-803. 
 
Wasti, SP, Van Teijlingen, E, Simkhada, P, Randall, J, Baxter, S & Kirkpatrick, Gc, VS 
2012. Factors influencing adherence to antiretroviral treatment in Asian developing 
countries: a systematic review. Tropical Medicine and International Health 17(1):71.  
 
WHO see World Health Organization. 
  
122 
 
World Health Organization. 2003. Adherence to long term therapies: evidence for action. 
From: http://www.who.int/chp/knowledge/publications/adherence_report/en/ (accessed 
15 May 2015). 
 
World Health Organization. 2007. WHO case definitions of HIV for surveillance and 
revised clinical staging and immunological classification of HIV-related disease in adults 
and children. From:  http://www.who.int/hiv/pub/vct/hivstaging/en/ (accessed 15 April 
2015). 
 
World Health Organization. 2013. HIV treatment global update on HIV treatment 2013: 
Results, impact and opportunities WHO report in partnership with UNICEF and UNAIDS. 
From: www.who.int (accessed 15 April 2015). 
 
World Health Organization HIV/AIDS Department. 2016a.  HIV/AIDS care and treatment. 
Geneva. Switzerland. From: http://www.who.int/hiv/en/ (accessed 26 June 2016). 
 
World Health Organization. 2016b. HIV/AIDS online question and answer. Geneva 
Switzerland. From: http://www.who.int/features/qa/71/en/ (accessed 26 June 2016). 
 
WHO/UNAIDS/UNICEF. 2011. Global HIV/AIDS response epidemic update and health 
sector progress towards universal access. Progress report.. 
From: http://www.who.int/hiv/pub/progress_report2011/en/ (accessed 20 February 
2016). 
  
  
123 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
124 
ANNEXURE A: ETHICAL CLEARANCE FROM UNISA 
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ANNEXURE B: APPLICATION TO NAMIBIA RESEARCH COMMITTEE TO CONDUCT 
STUDY 
 
LETTER FOR PERMISSION TO CONDUCT STUDY 
 
Mrs T. CHIGOVA 
P. BAG 2101 
KEETMANSHOOP 
 
18 March 2016 
 
TO: THE PERMANENT SECRETARY 
 MINISTRY OF HEALTH AND SOCIAL SERVICES 
 P. BAG 13198 
 WINDHOEK 
ATT: THE RESEARCH COMMITTEE 
 
RE: APPLICATION FOR AUTHORISATION TO CONDUCT RESEARCH FOR STUDY 
PURPOSE 
 
I would like to apply for authorisation to conduct research for the purpose of study. The 
title of the study is Factors associated with non-adherence to antiretroviral treatment in 
adult patients at a hospital in Namibia. The aim of the study is to minimise non-adherence 
to antiretroviral (ARV) treatment amongst HIV/AIDS adult patients at a hospital in Namibia 
thereby promoting successful outcomes in patients on ARV treatment. This study will be 
a quantitative descriptive study. Data will be collected through review of patients’ records 
and structured personal interviews using a questionnaire. The respondents’ interviews 
will take between 10–15 minutes. The research assistants will be third year student 
nurses from Keetmanshoop Regional Health Training Centre.  I am currently based at 
Keetmanshoop Regional Health Training Centre as a lecturer for the Registered Nurse 
diploma programme. I am currently undertaking a Master degree in Nursing with the 
University of South Africa. The research is a requirement for the completing of this course.  
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The research proposal, the questionnaire and other relevant documents are attached for 
your information. Patients will not incur any harm or costs due to participation in this study. 
All costs involved in the research will be covered by me. 
 
This research proposal has been approved by the UNISA ethics committee. 
 
Date of approval : 2 March 2016               Approval number:  HSHDC/513/2016 
 
Looking forward to your positive response  
 
Yours faithfully 
 
Mrs T. CHIGOVA  
Lecturer Diploma Project Keetmanshoop Regional Health Training Centre 
Ministry of Health and Social Services 
Cell: 0813420668, Tel: 063-2209016 
e-mail:temptationchigova@gmail.com 
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ANNEXURE C: CLEARANCE LETTER FROM NAMIBIA RESEARCH ETHICS 
COMMITTEE 
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ANNEXURE D: SIGNED DECLARATION FORM FOR DATA COLLECTORS 
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ANNEXURE E: DECLARATION FORM FOR DATA COLLECTORS 
 
Good day 
 
My name is ……………………………l am a third year student nurse  working in this 
hospital. I am a data collector in the study: Factors associated with non-adherence to 
antiretroviral (ARV) treatment in adults at a hospital in Namibia, and my role is to 
collect data from respondents. The aim of the  study is to minimise non-adherence to 
antiretroviral (ARV) treatment amongst HIV/AIDS adult patients at a hospital in Namibia 
thereby promoting successful outcomes in patients on ARV treatment. The study is being 
conducted by Mrs Temptation Chigova a UNISA Masters student. If you agree to take 
part in the research, a student nurse will ask you a few questions. This will be done at 
your home or any place you choose where the conversation will be private. The interview 
is expected to take between 10-15 minutes. A research assistant will use a questionnaire 
to ask you questions and you reply orally and your responds will be written down in the 
questionnaire by the research assistant. The information received from respondents will 
only be accessible to the researcher and will be analysed to draw meaning and results.  
The questions are available in English, Oshiwambo and Afrikaans.  You are free to 
choose the language you are comfortable with. You have full right to decline to be 
interviewed either partly or totally without any effect on the care provided to you or your 
significant others. You may withdraw at any time. In case you consent to participate in 
the interview, I kindly request you to provide me your honest answer to the questions you 
want to respond to as this would help me to come up with genuine conclusions and 
recommendations that would potentially help Namibia Ministry of Health and health 
facilities improve these HIV care services. There are no rewards for participating in this 
investigation. The findings from this study will be communicated to the Sister in Charge 
of this clinic via the office of the senior medical officer. I am happy to answer any questions 
you may have; do you have questions?  
 
For further questions about this research and related issues, contact Mrs Temptation 
Chigova, principal investigator at +264813420668. Address: Keetmanshoop Regional 
Health Training Centre. Keetmanshoop Hospital grounds. Keetmanshoop.  
 
  
131 
If you feel human rights are not being correctly followed in this study you are free to 
contact chairperson of the UNISA Department of Health Ethics Committee:      
Prof. L. Roets 
 
 E-mail: roetsl@unisa.ac.za  
Phone: (012) 429 2226                                           Fax: (012) 429 6688 
If you so wish to participate in this study, before we commence our interview I kindly ask 
you to sign the consent form below 
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ANNEXURE F: INFORMED CONSENT FORM 
 
CONSENT TO PARTICIPATE IN THE RESEARCH  
 
I can confirm that before l participated in this study l read the above invitation to participate 
in the study / the above invitation has been read to me; I have fully understood its contents 
and I volunteer to participate in this study. 
 
Respondent code____________          Signature_______________ Date__________ 
 
Name of interviewer _____________Signature___________ Date______ 
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ANNEXURE G: ENGLISH DATA COLLECTION TOOL 
English Questionnaire 
Research Title: Factors associated with non-adherence to antiretroviral (ARV) treatment in 
adults at   a hospital in Namibia  
 
Research Aim: The aim of the study is to minimise non-adherence to antiretroviral (ARV) 
treatment amongst HIV/AIDS adult patients at a hospital in Namibia thereby promoting successful 
outcomes in patients on ARV treatment. 
 
1. Socio- demographic  and economic characteristics 
Instruction: - please provide short answer to the socio-demographic questions  
 
Sequential number Questions Coding categories code Skip 
 Patient unique 
code 
   
1.1.  Sex  Male   
1 
 
 
Female  
2 
1.2.  Age in completed 
years 
 
21-30 1  
31 - 45 2 
46-64 33 
65 and above   
1.3.  Ethnicity  Nama- Damara   
1 
 
Oshiwambo  2 
Caprivian /Okavango 3 
Otjiherero 4 
1.4.  Religion 
 
 
 
 
 
 
 
Catholic 1  
 
 
 
 
 
 
 
 
Orthodox  2 
Protestant  3 
Islam  4 
Hindu  5 
African tradition  6 
1.5.   
 
 
 
 
 
 
 
 
Marital status   unmarried 1 skip 
 Married  2 
separated/divorced 3 
widow or widower 4 
                1.6.  Level of education  illiterate 1 skip 
Basic education 2 
Elementary education  3 
college diploma and 
above 
4 
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               1.7.  Living condition  living alone  1  
living with family 2 
living with friend 3 
living with others 
 
4 
               1.8  source of support  self-support 1  
Families 2 
NGOs 3 
No support 4 
              1.9.  current 
employment 
status 
Employed 
 
1 
 
 
Unemployed  2 
 
 
 
2. Patient related factors  
 
Instruction: for the statements assessing relationship between individual patient 
related factors and non-adherence to antiretroviral treatment.  
 
Sequential Number Questions  Coding categories Code Skip 
2.1.  ART is essential 
for the HIV 
patient 
 
 
 
strongly agree 1  
agree 2 
Uncertain  3 
disagree 4 
2.2.  Are you feeling 
comfortable to 
take ART in the 
presence of 
others  
Comfortable  1  
Undetermined  2 
Uncomfortable  3 
2.3.  Do use any 
active 
substances 
 
No 
 
1  
Yes  
 
 
2 
2.4.  In the past 1 
month how often 
did you take 
active 
substances  
 Did not use alcohol         1  
1-2 times a week  2 
3-4 times a week 3 
   
 4-7 times a week           
4 
                    2.5.    Community 
disclosure 
Yes 1 
 
2 
 
No 
 2.6.  In the past 1 
month how would 
you describe 
  Generally happy            1  
  Neutral   2 
  
Somehow depressed 
3 
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3. System related factors  
 
Instruction: for the following statements related to the system of HIV care at this 
hospital, please express your opinion  
  
  SA A Skip  
3.1.  How convenient  do you 
find this clinic for your 
HIV care services     
Convenient  2  
undetermined 
Inconvenient  
3.2.  How satisfied are you 
with the healthcare 
workers  
Satisfied  1  
undetermined 2 
Dissatisfied  3 
3.3.  Have you ever found 
the pharmacy out of 
stock of your ARVs 
Never  
 
1  
Once  2 
 More 
than 
once 
3 
 
 
4. Disease and treatment related factors.     
 
Instruction: for the following statements related to the HIV disease and ARV 
treatment, please express your opinion using provided answers  
4.1.  Duration on ARV 
treatment  
 
 
3 – 12 months  
1 – 3 years  
More than 3 years 
 
1 Skip 
4.2.  Have you ever 
experienced any side 
effects to ARVs  
No  
 
1  
Yes  
 
2 
4.3.  Is there a special 
instruction regarding 
your  ARVs and food 
No  1  
Yes  
 
 
2 
4.4.  How have your 
general health status 
healthy     1  
somewhat healthy 2 
sick                               3 
your emotional 
status 
Very depressed 
 
4 
2.7.  Do you feel  
taking your ARVs 
remind you of the 
HIV infection 
No      1  
 
 
 
 
 
Somewhat  so 2 
strongly feel so 3 
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been in past 1 
months 
Very sick 
 
4 
 
 
5. Cultural and religious beliefs related factors  
 
Instruction: for the following statements are related to HIV, culture and religion, 
please express your opinion using provided answers 
 
Sequential number  Questions  Code Skip 
5.1. 5 Does taking ARV medicines 
offend any of your cultural 
beliefs 
 no 1  
 somewhat offend 2 
 Strongly offend  3 
5.2.  Do you think HIV infection 
can be treated by cultural 
methods without ARV  
medicines  
no 1  
Don’t know  
  
2 
Yes  3 
5.3.  Does taking ARV medicines 
offend any of your  religious 
beliefs 
 
 
1. no 1  
2. somewhat offend 2 
3.  strongly offend  3 
   5.4.  Do you think HIV infection 
can be treated by religious  
methods without ARV 
medicines  
 no 1  
 Don’t know 
 
2 
 Yes  3 
 
 
When you missed your ARV medicines what do you feel was the reason/s 
.………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
…………………………………………………………………………………………………………… 
 
Any other comments  
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
……………………………………………………………………………………………………………… 
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Dependent variable: Non-adherence markers  
 
Sequential 
number  
Questions Category  Code Skip 
6.1 Number of missed doses in last 
30 days (once daily dose 
regimens) 
 
0 or 1 (95% :good 
adherence) 
1  
2–8 doses (75<95 : fair 
adherence) 
 
2 
>8 doses or more(<75 : 
poor) 
3 
 
   6.2. Patient last viral load  Non-detectable  1  
Below 1000copies per ml   
  
2 
More than 1000 copies 
per ml 
3 
          6.3 Patient WHO clinical stage   Stage 1 1  
 Stage 2 
 
2 
 Stage 3 and 4 3 
 
 
Thank you very much for your time. 
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ANNEXURE H: OSHIWAMBO TRANSLATION TOOL 
 
Momudhingoloko gwomuntu 
Elombwelo: gandja omayamukulo pauhupi kokapulaapulo momudhingoloko gwomuntu. 
Elandulathano 
lyoonomola 
omapulo Coding categories code skip 
 Omomola 
yomeholamo 
   
1.1 Omukwashike Omukiintu 1  
omulumentu 2 
1.2 Oomvula 
dhagwanapo 
21-30 1  
31-45 2 
46-64 3 
65 nopombanda 4 
1.3 Omuhoko Nama/Damara  1  
Omuwambo 2 
omuCaprivi/Kavango 3 
omuherero 4 
1.4 Eitaalo Omukriste 1  
Omumoslema 2 
omuHindu 3 
African tradition 4 
1.5 
 
 
 
 
Ehokano Ina hokana 1 skip 
A hokana 2 
Ya topoka/ teka 3 
Omuselekadhi/ 
omusilwalume 
 
4 
1.6 Onkatu yeilongo Inaa longwa  1 skip 
Ahulila mondondo 8 2 
A hulila mondondo 
12 
3 
Iiputudhilo 
yopombanda 
 
4 
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1.7 Ehala lyokuza Oye awike  1  
Hazi naakwanezimo 2 
Hazi nookuume 3 
Hazi na yalwe 4 
1.8 Iiyemo  Kuyemwene  1  
Kaakwanezimo  2 
Omahangano gaashi 
gepangelo  
3 
Kapuna iiyemo 4 
1.9 Iilonga pethimbo 
ndika 
Omunashilonga  1  
Halongo kuye 
mwene 
2 
Eli moshipundi 
shevululuko 
3 
Iha longo 4 
  
2. Uuyelele wunasha nomnuuvu. 
Elandulathano 
lyoonomola 
Omapulo  Coding 
categories 
Code  skip 
2.1 Ethimbo waninga 
kepango lyo HIV 
Oomwedhi ndatu 
sigo omulongo 
nambali 
1  
Omvula yimwe 
sigo ndatu 
2 
Ethimbo livule 
poomvula ndatu 
 
3 
2.2 Konima 
yomwedhi 
gumwe oho kala 
wu uvite ngiini 
momaiuvo goye 
Ndahafa  
 
1  
Ndili ngaa pokati  
 
2 
Ndalimbililwa  
 
3 
Ndalimbulilwa 
shinene 
 
4 
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2.3 Oho longitha 
ngiini omalovu 
konima 
yomwedhi 
gumwe? 
Ihandi longitha  1  
Lumwe sigo 
lwaali moshiwike 
2 
Lutatu sigo lune 
moshiwike 
3 
Iikando ine sigo 
iheyali 
moshiwike 
4 
2.4 Ohonu shithike 
peni? 
Uuhalasa utatu  1  
Uuhalasa utatu 
sigo utano 
2 
Uuhalasa 
wuvule utano 
3 
2.5 Konima 
yomasiku 
omilongo ndatu 
owa dhimbwa 
lungapi okunwa 
omiti dhoye dho 
ARV 
Inandi dhimbwa 
nande osha 
1  
Lumwe  2 
Lwaali nenge shi 
vule po 
3 
2.6 Ohashi 
kudhimbulukitha 
kutya owuna 
ombuto yo HIV 
ngele tonu omiti? 
Aaye  1  
Oompito dhimwe 2 
Osho handi kala 
nduuvite 
3 
2.7 Oho dhiladhila 
kutya aantu ita ya 
kala yeku hole 
ngele oya tseya 
kutya ohonu 
ooARV? 
Aaye  1  
Oompito dhimwe 2 
Ohandi shi ipula 
kehe ethimbo 
3 
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3. Omukithi nepango 
Elandulathano 
lyoonomola 
omapulo Coding 
caegories 
code skip 
3.1 Ngele wanu 
omiti dho ARV 
ohadhi ku etele 
uupyakadhi 
washa? 
Aaye  1  
Oompito 
dhimwe 
2 
Kehe ethimbo 3 
3.2 Iikando ingapi 
wa adhika 
kuupyakadhi 
mbono kuza shi 
wa tameka 
okunwa 
ooARV? 
Inandi adhika 
sha 
1  
Oshikando 
shimwe sigo 
itatu  
2 
Iikando yi 
vulithe pu itatu 
3 
3.3 
 
Ohonu omiti 
lungapi 
mesiku? 
Lumwe  1  
Lwaali  2 
4.1 Ohonu oopela 
ngapi dho ARV 
poshikando? 
Yimwe  1  
Mbali  2 
Dhi vulithe pu 
mbali 
3 
4.2 Opuna 
elombwelo 
lyasha lyo ARV 
li ikwatelela 
kiikulya yoye? 
Kapuna 
elombwelo 
lyasha 
 
1  
Okunwa oopela 
manga 
mepunda mwaa 
nasha 
 
2 
Inolya iikulya 
yimwe manga 
to longitha 
oopela dho 
ARV 
 
3 
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4.4 Uukolele woye 
owuli ngiini 
kuza 
koomwedhi 
ndatu dha piti? 
Owu li nawa 1  
Owu li ngaa 2 
Onda li tandi 
ehama 
3 
Onda li tandi 
ehama unene 
4 
 
5. Omithigululwakalo nomaitaalo. 
Elombwelo: omatumbulo tag landula ogi ikwatelela ko HIV nomithigululwakalo osho wo 
omaitaalo. Alikana gandja omaiuvo goye to longitha omayamukulo ga gandja. 
Elandulathano 
lyoonomola 
omapulo Coding 
categories  
code Skip  
5.1 Okunwa oopela dhoye 
dho ARV otashi 
shundula eitaalo lyoye 
lyopamuthigululwakalo? 
Aaye  1  
Otashi 
shundula 
kashona 
2 
Otashi 
shundula 
unene 
3 
5.2 Owi itayela kutya 
ombuto yo HIV ota yi 
vulu kupangwa 
pamuthigululwakalo 
pwaana okunwa oopela 
dho ARV? 
Aaye  1  
Kandishiwo 2 
Ee  3 
5.3 Okunwa oopela dhoye 
dho ARV ota ku 
shundula eitaalo lyoye 
lyopangeleka? 
Aaye  1  
Oompito 
dhimwe 
 
2 
Otashi 
shundula 
 
3 
Otashi 
shundula 
unene 
 
4 
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5.4 Owa itayela kutya 
ombuto yo HIV ota yi 
vulu kupangwa 
pamukalo weitaalo 
lyoye kaapuna oo ARV? 
Aaye  1  
Kandishishi  2 
Ee  3 
 
……………………………………………………………………………………………………
……………………………………………………………………………………………………
…………………………………………………………………………………………………… 
Tangi unene kethimbo lyoye 
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ANNEXURE I: AFRIKAANS TRANSLATION TOOL 
 
Data-insameling hulpmiddel 
Vraelys 
Navorsingstitel: faktore wat verband hou met nie nakoming van antiretrovirale    
behandeling (vigs behandeling) spesifiek vir volwassenes by ‘n hospital in Namibie.  
Navorsingsdoel: Die doel van die studie is om nakoming te fasiliteer onder MIV/VIGS 
volwasse pasiente by n hospital in Namibie sodoende suksesvolle uitkomste te bevorder 
in pasiente op antiretrovirale behandeling. 
 
1.Sosio-demografiese vrae 
Opdrag: Verskaf asseblief kort antwoorde op die sosio-demografiese vrae. 
Sekwensiele 
nommer 
Vrae Kodering kategoriee Kode Slaan oor 
 Pasient unieke 
kode 
 
1.1 Geslag Manlik 
 
1  
Vroulik 2 
1.2 Ouderdom in 
voltooide jare 
21-30 
 
1  
31-45 
 
2 
46-64 
 
3 
>65 
 
4 
1.3 Verkieste taal Nama-damara 
 
1  
Oshiwambo 
 
2 
Caprivian/ Okavango 
 
3 
Otjiherero 
 
4 
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1.4 Godsdiens Catholic 
 
1  
Orthodox 
 
2 
Protestant 
 
3 
Islam 4 
Hindu 
 
5 
6 
Afrikaner-tradisie 
1.5 Huwelikstatus Enkel  
 
1  
Getroud 
 
2 
Samewoning 
 
3 
Geskei 
 
4 
1.6 
 
Vlak van 
opvoeding 
Ongeletterd 1  
Basiece opvoeding 2 
Elementere opvoeding 3 
Kollege diploma of 
hoer 
4 
1.7 Lewenstoestand Leef alleen 1  
Leef met familie 2 
Leef met vriende 3 
leef met ander 4 
1.8 Bron Van 
ondersteuning  
Self onderhoudend 1  
gesinne 2 
Nie-regerings 
organiasies 
3 
Geen ondersteuning 4 
1.9. Huidige werks 
status 
Werkend 1  
Werkloos 2 
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2. Pasient- verwante faktole 
Opdrag: Vir die stellings beoordeling vir di verhouding tussen pasient verwante 
faktore en nakoming van antiretrovirale behandeling. 
Sekwensiele 
nommer 
Vrae Kodering kategoriee Kode Slaan oor 
2.1 In die afgelope 1 
maand, hoe sou jy 
jou emosienele 
status beskyf? 
Oor die algemeen gelukkig 
Neutraal 
Een of ander manier depressief 
Baie depressief 
1  
2 
3 
4 
2.2 In die afgelope 1 
maand. Hoe 
dikwels het jy 
alcohol geneem 
Geen alcohol 
1-2 maal per week 
3-4 maal per week 
4-7 maal per week 
1  
2 
3 
4 
2.3 Waneer jy alcohol 
neem, hoeveel 
drink jy 
 1  
2 
3 
4 
2.4 In die afgelope 30 
dae, hoeveel keer 
het jy vergeet om 
jou MIV/VIGS 
behandeling te 
neem. 
Nooit 
Een maal 
Twee keer of meer 
1  
2 
3 
2.5 Voel jy deur dat jy 
die MIV/VIGS 
behandeling neem 
herinner jou aan di 
MIV infeksie 
Nee 
Op een of ander manier 
Ek voel sterk so 
1  
2 
3 
2.6 Voel jy dat mense 
nie van jou gaan 
hou sodra hulle 
bewus word dat jy 
op MIV/VIGS 
behandeling is 
Nee 
Ja 
1  
2 
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2.7 Voel jy gemaklik 
om jou 
antiretrovirale 
behandeling te 
neem voor ander 
mense 
Gemaklik 
Ongemaklik 
Ken nie 
 
1 
 
 
2 
3 
 
3. Stelsel verwante faktore 
Sekwensiele 
vrae 
Vrae Kode 
kategorie 
kode Slaan oor 
3.2 Van waar ek bly kan ek toegaan 
het tot hierdie kliniek sonder 
problem. 
Ja 
Nee 
Ander 
(spesifiseer) 
1  
2 
3 
3.1 Ek voel my verhouding met 
gesondheid personeel in di 
kliniek is van professionele 
standard 
 1  
2 
3 
3.3 Het jy al ooit ondervind dat die 
apteek uit voorraad was van jou 
antiretrovirale behandeling. 
 1  
2 
3 
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4. Siekte en behandeling verwante faktore 
Opdrag: Vir die volgende stellings wat verwand hou met die MIV/VIGS siekte en 
behandeling, stel asseblief jou mening met behulp van verskafde aantwoorde. 
Sekwensiele vrae Vrae Kode kategorie kode Slaan oor 
4.1 Hoe lang is jy  op 
antiretrovirale 
behandeling  
3-12 maande 
1-3 jare 
Meer as 3 jaar 
1  
2 
3 
4.2 Hoeveel keer het jy gely 
aan newe-effekte van 
antiretrovirale 
behandeling vandat jy 
daarmee begin het 
Nooit 
1-3 keer vandat ek 
begin het met die 
behandeling 
Meer as 3 keer 
vandat k begin het 
met die 
behandeling 
1  
2 
3 
4.3 Is daar ‘n spesiale 
instruksie in verband met 
jou antiretrovirale 
behandeling en kos 
Neem op n lee 
mag 
Moenie met 
sekere kos tipes 
neem nie 
Ander 
1  
2 
3 
4.4 Hoe is jou algeme 
gesondheid status in die 
afgelope 3 maande 
Gesond 
Een of ander 
manier gesond 
Siek 
1  
2 
3 
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5. Kulturele en godsdienstige oortuigings 
Opdrag: vir die volgende stellings in verband met die MIV/VIGS, kultuur en 
godsdiens, lug asseblief jou opinie deur gebruik van die voorgestelde antwoorde. 
 
Sekwensiele 
nommer 
Vrae Kode kategoriee kode Slaan oor 
5.1 Beledig die gebruik van antiretrovirale 
behandeling enige van jou kuulturele 
oortuigings 
Nee 
Een of ander 
manier 
beledigend 
1  
2 
3 
5.2 Dink jy die MIV- infeksie kan 
behandel word deur culture metodes 
sonder antiretrovirale behandeling 
Ja  
Nee 
Ek weet nie 
1  
2 
3 
5.3 Beledig die gebruik van antiretrovirale 
behandeling jou godsdienstige 
oortuigings 
Nee 
Een of ander 
manier 
beledigend 
Beslis beledigend 
1  
2 
3 
5.4 Dink jy die MIV- infeksie kan 
behandel word deur godsdiens 
metodes sonder antiretrovirale 
behandeling 
Ja 
Nee 
Ek weet nie 
1  
2 
3 
 
Volgorde 
nommer 
Vrae  Kode  Skip  
6.1. Pasient se gehegtheid 
telling by tablet tel metode 
Goed 1  
Redelik 2 
Swak 3 
6.2. Pasiente se laaste virus Nie meet baar 1  
Laer as 1000 kopieë 
per milliliter 
2 
Meer as 1000 kopieë 
per milliliter 
3 
6.33. Pasient se kliniese fase Laag 1 1  
Laag 2 2 
Laag 3 en 4 3 
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6.2. Enige ander komintaar  
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
…………………………………………………………………………………………………… 
 
Dankie vir u tyd 
 
